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Abstract 
Background: High blood pressure is common in acute stroke and has been linked with 
poor outcome. Hence, outcome might be improved by lowering blood pressure. This 
thesis investigates the potential for glyceryl trinitrate, a nitric oxide donor, for lowering 
blood pressure in acute stroke. Methods: A systematic review was employed to clarify 
the relationship between outcome and BP in observational studies. Next two systematic 
reviews of animal studies using nitric oxide therapeutics in experimental stroke were 
performed to assess the effects on infarct volume and cerebral perfusion. Finally, two 
randomised controlled clinical trials of glyceryl trinitrate were performed in acute stroke 
patients to measure the systemic and cerebral haemodynamic effects. Results: In 
observational studies high blood pressure in acute stroke was associated with 
subsequent death, death or dependency, and death or deterioration. In experimental 
stroke nitric oxide sources and selective nitric oxide synthase inhibitors significantly 
reduced stroke volume. Glyceryl trinitrate lowered peripheral and central blood pressure 
and increased aortic compliance when given <48 hours from stroke. Glyceryl trinitrate did 
not alter quantitative measures of cerebral perfusion despite significantly lowering blood 
pressure <5 days from stroke. Conclusion: High blood pressure is a therapeutic target in 
acute stroke and animal data support the use of nitric oxide sources for lowering blood 
pressure. It is feasible to use glyceryl trinitrate for this purpose since it does not 
compromise cerebral perfusion. Trials now need to urgently assess the effect of lowering 
BP on outcome. 
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Chapter 1. 
Background 
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1.1 Stroke – the problem 
Stroke may be defined as a sudden neurological deficit of presumed vascular origin 
which lasts for >24 hours or leads to death.1 There are 4.5 million deaths a year from 
stroke and more than 9 million stroke survivors worldwide.2 In addition, approximately 
one in four men and one in five women aged over 45 will have a stroke if they survive to 
85 years.2 As a consequence, the impact of stroke on society is enormous. In the UK 
stroke services account for 4-6% of the NHS budget, excluding social service and carer 
costs.2 This burden is likely to increase in the future, as incidence increases with age and 
the population ages.3 In the past, both the medical profession and the general public 
have considered stroke to have a low priority. However in recent years this perception 
has changed as awareness of the impact of stroke on society has increased. As a result, 
UK stroke services have been identified as an important area for development in the 
National Service Framework for Older People.4 
 
1.1.1 Risk Factors 
Both ‘modifiable’ and ‘non-modifiable’ risk factors have been linked to stroke in 
observational studies. Age is one of the strongest ‘non-modifiable’ risk factors; for 
example, stroke incidence rises from ~3 per 10,000 population in the 30 – 40th decades 
to ~300 per 10000 in the 80 – 90th decades.5 In addition, males have a higher risk, 
although because women tend to live longer they are more likely to die from stroke.6 
Also, UK mortality is worst in Black Africans, Black Caribbean’s and Asians7, partly due 
to higher prevalence of diabetes and hypertension in these populations.8 Elevated blood 
pressure (BP) is the strongest of the ‘modifiable’ factors.8 In one meta-analysis every 
7.5mmHg increase in diastolic BP increased stroke incidence by 46%.9 Other ‘modifiable’ 
factors that have been linked to stroke include; smoking10, diabetes11, atrial fibrillation 
(AF)8, alcohol consumption12, high salt intake13, low social status, obesity14, plasma 
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homocysteine15, elevated white cell count16, fibrinogen levels17 and haematocrit.18 Some 
of these associations have not been widely accepted as causal.19 
 
1.1.2 Types of stroke 
Stroke can be classified by pathology, aetiology, duration, location, or clinical syndrome.5 
There are three main pathological types; ischaemic stroke (IS), primary intracerebral 
haemorrhage (PICH) and sub-arachnoid haemorrhage (SAH). 
 
a) IS 
Arterial occlusion accounts for 85% of stroke presentations.20 IS may be further classified 
by aetiological sub-type according to the TOAST classification:21 
 
i) Large artery atherosclerosis. The major brain arteries and carotids are prone to 
atherosclerotic narrowing, especially at sites of origin or bifurcation. This can 
cause infarction by reducing blood flow distal to the point of stenosis or by 
acting as a nidus for platelet aggregation leading to distal embolisation.  
ii) Small vessel occlusion. Lipohyaline degeneration or micro-atheroma in deep 
perforating arteries can lead to infarcts within sub-cortical areas, such as the 
basal ganglia, thalamus and internal capsule. So called ‘lacunar strokes’ 
account for up to 25% of IS.22  
iii) Cardioembolism. Embolism from thrombi that form in the heart and aorta 
account for approximately 30% of IS.22 A variety of cardiac sources have been 
identified, including valvular lesions, rhythm disturbances and hypokinesis of 
the left ventricle. Non-rheumatic AF is the commonest cause of cardioembolic 
stroke in the west. Untreated AF results in an absolute risk of stroke of 5% per 
year.8 
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iv) Stroke of undetermined aetiology. When no likely aetiology can be determined 
despite a complete evaluation. 
 
 b) PICH 
10% of strokes are due to PICH. The major causal factors can be divided into 3 
categories:8 
 
i) Anatomical factors. Bleeding caused by defects in the brain vasculature, for 
example; microaneurisms, arteriovenous malformations, amyloid angiopathy. 
ii) Haemodynamic factors. Hypertension is the most powerful risk factor for both 
ischaemic and haemorrhagic stroke. Chronic high BP underlies microaneurism 
formation and rupture, leading to PICH at well-defined sites, such as the basal 
ganglia, pons and sub-cortical white matter. 
iii) Haemostatic factors. Bleeding caused by problems with platelet or coagulation 
function; for example, with thrombolysis or anticoagulant usage. 
 
c) SAH  
Leakage of blood from vessels as they transverse the subarachnoid space. Although the 
World Health Organisation (WHO) definition of stroke includes SAH,23 for the purposes of 
this thesis the term ‘stroke’ refers to IS and PICH only. 
 
1.1.3 Bamford classification 
The Bamford classification defines several clinical syndromes.24 This system works well 
at the bedside25 and may be used to predict prognosis;20,26 
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i) Total Anterior Circulation Syndrome (TACS). A triad of a unilateral weakness 
(hemiparesis), a visual field defect (hemianopia) and higher cerebral 
dysfunction (e.g. speech difficulty, sensory neglect, difficulty performing 
complex tasks). Usually a result of damage to a large part of a cerebral 
hemisphere involving the proximal anterior cerebral circulation. The prognosis 
is poor with 60% mortality and 35% dependency at 1 year.20 
ii) Partial Anterior Circulation Syndrome (PACS). Patients present with 2 out of 3 
of hemiparesis, hemianopia or higher cerebral dysfunction. Alternatively, an 
isolated defect in higher cerebral dysfunction or a weakness in one area out of 
face, arm or leg. Usually a result of stroke involving a distal portion of the 
anterior cerebral circulation. Prognosis is better than TACS with 20% mortality 
and 30% dependency at 1 year.20 
iii) Lacunar Syndrome (LACS). Present with hemiparesis and / or sensory 
symptoms alone in at least two regions of face, arm and leg. Caused by stroke 
located in sub-cortical areas (see above). Often associated with hypertension 
and diabetes. The prognosis is relatively good with10% dead and 25% 
dependent at 1 year.20  
iv) Posterior Circulation Syndrome (POCS). Patients present with visual problems 
(isolated visual field defect or loss of eye movement), poor swallowing, 
coordination problems (ataxia) or bilateral weakness. Usually due to a lesion in 
the posterior circulation, involving the occipital lobes, cerebellum or brainstem. 
1year mortality and dependency are both 20%.20  
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1.1.4 Pathophysiology of IS 
An IS begins with thrombotic occlusion of a cerebral artery, or less often a reduction in 
perfusion due to a severe stenosis. Typically the thrombotic process is initiated by 
rupture of an atherosclerotic plaque and injury to the vascular endothelium.27 Exposed 
sub-endothelial structures activate platelet aggregation and the blood coagulation 
cascade, leading to thrombus formation and vessel occlusion. The brain is especially 
vulnerable to vascular occlusion because it requires a constant supply of oxygenated 
blood and glucose to meet it’s high energy demands (equivalent to a 20 Watt light bulb).8 
If cerebral perfusion falls below ~20ml/min/100g there is a rapid loss of neuronal 
electrical function.28 Restoration of blood flow at this stage can reverse the situation 
because the neurones involved remain viable. However, if cerebral blood flow (CBF) falls 
below a critical level (~10ml/min/100g) the situation becomes irreversible.29 At this point 
aerobic respiration fails and neurones become unable to generate sufficient adenosine 
triphosphate (ATP) to maintain energy dependent cellular ion homeostasis. Intracellular 
calcium levels rise because of failure of ATP reliant ion pumps, increased cellular 
permeability and release of excitatory neurotransmitters (glutamate).30 Calcium then 
triggers cell death by activating enzymes, such as phospholipases, proteases and nitric 
oxide synthase (NOS, see section 1.3.3). Furthermore, tissue hypoxia leads to the 
development of acidosis (through lactate formation) and the formation of free radicals 
(O2-, OH•) that further contribute to irreversible neuronal damage.30  
 
In theory, the presence of 2 separate CBF thresholds leads to the development of an 
irreversibly damaged infarct core surrounded by an area of brain, called the ischaemic 
penumbra, which is in electrical failure.29 Possibly penumbra could be salvaged if 
perfusion is restored (e.g. thrombolysis) or if agents that protect the vulnerable neurones 
from further damage are administered (neuroprotection).31 Positron Emission 
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Tomography (PET) studies in humans suggest that the penumbra may remain viable for 
up to 17 hours.32 
 
1.1.5 Pathophysiology of PICH 
Several factors can lead to PICH (see section 1.1.2b). In young patients arteriovenous 
malformations and microangiomas are the commonest causes, whereas in older people 
hypertension and amyloid angiopathy are more frequently responsible.8 When an 
intracranial vessel ruptures, blood immediately disrupts neurones in the vicinity of the 
bleed. In addition, the surrounding zone becomes ischaemic because of direct 
mechanical compression, oedema, loss of cerebral autoregulation and the presence of 
vasoconstrictor substances in extravasated blood.33 Since the brain is encased in a rigid 
skull the presence of a large haematoma mass can lead to a fatal rise in intracranial 
pressure.  
 
1.2 Treatment of Stroke – the current situation 
 
1.2.1 Acute medical treatment of IS 
a) Antiplatelet therapy 
Two large trials found that aspirin (160-300mg daily) given within 48 hours of onset of IS 
reduces the risk of subsequent death or dependency.34,35 However, the effect of aspirin is 
small (13 less patients dead or disabled per 100034 and probably reflects reduced risk of 
early recurrence rather than a direct effect on the stroke itself. Other antiplatelet agents 
that are effective in secondary prevention have not been studied in large trials.  
 
b) Thrombolysis 
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Thrombolytic agents have been long established as a treatment for acute myocardial 
infarction. By contrast, evidence for efficacy in acute IS has only recently become 
available. Commonly used agents include: streptokinase, recombinant tissue 
plasminogen activator (rTPA) and urokinase. A recent systematic review of 18 trials 
found a significant reduction in death or dependency at 3 months (odds ratio, OR 0.84, 
95% confidence interval, CI 0.75 to 0.95) when these drugs were administered up to 6 
hours after onset.36 However, there was a net increase in deaths during the first 10 days 
due to secondary cerebral haemorrhage. Interestingly, administration within 3 hours of 
onset was more effective and did not have an adverse effect on death.36 Hence, it seems 
reasonable to use thrombolytic agents within the 3-hour time window on patients that are 
similar to those included in the trials. Further studies are required to determine the 
patients most likely to benefit and the latest time window for administration.37 
 
c) Neuroprotection 
Many compounds that provide effective neuroprotection in animal models have 
progressed to full human studies. However, as of 2001 more than 37 potential 
neuroprotective agents had been studied in over 114 clinical trials and yet none is in 
routine clinical use.38  
 
1.2.2 Acute treatment of PICH 
There is no acute medical treatment for PICH, although agents that reduce intracranial 
pressure are often given, e.g. osmotic diuretics. In a recent phase II trial, recombinant 
activated factor VII (eptacog alfa) reduced haematoma expansion, mortality, and 
disability when given within 4 h of ICH onset; a phase III trial (the FAST trial) is now in 
progress.39 Craniotomy and evacuation of supratentorial PICH was found to be harmful in 
one systematic review.40 However, this did not include findings from a recent randomised 
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controlled trial (1033 patients) that assessed a policy of initial conservative treatment 
against early surgery.41 Using a prognosis based dichotomous outcome, assessed at 6 
months follow up, there was no significant difference between treatment groups. Pre-
specified sub-group analysis revealed that early surgery conferred an advantage when 
the lesion was located superficially (<1cm deep). It is widely accepted that selected 
patients with infratentorial haemorrhage benefit from craniotomy, however this has not 
been formally tested in a trial.8  
 
1.2.3 Secondary Prevention for IS and PICH 
In the first year after IS or TIA there is an 8% risk of recurrent cerebrovascular events.42 
There are several pharmacological and non-pharmacological ways of reducing this 
threat: 
 
a) Antiplatelet therapy 
Treatment with an antiplatelet agent is an essential part of the armamentarium for 
secondary prevention of IS. Three drugs in common use have independent modes of 
action on platelets: Aspirin irreversibly inhibits cyclo-oxygenase, clopidogrel is an indirect 
antagonist of the adenosine diphosphate (ADP) receptor, and dipyridamole prevents the 
uptake by red cells of adenosine (which has antiplatelet properties). A recent meta-
analysis (21 trials) found that allocation of antiplatelet therapy to stroke patients resulted 
in 36 fewer serious vascular events per 1000 treated.43 This benefit included a highly 
significant reduction in non-fatal stroke (25 fewer per 1000) that exceeded the estimated 
excess risk of bleeding (1-2 per 1000).43 Aspirin was the most widely studied antiplatelet 
drug, with doses of 75-150 mg as effective as higher daily doses. Interestingly, 
clopidogrel was slightly more effective than aspirin in a large trial.44 However it is not cost 
effective for initial treatment and is usually rese
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intolerant. Combination of aspirin with other antiplatelet agents may be an alternative 
since it is presumed that the individual effects on platelets will be additive. Aspirin and 
dipyridamole were found to have an additive effect as compared with aspirin alone in two 
trials.45,46 However, the combination of aspirin with clopidogrel did not confer any 
additional benefit and led to increased bleeding in the MATCH study.47 Further work is 
ongoing in this area with the CHARISMA and PROFESS trials.  
 
b) Anticoagulant therapy 
Several trials have demonstrated superiority of full anticoagulation with warfarin over 
aspirin or placebo for the prevention of cardioembolic IS. A recent meta-analysis of 
antithrombotic therapy in AF showed that adjusted dose warfarin reduced stroke by 
about 60%, with absolute risk reductions of 3% a year for primary prevention and 8% per 
year for secondary prevention.48 In addition, warfarin reduced the risk by about 40% 
relative to aspirin therapy. Treatment with full dose anticoagulation carries with it the risk 
of inducing major bleeding, although in the European AF Trial (EAFT) this was only 2.8% 
per year.49 Titration to an International Normalised Ratio of 2.0 – 3.0 is generally 
accepted as the optimum and safest level, however patients with mechanical heart 
valves require a higher range (2.5 – 4.5).42 
 
c) Surgery for carotid stenosis 
Large-scale trials have provided data that allow selection of appropriate stroke patients 
for carotid endartrectomy.50,51 Both these studies found that the immediate risk of surgery 
was worth trading off against the long-term risk of stroke (without surgery) when high-
grade stenosis was present (70 to 99%). The benefits were found to persist with surgery 
up to 12 months after the most recent cerebral event.42 
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d) BP reduction 
Treatment with antihypertensive agents not earlier than one week after the onset of IS or 
PICH was associated with reduced risk of subsequent stroke (fatal and non-fatal), 
myocardial infarction and total vascular events in one systematic review.52 The majority 
of the included studies recruited patients irrespective of their BP, suggesting that there 
may be no treatment threshold. In addition, one trial found that dual therapy was superior 
to monotherapy, implying that the benefits relate, in part, to the magnitude of BP 
reduction.53 By contrast with primary prevention studies54, significant differential effects 
were observed between drug classes.52 For example, diuretics and (angiotensin 
converting enzyme (ACE) inhibitors appeared to be beneficial, whereas β blockers had 
no effect on any outcome. This could be attributed to paucity of data, although studies 
with β blockers in the acute stroke period had similarly disappointing findings.55  
 
e) Cholesterol Reduction 
Individual studies have shown that interventions which reduce cholesterol levels, 
especially 'statins', are of benefit in reducing coronary heart disease and stroke events in 
those with a history of cardiovascular disease. Current clinical practise in IS patients is 
based on extrapolations and subgroup analyses from these studies. A recent systematic 
review of 5 trials involving 1700 patients found no evidence of a difference in stroke 
recurrence between the treatment and placebo groups for those with a previous history 
of stroke or TIA.56 However, this review did not include the Heart Protection Study57, 
which subsequently found a significant reduction in vascular events in a subgroup of 
3280 patients with cerebrovascular disease. Ongoing trials are continuing to examine this 
question.58 
 
f) Management of risk factors 
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 ‘Modifiable’ risk factors should be identified and corrected. Smoking should be strongly 
discouraged since the risk of stroke in a smoker reduces to that of a non-smoker around 
3 to 5 years after stopping.42 In addition, patients should normalize weight, exercise 
regularly, moderate alcohol intake and eat a healthy diet.20  
 
1.2.4 Rehabilitation 
Rehabilitation involves the coordinated use of medical, social, educational and vocational 
measures to train or retrain individuals to the highest levels of functional ability.59 For 
hospitalised patients this is best achieved in an organised (stroke unit) setting, since this 
environment is associated with the best outcome.60 However, it is not clear which 
components of ‘organised stroke unit care’ account for these findings. A recent 
systematic review identified significant improvements in primary activities of daily living 
(ADL), extended ADL, and social participation for patients receiving comprehensive 
occupational therapy (OT).61 Likewise, greater physiotherapy input results in reduced 
death and deterioration.62 However, cardiovascular exercise interventions63 and 
physiotherapy using the Bobath technique both failed to alter stroke outcome in other 
meta-analyses.64 Similarly, speech and language therapy was found not to be effective in 
one systematic review of 12 trials.65 More rehabilitation research needs to be conducted. 
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1.3 Nitric Oxide – a potential therapeutic target in stroke 
The therapeutic modulation of nitric oxide (NO) has generated considerable interest in 
recent years as a new strategy for the treatment of many disease processes where NO is 
implicated. The purpose of this section is to discuss the theoretical basis behind the use 
of NO related therapeutics for treatment of stroke. 
 
1.3.1 NO synthesis 
In 1980 it was demonstrated that endothelial cells release a potent vasodilating 
substance called endothelium derived relaxing factor (EDRF).66 It was later established 
that NO accounted for the biological activity of this substance67, and that many other 
types of eukaryotic cells were also capable of synthesising it.68 NO is a gas that is water-
soluble and can freely diffuse across biological membranes. It is synthesised from L-
arginine (L-Arg) by the enzyme NOS in the presence of several co-factors, including 
nicotinamide adenine dinucleotide phosphate (NADPH), flavin adenine dinucleotide 
(FAD), flavin mononucleide (FMN), and tetrahydrobiopterin (BH4). 
 
Three distinct isoforms of NOS have been isolated, and these can be divided into 
constitutive and inducible subtypes. The constitutive forms of NOS are expressed under 
‘basal’ conditions and are labelled neuronal NOS (nNOS, NOS I) and endothelial NOS 
(eNOS, NOS III). These are calcium dependent enzymes and are preferentially, but not 
exclusively, associated with the nervous system and endothelium respectively. In 
contrast, a calcium independent, inducible NOS (iNOS, NOS II) exists that is produced 
by many cell types in response to endotoxins or cytokines. Expression of this protein 
occurs over a number of hours and results in higher concentrations of NO than is 
produced by the constitutive forms of NOS.69  
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1.3.2 General functions of NO 
NO is a ‘multimodal’ molecule with complex actions that can be either detrimental or 
beneficial in differing pathological and physiological situations. The main physiological 
effects of NO are mediated through activation of soluble guanylate cyclase (SGC) in 
smooth muscle cells, platelets, leucocytes, neurones and other cells to increase levels of 
the secondary messenger cyclic GMP (cGMP)70 (Figure 1.1). However, NO is a free 
radical and by virtue of it’s unpaired electron it can interact directly with other molecules 
to produce cGMP independent effects. For example, NO can react with reactive oxygen 
species like superoxide anion radical (O2.-) to produce peroxynitrite. This can disrupt 
many cellular processes through direct oxidising effects and by altering protein 
conformation through a process termed nitration.71  
 
Under physiological conditions, and when released in small controlled amounts, NO is 
involved in the regulation of several important biological processes. In the cardiovascular 
system, NO acts as a mediator of vascular tone and blood flow.72 The release of NO 
within the vascular tree primarily occurs in response to increased shear stress on blood 
vessels.73 Vasodilation then occurs via activation of cGMP in smooth muscle cells. In this 
way NO not only participates in the control of vascular tone, but contributes to BP 
control74 and regulates blood flow distribution in vascular beds75 (e.g., brain, skeletal 
muscle76, penile erection77). In addition, NO acts to protect the vascular endothelium 
against atherosclerosis. It may achieve this through several processes including; 
suppression of leukocyte migration and adhesion to endothelium78,79, antiproliferative 
effects on vascular smooth muscle cells80, and reducing lipoprotein oxidation and 
absorption into blood vessels.81 Moreover, NO has antiplatelet properties, and protects 
against thrombosis by inhibiting platelet adhesion and aggregation.75   
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NO has many additional roles outside of the cardiovascular system. Interestingly, it 
appears to be able to either promote or prevent cellular inflammation and death. 
Evidence shows that NO can be anti-inflammatory through several activities including; 
inhibition of the maturation of cytokines, such as interleukin -18 and interleukin -1ß82, 
blocking effects of interferon γ83, and preventing the expression of cellular adhesion 
molecules via effects on nuclear transcription factor - κB (NF-κB).83,84 Alternatively, NO 
can be pro-inflammatory by increasing expression of certain cytokines like tumour 
necrosis factor (TNFα) and interleukin – 6.83 Such disparities are also present in the case 
of cell death. For instance, NO is known to promote apoptosis by activation of caspases85 
and by direct damage to mitochondria, in association with peroxynitrite species.86 
Alternatively, however, NO can enhance neuronal survival by attenuation of Ca2+ influx 
via antagonism of the NMDA glutamate receptor.87  
 
The reasons for the dual effects of NO are unclear, although it may be that where there 
are high local concentrations of NO or where it is derived from a particular source (such 
as iNOS or nNOS) the toxic effects predominate. Similarly, the redox status of NO could 
be an important contributory mechanism since NO in the form NO· is neurodestructive 
via peroxynitrite formation as described above, whereas NO+ (which has one less 
electron) and NO- (with an extra electron) can interact with thiol groups on NMDA to 
reduce calcium influx88 (although interestingly, it is still controversial as to whether NO- 
and NO+ have any role at physiological pH).  
 
The toxic effects of NO are employed to our benefit by the immune system. In particular 
iNOS derived NO, produced in high concentrations, can attack several targets in micro 
organisms. In viruses, there is evidence that NO interferes with enzymes containing 
cysteine residues (e.g. reverse transcriptase) and viral encoded transcription factors.89 
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Moreover, NO has a pivotal role in defence against parasites, e.g. malaria90 and is 
bactericidal against a large range of bacterial pathogens in vitro and in vivo.89  
 
Finally, NO has a role in cell signalling and neurotransmission. Several studies have 
demonstrated that as well as activating soluble guanylate cyclase NO can stimulate other 
cellular signalling proteins, e.g. poly (ADP-ribose) synthetase, or inhibit others, e.g. 
adenylate cyclase type 1, protein kinase C, and cytochrome P450.83 Furthermore, NO 
released from nitrergic neurones has a role in modulating the release of 
neurotransmitters at the neuromuscular junction.91 Likewise, some actions of the 
autonomic nervous system are mediated by NO. In particular, NO is thought to 
participate in the non-adrenergic, non-cholinergic (NANC) control of gut motility through a 
direct action on intestinal smooth muscle.92  
 
Altogether, when released in controlled amounts it is evident that NO plays a 
fundamental role in many biological processes. However, when this critical NO 
homeostasis is disturbed, leading to too much or too little NO, then tissue injury and 
disease can occur. Excess NO production has been linked to septic shock93 and arthritis. 
Similarly, NO deficiency states have been associated with acute stroke,94 hypertension95 
hypercholesterolemia, diabetes and atherosclerosis.96  
 
1.3.3 Role of NO in stroke  
Calcium influx plays a major part in neuronal death following stroke by up-regulating 
many detrimental intracellular signalling pathways and enzymes, including nNOS and 
eNOS. Consistent with up-regulation of NOS are findings of increased NO concentration 
in the cerebrospinal fluid (CSF) of patients with recent stroke.97,98 NO release in stroke 
appears to have positive as well as negative effects (Table 1.1). For instance, transgenic 
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mice which do not express eNOS develop larger infarcts after middle cerebral artery 
(MCA) occlusion and show decreased blood flow at the periphery of the ischaemic 
lesion99, supporting the notion that eNOS derived NO is neuroprotective. NO from this 
source probably exerts its beneficial effects in the vasculature, through maintaining CBF 
and by inhibiting platelet aggregation and leukocyte adhesion.100 However, these 
beneficial effects may be outweighed by synthesis of very large amounts of NO derived 
from nNOS. The detrimental effects of nNOS derived NO were confirmed by the 
observation that nNOS deficient transgenic mice showed reduced infarct volumes 
compared with controls after focal MCA occlusion.101 Several destructive properties of 
high local concentrations of NO may be involved here, such as production of peroxynitrite 
reactive oxygen species and direct DNA and mitochondrial damage.  
 
The molecular cascade that follows excitotoxicity also includes several delayed neuro-
destructive processes, including inflammation and programmed cell death (apoptosis).102 
NO is known to contribute to both of these processes, but appears to have a major role in 
neurotoxicity due to inflammation. In particular NO derived from iNOS, which starts to be 
expressed around 12 hours post stroke and is maximal after 48 hours103, is neurotoxic. 
Indeed, transgenic mice that are deficient in iNOS have smaller infarcts and better 
outcomes than controls when subjected to MCA occlusion.104 The mechanism by which 
iNOS derived NO causes damage is unclear, but may relate to the attraction of 
increasing numbers of inflammatory cells and release of damaging cytokines as well as 
the direct neurotoxic effects of uncontrolled NO production.105  
 
1.3.4 NO as a treatment for acute stroke 
A useful strategy might be to increase NO availability and thereby exploit its beneficial 
haemodynamic, anti-thrombotic, anti-inflammatory and neuroprotective properties. 
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Potentially useful sources of NO are its essential amino acid substrate L-Arg and 
pharmacological donors. Exogenous L-Arg appears to increase NO levels partly via the 
NOS pathway, but also by the release of other vasoactive substances and arginase 
enzyme.106,107 In contrast, NO donors are drugs that generate NO through mechanisms 
that are independent of NOS. Commonly used agents are the organic nitrates (e.g. 
glyceryl trinitrate, GTN, isosorbide dinitrate, ISDN), sodium nitroprusside (SNP), 
sydnonimines (e.g. molsidomine, SIN-1), S-nitrosothiols (e.g. s-nitrosoglutathione), 
NONOates (e.g. SPERMINE-NONOate, DETA-NONOate), and hybrid donors (e.g. 
nitroaspirins, nicorandil). Pre-clinical studies of these agents have given variable results 
for effects on lesion size and CBF in animal models of cerebral ischaemia (table 1.2) 
 
An alternative strategy is to pharmacologically reduce NO availability and therefore limit 
its pro-inflammatory and neurotoxic properties. A large number of compounds exist that 
can reduce NO by inhibiting the three forms of NOS enzyme (table 1.3). The first NOS 
inhibitors were the guanidino aminoacids, many of which act competitively at the NOS 
active site. Examples include, NG-nitro-L-arginine (L-NNA), NG-nitro-L-arginine methyl 
ester (L-NAME, a methyl ester pro-drug that is activated to become L-NNA) and NG-
monomethyl-L-arginine (L-NMMA). Both L-NAME and L-NNA exhibit greater in-vitro 
potency than L-NMMA in inhibiting nNOS and eNOS versus iNOS. However, none of the 
guanidino aminoacids discriminate sufficiently to enable them to be used to target a 
single NOS isoform. By contrast, some inhibitors possess higher affinity against one or 
other isoform and are commonly referred to as ‘selective’ inhibitors, although this term is 
used rather indiscriminately.108 Agents that are used to target iNOS include: 
aminoguanidine, NG-iminoethyl-L-lysine (L-NIL), NG-iminoethyl-L-ornithine (L-NIO), the 
bis-isothioureas (PBITU)109, 1400W (N-[3-(aminomethyl)benzyl]acetamidine), GW273629 
and GW274150.110 Other agents are used to target nNOS and include: 7-nitroindinazole 
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(7-NI), tri(fluoromethylphenyl)imidazole (TRIM)111, ARL 17477, AR-R18512112, BN 
80933113, S-ethyl and S-methyl thiocitrulline and vinyl L-NIO. Recent in-vitro studies have 
suggested that in some cases the distinction between selective iNOS and selective 
nNOS inhibitor may not be straightforward. For example, aminoguanidine is only mildly 
selective against nNOS in-vitro (~5 fold) and probably affects other molecular targets.108 
Similarly, 7-NI has been found to be an equipotent inhibitor of all three isoforms of NOS 
at the isolated enzyme level108,114 although it has more selectivity for nNOS in vivo, 
possibly a consequence of cell specific effects (neuronal verses endothelial).108 Again, 
pre-clinical studies of NOS inhibitors have given variable results for effects on lesion size 
and CBF in animal models of cerebral ischaemia (table1.2) 
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1.4 High BP – a potential therapeutic target in acute stroke 
 
Disturbances of physiological parameters are common in the setting of acute stroke. 75-
82% of strokes present with high BP (systolic BP > 140mmHg).35,115 Subsequently BP 
normalises in about 60% of patients over a period of 4 to 10 days.116,117 The causes of 
high BP are multifactorial and relate in part to activation of the sympathetic nervous 
system, renin-angiotensin axis, previous hypertension, increased CO, cortisol / stress 
response and ‘white coat hypertension’.118-122 By contrast, low BP (systolic BP < 140 
mmHg) is less common, occurring in approximately 18-25% of acute stroke patients.35,115  
 
1.4.1 Relationship of acute BP with stroke outcome 
In observational studies both high23,123-134 and low BP135 have been linked to poor 
outcome. Hence, BP might be related to stroke recovery by a ‘U’ or ‘J’ shaped curve. 
Evidence in favour of this comes from observational studies136,137 and the International 
Stroke Trial, where the best outcome occurred at a systolic pressure of 140-
160mmHg.138 Why high BP should relate to poor outcome is not clear.139 In IS it may 
involve early re-infarction138,140, or promotion of cerebral oedema138,141, although 
interestingly not haemorrhagic transformation.138 In haemorrhagic stroke high BP might 
promote continued intracerebral bleeding.142 Low BP may be related to poor outcome in 
IS through increased coronary events.138 Other studies directly contradict these findings 
and suggest that high BP might be protective in the acute phase.143-146 Possibly this is 
because acute stroke impairs cerebral autoregulation147,148, vascular reactivity149 and the 
autonomic nervous system150, making the brain prone to hypoperfusion when exposed to 
low BP. More studies are required to better understand the relationship between BP and 
outcome in acute stroke. 
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1.4.2 Acute BP lowering 
If high BP is associated with increased mortality and dependency then lowering it might 
lead to improved outcome. However, there is a risk that actively lowering BP could result 
in cerebral hypoperfusion because of impaired cerebrovascular control. Also, case 
reports of negative outcome in treated patients and findings from some trials, like the 
INWEST trial of nimodipine151, have raised additional concerns. Recent work is beginning 
to strengthen the case for a more aggressive approach with the discovery that some 
classes of antihypertensive drugs do not have detrimental effects on CBF in acute stroke 
(section 1.4.4). Results are urgently required from large trials of BP lowering in acute 
stroke to help settle this debate. Similarly, trials are required to determine whether the 
40% of stroke patients who are admitted on prior antihypertensive agents should stop or 
continue therapy.  
 
1.4.3 Indications for BP lowering 
Indications for intervention in hypertensive stroke patients vary in available 
guidelines.152,153 Stable patients should be observed for a period of time since BP tends 
to fluctuate in acute stroke and can spontaneously fall.116 Therapy is recommended when 
there is associated hypertensive encephalopathy, heart failure, myocardial ischaemia, 
aortic dissection or continued intracerebral bleeding.152,153 A specific BP threshold 
requiring intervention is not known. There are many suggestions in the literature, e.g. 
systolic pressures greater than 180-240mmHg and diastolic pressures from 105-
130mmHg in different guidelines. Where thrombolysis for IS is planned several trials 
have used the lower thresholds in these ranges.154 This is because there was evidence 
of increased rates of PICH in hypertensive stroke patients treated with alteplase.  
 
1.4.4 Which agent? 
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There is still no definitive, large randomised controlled trial (RCT) that favours any 
particular agent and the existing data argues both for and against different 
antihypertensive classes.  
 
Calcium antagonists. These were investigated as potential neuroprotective agents. A 
recent meta-analysis of 11 trials revealed a non-significant trend to increased case 
fatality and disability (OR 1.28, 95%CI 0.98, 1.67) in the presence of significant 
reductions in BP.155 Additionally, a post-hoc analysis of data from the INWEST trial found 
an association between diastolic BP reduction and neurological deterioration following 
i.v. nimodipine administration.156 Furthermore, some evidence suggests that calcium 
antagonists reduce regional CBF in stroke patients157 and have mild antiplatelet effects 
that might preclude their use in PICH.158 Hence, calcium channel blockers are not 
recommended. 
 
Beta blockers. Beta blockers are commonly used in the treatment of hypertensive 
emergencies, although it is less clear whether these drugs are appropriate for use in 
acute stroke. In one case series labetolol was given to PICH patients with no apparent 
detrimental effects.159 The only controlled trial of these agents was disappointing in that it 
found a non-significant increase in mortality and a decrease in neurological outcome in 
patients receiving the active treatment.55  
 
Diuretics. Thiazide diuretics are of proven benefit in primary and secondary stroke 
prevention. However, they did not alter BP in the immediate post stroke phase in one 
clinical trial.160 
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NO donors. Drugs that donate exogenous NO, like GTN, have been used for more than 
a century in vascular medicine. Some of these agents have been investigated for their 
therapeutic potential in animal stroke models because of possible neuroprotective 
qualities (table 1.2). Clinical trials in patients have been concerned more with possible 
haemodynamic benefits. NO donors may be particularly efficacious antihypertensive 
agents in stroke because of their concomitant cerebral vasodilatory properties.161 In one 
clinical study SNP was given to 15 acute stroke patients within 12 hours of ictus at a 
dose sufficient to reduce mean arterial BP by 10mmHg.162 Effects on regional CBF (using 
single photon emission computerised tomography - SPECT) and platelet function (whole 
blood aggregation and flow cytometry) were assessed. SNP significantly reduced platelet 
aggregation. In addition, in 3 out of the 4 patients who underwent SPECT scanning, there 
appeared to improvements in penumbral CBF related to treatment with SNP. However, 
there are limitations to the widespread use of SNP in stroke patients. Most importantly, 
its effects on BP require close monitoring since high doses can cause hypotension163 and 
can actually be detrimental in stroke.164 Similarly, infusions that last longer than 72 hours 
can lead to production of cyanide metabolite.165 More recently, two clinical trials have 
studied 5mg-10mg GTN patches given transdermally. A patch is a very practical means 
of delivering NO therapy to patients who can’t swallow safely. In one study, a 12-day 
course of transdermal GTN (5mg) or placebo was administered within 5 days of stroke 
onset to 37 patients.166 GTN significantly reduced 24 hour systolic and diastolic BP at 
days 1 and 7 respectively, and had no antiplatelet effect as measured by platelet 
aggregation studies and expression of platelet adhesion molecules. In the second 
study167 90 patients were randomised to a 10-day course of transdermal GTN (5mg, 5-
10mg or 10mg) patches or control. There was a similar antihypertensive effect on 24 
hour systolic and diastolic BP, which were lowered by 6.3% and 4.8% respectively in 
those on the 5 mg patch. In addition, there was no effect on indirect measures of CBF, 
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assessed by transcranial Doppler (TCD), suggesting that cerebral perfusion was 
maintained during the treatment period. Furthermore, in both studies the active drug was 
well tolerated, for example only one patient stopped GTN prematurely due to headache 
in the second trial, although there was evidence of limitation of therapeutic effect (nitrate 
tolerance) by the end of the treatment periods. Both studies were too small to assess 
effects on clinical outcome (death or death and dependency) and further assessment on 
regional CBF is required.168 A phase III trial (Efficacy of Nitric oxide in Stroke trial – 
ENOS) of 5mg GTN patches in ischaemic and haemorrhagic stroke is currently 
underway.169 Finally, another NO donor, better known as a treatment for ischaemic heart 
disease, has been investigated in stroke. Nicorandil is a hybrid compound consisting of 
an organic nitrate attached to N-[2-hydroxyethyl] nicotinamide vitamin group. It has a 
dual action, firstly via activation of cGMP to cause smooth muscle relaxation and 
secondly by opening K+ channels, leading to a shortening of muscle action potential and 
an indirect Ca2+ channel blocking effect.170 Taken orally, it is absorbed rapidly with 
minimal hepatic ‘first pass’ effect and it has the advantage of avoiding the problems of 
nitrate tolerance. Furthermore, in addition to its coronary vasodilating effect, nicorandil 
was shown to significantly increase CBF and reduce BP in one study of 9 stroke 
patients.171 
 
Angiotensin Converting Enzyme (ACE) inhibitors. Whilst ACE inhibitors (in 
combination with diuretics) are now well established for secondary prevention of 
cerebrovascular disease172,173, there is currently limited data available in the setting of 
acute stroke. In one study (12 patients) captopril was administered within 5 days of onset 
and the effects on regional CBF were monitored with SPECT.174 No significant changes 
in hemispheric blood flow or mean arterial BP were documented. These findings were 
subsequently confirmed in another small trial.157 In a further controlled trial the 
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administration of perindopril 2-7 days after IS did not alter total CBF, despite significant 
reductions in BP.175 None of these studies found an association with reduced death or 
death and dependency, however they were all too small to accurately assess this. A 
medium-sized RCT is presently investigating lisinopril.56  
 
Angiotensin receptor blockers (ARB). A recent but relatively small trial evaluated the 
use of candesartan in hypertensive IS patients (n=342).176 There was a significant 47.5% 
reduction in a secondary outcome comprising all-cause, cerebral and cardiovascular 
mortality, but there was no effect on the primary outcome (combined death and 
dependency) at 3months. Another trial assessed the effect of losartan 2-7 days after 
admission with stroke on 24 patients without occlusive carotid disease but with mean 
arterial BP between 110 and 145 mmHg.177 The effects on mean arterial BP, internal 
carotid artery (ICA) flow and CBF (using hexamethylpropyleneamine oxime SPECT) 
were measured. No change occurred in ICA flow, or cortical or hemispheric CBF despite 
a reduction in mean arterial BP of 9.5 mmHg in the treated patients. Further clinical trials 
of ARBs are now warranted, with the main emphasis being on clinical stroke outcome. 
 
Other antihypertensives. There is little evidence on the merits of other classes of 
antihypertensives, such as the alpha-blockers, hydralazine or centrally acting agents.178 
Work in animals suggests that the alpha-blockers might reduce recovery.179 
 
1.4.5 Acute BP elevation 
An alternative therapeutic strategy is the pharmacological elevation of BP in an attempt 
to improve stroke outcome by increasing intraluminal hydrostatic pressure, opening 
collaterals and improving penumbral perfusion.180 There are no definitive outcome 
studies that can justify the routine use of such therapy, although promising results were 
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reported in case series with dobutamine181, phenylephrene180, norepinephrine182 and 
levarterenol.183 However, other studies that used interventions which raise BP, including 
haemodilution184, aptiganel185, and diaspirin cross-linked haemoglobin186 were 
disappointing. In any case, prompt treatment with fluids should be instigated in any 
episode of hypotension relating to under-hydration, since increased plasma osmolality is 
a marker of increased mortality in stroke. 
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Figure 1.1 Schematic diagram of NO synthesis and action on smooth muscle cells.  
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 Table 1.1 Summary of effects of NOS isoforms in stroke. 
 
 
Isoform eNOS nNOS iNOS 
Main source Endothelium Neurones Macrophages 
Role in acute stroke Beneficial Detrimental Detrimental 
Result of gene knockout in stroke 
model 
Larger 
infarct 
Smaller 
infarct 
Smaller 
infarct 
Result of pharmacological knockout 
in stroke model 
Larger 
infarct 
Smaller 
infarct 
Smaller 
infarct 
 Table 1.2 NO donors and stroke. 
 
TYPE OF DONOR EXAMPLES COMMENTS 
Organic nitrates Glyceryl trinitrate (GTN)  Cerebral vasodilatory properties in normal volunteers.161 Beneficial haemodynamic 
effects demonstrated in stroke patients.166,167 Conveniently administered as a patch 
but tolerance is a problem. A definitive phase III trial is ongoing.169  
 Isosorbide dinitrate (ISDN) Neuroprotective effect demonstrated in one stroke model.187 
Organic nitrites Amyl nitrite No studies in stroke 
Inorganic nitroso-
compounds 
Sodium nitroprusside 
(SNP) 
Reduces infarct size in animal models.163,188,189 Several case series in humans 
show protection against SAH induced vasospasm. One small clinical trial 
demonstrated an antiplatelet effect in stroke patients.162 Unlikely to have wide utility 
because of several therapeutic limitations.  
Sydnonimines Molsidomine An oral NO donor. Does not improve outcome post MI.190 Not studied in stroke 
clinically. 
 3-Morpholinosydnonimine 
(SIN-1) 
An i.v. NO donor with short duration of action. Has antiplatelet and anti-atherogenic 
effects in animal models. Reduced infarct in one pre-clinical study189 but didn’t in 
another.191 
 CAS754 Reduced infarct size in one pre-clinical study.192 
S-nitrosothiols S-nitrosoglutathione 
(GSNO) 
Has a significant antiplatelet effect with relatively little haemodynamic compromise. 
Evidence in two trials of clinical benefit in patients with carotid artery disease.107,193 
 S-nitroso-N 
acetylpenillamine (SNAP) 
No studies in stroke. Reverses vasospasm in experimental SAH.194 
 S-nitrosocysteine (SNOC) No studies 
Diazeniumdiolates 
(NONOates) 
DETA NONOate Improved neurological outcome and increased neurogenesis in rats195, but did not 
effect infarct size in another pre-clinical model.191 
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 Spermine NONOate Reduced infarct volume and increased blood flow in one stroke model.163 
 DEA NONOate Not studied in stroke 
Mesionic oxatriazole 
derivatives 
GEA-3162 Not studied in stroke 
 GEA-3175 Not studied in stroke 
Hybrid NO donor 
drugs 
Nitroaspirins (NCX-4016, 
NCX-4215) 
Effective antiplatelet agents with less gastric toxicity than aspirin.196-198 
Neuroprotective in one animal model.199  
 Nicorandil Increased CBF in one small study of stroke patients.171 
Others Iron sulphur nitrosyls 
(sinitrodyl)  
No studies in stroke 
 FK-409 No studies in stroke 
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Table 1.3 NOS inhibitors and stroke 
 
TYPE OF INHIBITOR EXAMPLES COMMENTS 
L-Arg analogues NG-monomethyl-L-arginine (L-NMMA) Non-specific inhibitor causing hypertension, systemic 
vasoconstriction and reduced CBF in normal humans.200-202 
Unlikely to be of benefit in stroke.  
 NG-nitro-L-arginine methyl ester (L-
NAME) 
Widely used non-specific inhibitor. Contradictory effects 
demonstrated in stroke models.188,203-210 No clinical stroke 
studies. 
 NG-nitro-L-arginine (L-NNA) Widely used non-specific inhibitor. Contradictory effects 
demonstrated in stroke models.211-221 No clinical stroke 
studies. 
L-citrulline analogues S-methyl-L-thiocitrulline No stroke studies 
 S-ethyl-L-thiocitrulline No stroke studies 
Guanidines Aminoguanidine Partially selective iNOS inhibitor which exhibits 
neuroprotection up to 24 hours after experimental stroke.222-224 
No clinical stroke trials but well tolerated in humans. 
Mercapto-alkyl-guanidines 2-Mercaptoethyl guanidine No stroke studies 
Isothioureas S-isopropyl-isothiourea No stroke studies 
 S-methyl-isothiourea No stroke studies 
Bis-isothioureas N-(3-(Aminomethyl)benzyl)acetamidine 
(1400W) 
Selective iNOS inhibitor which significantly reduces stroke 
volume and improves outcome in animal models.225 
Indazoles  7-Nitroindazole (7-NI) Partially selective nNOS inhibitor. Reduces infarct in animal 
models210,226,227, but can also reduce CBF.228 No clinical 
studies. 
 Trimethylphenylfluoroimidazole No stroke studies 
Heterocyclic substituted 
amidines 
AR-R17477 A nNOS inhibitor. Pre-clinical studies show a bell shaped dose 
response curve for infarct volume reduction.112 Some 
detrimental effects on CBF.112 
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Acetamidine derivatives GW273629, GW274150 Selective iNOS inhibitors. No studies in stroke 
Neuroprotectants which 
also influence NOS 
Lubeluzole 
 
Development discontinued 
 PBN derivatives (CPI-22) Promising in phase II studies. Further development expected. 
  
 
 
 
Chapter 2. 
General Methods 
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2.1 Cardiac Haemodynamics 
 
2.1.1 BP Measurement 
Background 
Early electronic BP monitors were inaccurate229, but recent models have shown good 
agreement with intra-arterial and Korotkoff sound measurements.230,231 In 2001 23 
devices had been tested against the British Hypertension Society (BHS)232 and 
Association for the Advancement of Medical Instrumentation (AAMI)233 protocols, 
however only 5 passed.232 Nevertheless there are considerable advantages to using 
validated monitors. For instance, no transducer needs to be placed over the brachial 
artery, so cuff placement is not critical. In addition, the lack of a requirement for 
auscultation makes it a suitable technique for ambulatory monitoring. Lastly, inaccuracies 
can occur with conventional sphygmomanometry due to observer error and terminal digit 
preference. These can be avoided using electronic monitors.234 
 
Method 
The patient was sat at 45o and the non-hemiparetic arm was held horizontally at 
midsternal level. All restrictive clothing was removed. An appropriate sized cuff was then 
applied to the arm so that the tubing was over the position of maximal pulsation of the 
brachial artery. The cuff was connected to a validated electronic device (Omron HEM-
705CP, Omron Corp, Tokyo, Japan, figure 2.0). This digital readout oscillometric device, 
which inflates and deflates the cuff at the push of a button, was selected because 
previous work has shown that it is reliable and complies with AAMI and BHS 
standards.235 Two or three readings were taken and mean values of systolic BP and 
diastolic BP were determined.  
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2.1.2 Cardiac Output Measurement 
Background 
The blood volume of the finger varies with each cardiac cycle because of changes in 
arterial BP. An infrared plethysmograph can detect this variation. If a pneumatic finger 
cuff can be inflated and deflated quickly enough to maintain a constant finger blood 
volume (when the arterial wall is said to be ‘unloaded’) then the cuff pressure must be 
equal to the intra-arterial pressure.236 The first device that exploited this principal, known 
as the volume-clamp technique, was the Finapres. Validation studies have demonstrated 
comparable BP values to intra-arterial recordings.237,238 A new portable version of the 
Finapres has subsequently become available, called the Portapres. This device can be 
used to measure 24-hour ambulatory beat to beat BP since it can be worn on a belt.  
 
The 7 channel version of Portapres records continuous non-invasive finger BP waveform, 
height compensation data, beat to beat BP (systolic BP, diastolic BP, mean arterial BP), 
heart rate and interbeat interval.236 BP measurements from Portapres have been 
validated against intrabrachial measurements.239 Both Finapres and Portapres can also 
be used to non-invasively measure cardiac output (CO) by the Modelflow method. This 
computes stroke volume (SV) from the arterial pressure wave, taking into account 
pressure and age dependent compliance of the aorta, as well as heart rate to correct for 
wave reflections.240 CO is then calculated by multiplying SV by heart rate (CO = SV x 
HR). Studies in patients with cardiovascular disease show that Modelflow values from 
arterial pressure accurately track changes in CO when compared with thermodilution 
based estimates.240-242  
 
Method 
 42 
Patient information (sex, age, weight and height) was entered into the main unit of the 
Portapres model-2 (TNO-TPD Biomedical Instrumentation, figure 2.1). The subject was 
sat at 45o and the front-end box was applied to the non-hemiparetic arm. Next, the height 
correction unit was fixed at the level of the apex beat (usually 5th left mid clavicular line) 
and an appropriate sized finger cuff was selected and applied to the middle phalanx of 
the middle finger (figure 2.2). Measurements were taken for 5 minutes and were 
monitored using the BeatScope 2 software (TNO-TPD Biomedical Instrumentation) on a 
laptop computer (Toshiba, Japan). The same software was used to calculate CO by the 
Modelflow method from the arterial pressure waveform. All subsequent measurements 
were taken using the same arm and with the same sized finger cuff.  
 
2.1.3 Pulse wave analysis 
Background 
BP measurements from the brachial artery are widely used in clinical trials, however the 
brachial artery is not subject to the adverse effects of atherosclerosis like the major 
central arteries. Moreover, the onset of left ventricular damage is more likely to be 
influenced by the pressure in the aorta rather than in the arm. Hence it can be argued 
that peripheral BP measurement might not be the best way to assess future risk of 
cardiovascular disease. Instead, measurement of central haemodynamics derived from 
the aortic pulse waveform may be better indicators.  
 
The aortic arterial pressure wave may be simply and rapidly assessed by means of 
applanation tonometry. This technique involves compressing a peripheral artery against 
its underlying structures with a micromanometer tipped probe. The intra-arterial pulse 
pressure is transmitted through the arterial wall to the sensor and can be displayed on a 
sphygmograph. A computer, which is calibrated using brachial BP, calculates the central 
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aortic pressure and waveform from the peripheral waveform. This requires the use of a 
mathematical equation called the ‘generalised transfer function’. This has been validated 
in a number of studies243-245, although there are some concerns that it may not be 
accurate when calibration is done non-invasively.246  
 
Once the aortic pulse wave has been calculated it is possible to determine central BP 
values and a measure of central compliance called the augmentation index (AI). The AI 
is calculated as the difference between peak 2 (P2) and peak 1 (P1) of the aortic pulse 
(see figure 2.3), expressed as a percentage of pulse pressure (PP). AI is negative in 
healthy young people, but increases becoming positive with aging or increasing 
cardiovascular risk. It is strongly influenced by pulse wave velocity (PWV), since this 
determines the timing of arrival of P2. It is also affected by mean arterial BP247, heart 
rate248 and height.249 Various cross-sectional studies have demonstrated increases in AI 
in populations with high cardiovascular disease risk, such as type-1 diabetes250, 
hypercholesterolemia251 and increased age.252 As of yet there are no data on the 
prognostic value of AI when derived from the radial artery. However, carotid artery 
measurements independently predict all cause and cardiovascular mortality in patients 
with renal failure.253  
 
In addition to AI, Buckberg et al have demonstrated that the ratio of the area of the 
diastolic to the systolic phase in the aortic pulse has a close correlation with the blood 
supply to the subendocardium in animals.254 This ratio was designated as the 
subendocardial viability ratio (SEVR) or Buckberg index (BI). Low SEVR is associated 
with the presence of coronary heart disease risk factors255 and predicts death after 
coronary surgery.256  
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Method 
Initially, brachial BP was recorded twice in the non-hemiparetic arm using a validated 
automatic sphygmomanometer (Omron 705CP, Japan). The mean systolic BP and 
diastolic BP were then entered into the pulse wave analysis software (Sphygmocor Pulse 
Wave Analysis System, Sydney, Australia) along with standard patient demographics. 
Next the non-hemiparetic wrist was rested on a stable surface and gently extended to 
expose the radial artery. The strongest location of the radial pulse was found by placing 
the index and ring finger over the artery. A micromanometer tipped probe (a tonometer) 
was then used to compress the radial pulse against the underlying bone until a 
characteristic sphygmograph was found (figure 2.4). Once a consistent pressure 
waveform was displayed a recording was made for 10 seconds before the data were 
captured. Measurements were taken until two satisfied the quality control system built in 
to the software (pulse height and variability ≤ 10%). All subsequent readings were taken 
from the same arm and the mean values for central systolic BP, diastolic BP, mean 
arterial BP, BI and AI were extracted for analysis. 
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2.2 Cerebral Haemodynamics 
 
2.2.1 Transcranial Doppler (TCD) 
Background 
TCD uses an ultrasound transducer to emit high frequency sound waves that reflect off 
the surfaces of moving erythrocytes in blood vessels. The transducer detects the 
frequency shift in the reflected waves and a computer displays the data. Before the 
signal can be viewed it is processed so that the three-dimensional Doppler data (time, 
frequency and signal intensity) can be displayed in a colour coded two-dimensional 
format (Spectral analysis). A ‘Fast Fourier Transformation’ is used to make this 
conversion.  
 
In a typical examination several blood flow parameters are measured directly, such as 
peak systolic velocity (PSV), end diastolic velocity (EDV) and direction of blood flow. 
Other parameters can be derived through calculations, such as mean flow velocity 
(MFV), pulsatility index (PI) and resistance index (RI). The PI (or Gosling Index) is used 
to describe the shape of the waveform and is calculated by the formula PI = (PSV-
EDV)/MFV. Likewise, the RI (or Pourcelot Index) is calculated by the formula RI = (PV-
EDV)/PV. Both of these parameters act as an index of vascular resistance distal to the 
point of insonation, and in general they decrease as resistance decreases. As humans 
age PI tends to increase and velocity gradually decreases, probably because of reduced 
vascular compliance.257 Typical values for MFV and PI in healthy elderly (>60yrs) 
volunteers are shown in table 2.1.257 
 
Haemodynamic abnormalities on TCD have been found to correlate well with the 
presence of intracranial stenosis or occlusion.258 Common anomalies are focal increases 
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in MFV (~ >30% of normal) and dampened or blunted waveforms. For example, a PSV 
above 90 cm/sec is 99% specific for the presence of MCA stenosis.259 In contrast, the 
relationship between velocity determined by TCD and CBF is much less certain. One 
article found a good correlation between the absolute velocity and absolute CBF 
measured by Xe 133 SPECT260, however this was not supported by subsequent 
studies.261,262 Similarly, several investigators have studied the relationship between 
changes in blood velocity and changes in regional CBF. Again, the results were variable 
with some in favour262-265 and some against.161,260,266 Hence, blood velocity is probably 
not a good indicator of CBF, although research is still ongoing in this area.  
 
Method 
A Nicolet EME Companion TCD system was used connected to a 2 Mhz probe. Initially 
the patient was placed in a supine position in bed with the Doppler equipment near to 
hand. A small amount of ultrasound gel (Aquasonic 100, Parker laboratories USA) was 
applied to the patient’s skin in the trans-temporal window. This area is located over the 
temporal bone, just superior to the zygomatic arch (figure 2.5). Next the TCD was 
adjusted to record at a depth of 56mm using a 10mm sample size. The signal power was 
adjusted to the lowest possible setting according to FDA guidelines. Then the probe was 
placed flat against the skin and gently manoeuvred until an audible Doppler signal 
originating from as near as possible to the M1 segment of the MCA was found. The TCD 
settings were adjusted in order to obtain the highest possible velocity before 
measurements of PSV, EDV, MFV, PI and RI were made. Finally the procedure was 
repeated on the contralateral MCA. A typical MCA waveform is shown in figure 2.6. 
 
2.2.2 Xenon CT (XeCT) 
Background 
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Stable (non-radioactive) xenon (Xe) is a highly lipid soluble gas which can freely cross 
the blood brain barrier. The radio-density of Xe was first recognised in 1966267, however 
it took another decade before it was first used as a contrast agent for CT.268 Like most 
methods for measuring CBF, the XeCT technique is based on the Fick principal of 
indicator dilution.269 This states that the concentration of an indicator absorbed in a tissue 
per unit time can be deduced from the difference in concentrations of the indicator in 
arterial and venous blood. Determination of the venous concentration is not necessary in 
XeCT since the CT scan can directly measure the time dependent concentration of Xe in 
the brain (CxeBr(t)) instead. This is done by initially obtaining two baseline scans at up to 
8 levels. Six enhanced scans are then taken at each level during a 4.5 minute Xe 
inhalation. The pairs of baseline scans are averaged and then subtracted from each of 
the enhancement images to yield CxeBr(t). Likewise, the time dependent concentration 
of Xe in the arterial blood (CxeArt(u)) can be determined from the (expired) end-tidal Xe 
measured by a thermoconductivity analyser. Both CxeBr(t) and CxeArt(u) are related 
mathematically to the affinity of the brain for Xe (λ - the blood brain partition coefficient) 
and the brain uptake flow constant (k), in a formula known as the Kety-Schmidt equation 
(modified for Xe): 
 
CxeBr(t) = λk∫ CxeArt(u)e-k(t-u)du 
 
Solving this equation enables calculation of the blood flow (F) from the second Kety-
Schmidt formula, F = λk.270 The image that results is a CBF map which uses a colour 
scale denoting the blood flow at each pixel on the image (figure 2.7). Numeric flow values 
(ml/min/100g) can be extracted by placing regions of interest (ROIs) of any shape or size 
on the image. Numeric values from small ROIs can be inaccurate. Accuracy improves as 
the ROI size increases until it reaches an acceptable error of ~12% at >1cm2.271  
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The validity of the XeCT has been confirmed in baboons using a radio labelled 
microsphere technique272-274 and a 14C iodoantipyrine technique for CBF measurements 
< 5ml/min/100g.275 Primate stroke models have also confirmed that Xe-CT provides a 
sensitive technique for acquiring serial CBF measurements following transient or 
permanent occlusion.276,277 In humans a number of studies have demonstrated good 
correlations between XeCT and CBF values obtained by SPECT278,279, CT 
perfusion280,281 and MR perfusion studies.282  
 
Although Xe is biologically inert administration can lead to side effects. At concentrations 
of <33% some individuals experience paraesthesiae, drunkenness and dizziness. Such 
symptoms are transient, but can cause patient motion and movement artefact. At higher 
concentrations (>71%)283 Xe has several properties of an ideal anaesthetic; including 
analgesic and hypnotic abilities, rapid induction and emergence, but negligible 
cardiovascular effects.284 Short periods of apnoea can occur in response to any 
concentration of Xe, probably through a direct effect on the medulla. In one study (1830 
subjects) the incidence of apnoea (>10 seconds) was 3.6%, however in no instance was 
this prolonged enough to require ventilatory assistance.285 Xe is known to cause cerebral 
vasodilation (flow activation), which has led to the suggestion that it should not be 
administered to patients with raised intracranial pressure.286 However, recent work 
suggests that flow activation is minimal with current protocols (< 5% increase in flow) and 
is reversed by mild hyperventilation.271  
 
Method 
The Enhancer 3000 unit (figure 2.8, Diversified Diagnostic Products XeCT system 2, 
Houston, USA) was switched on and connected to 100% oxygen (5-10psi, 3L/min) and 
 49 
an 80% Xe / 20% oxygen cylinder (5-10 psi, 10L/min, Air Products Plc, Crewe, UK). After 
the Enhancer had warmed up (~6 minutes) the internal re-breathing system was filled 
with a mix of 28% Xe / 25% oxygen. Meanwhile, the patient was positioned on the CT 
scanner (GE Medical Systems ‘Smalleye’ CT scanner, USA), with their head held by a 
vacuum beanbag (Olympic Medical, Seattle, USA) in order to limit movement artefact. 
Once they were comfortable a non-contrast CT head was performed to obtain a ‘scout’ 
so that XeCT images could be taken through the region of the stroke lesion. After this 
was complete the breathing interface between the patient and the Enhancer was set up. 
This consisted of a disposable face mask (Intersurgical Complete Respiratory Systems, 
Berkshire, UK), breathing circuit (Pennine Ventalink Derby, UK), CO2 sample tube 
(Vygon UK Ltd, Gloucestershire, UK) and a bacteriological filter (Pennine Ventalink 
Derby, UK). Since the mask prevented verbal communication patients were given 
instructions to use hand gestures to answer to any queries during the procedure. The 
facemask was then securely strapped to the patient’s head and the connections were 
checked for leaks. A good seal was confirmed by checking the expired CO2 
concentration on the XeCT computer (XeCT – NT software, Diversified Diagnostic 
Products, Houston, USA). The dynamic scanning protocol on the CT scanner was then 
started simultaneously with the Xe administration protocol. For the first 30 seconds the 
patient breathed in room air whilst the CT scanner took two baseline images at four 
levels. During the next 4 minutes 30 seconds the Enhancer entered the ‘wash-in’ phase 
and the patient was exposed to a mix of 28% Xe / 25% oxygen gas. End tidal Xe 
concentrations were measured in the expired air by a thermoconductivity analyser. A 
further 4 CT scans were taken at each level throughout this period, totalling 24 images 
altogether. A physician and a registered nurse were present in order to reassure the 
patient and monitor for apnoea. After the study was complete the patient was 
disconnected from the Enhancer and allowed to recover. A second XeCT scan was 
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repeated 1 hour after randomisation to treatment. During the intervening period patients 
were asked to remain on the CT scanner to ensure that the pre and post treatment CBF 
images came from similar axial planes. Patients that could not tolerate this had a second 
‘scout’ scan to confirm correct positioning prior to the second XeCT. 
 
CBF images were processed and analysed blinded to treatment using the XeCT – NT 
software. Before calculations were performed images with excessive movement artefact 
were discarded (where > 15% of the bone pixels moved compared with the 1st baseline 
image). Those that remained were used to produce CBF maps with a colour scale 
denoting the blood flow at each pixel (ml/min/100g). Global and hemispheric regions of 
interest (ROIs) were sited using a rectangular shaped template, the former touching the 
inside of the skull anteroposteriorly and laterally, and the latter dividing the skull at the 
midline. Anterior, middle and posterior cerebral artery territory ROIs were placed over the 
cortex using a template generated by the XeCT software (figure 2.7). An additional pixel 
based analysis was used to assess the effect of GTN on CBF in the stroke lesion, if 
visible. A rectangular ROI was placed to cover the whole of the stroke lesion and 
surrounding brain tissue. A CBF filter was then used to determine the number of pixels 
within the ROI matching pre-specified CBF values for ‘core’ <10 ml/min/100g, ‘penumbra’ 
10-19 ml/min/100g, and ‘oligaemia’ 20-36 ml/min/100g (figure 7.2b).287-290 Matching ROIs 
were sited on pre and post treatment scans to ensure consistency and the areas (in 
pixels) of reduced CBF compared. 
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2.3 Laboratory Methods 
 
2.3.1 NO measurement 
Background 
Measurement of NO in biological specimens is difficult because of the small amounts 
present (nanomolar) and because it reacts readily to produce oxidation products, such as 
nitrate (NO3-), nitrite (NO2-) and NO2. Most methodologies chemically trap NO with an 
adduct and then use one of several detection strategies291: 
 
i) Measure the adduct; for example, by spectrophotometry with a diazotisation 
assay292,293, or by electron paramagnetic resonance with nitroso or 
haemoglobin traps.294,295 
ii) Spectrophotometric measurement of the conversion of reduced haemoglobin 
to met haemoglobin.292,296 
iii) An amperometric method involving oxidation of NO at the surface of an 
electrode.297 
iv) Measure the light emission that occurs when ozone interacts with NO 
(chemiluminescence).67,74,298 
 
Chemiluminescence was the chosen method in this thesis since it is highly sensitive 
(detects < 1 part per billion of gas phase NO299) and allows large numbers of samples to 
be processed rapidly.291 In the chemiluminescence assay detection of NO is based on 
the observation that ozone interacts with NO to form excited state •NO2, which then emits 
a photon during conversion to its ground state: 
 
•NO + O3 → •NO2* (excited state) + O2 
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•NO2* → •NO2 (ground state) + photon 
 
The luminecesence that is generated is directly proportional to NO levels and can be 
detected by a sensitive photomultiplier tube (PMT). If the specimen is gaseous then it is 
simply mixed with ozone gas in the ‘reaction chamber’. Alternatively, if the specimen is 
liquid the NO has to be driven (‘stripped’) into the gas phase first. This is achieved by 
bubbling the solution in a sample chamber (or purge chamber, figure 2.9) with an inert 
gas under vacuum conditions. In addition, acids or reducing agents are sometimes 
added to transform previously formed oxidation products back to NO and enhance 
detection; e.g. vanadium and hydrochloric acid will convert nitrate and nitrite back to NO. 
However, since these agents also release biologically inactive NO from nitroso 
compounds, inorganic nitrites and nitrosamines, there is a risk that NO levels will be 
overestimated.300 The gaseous NO that is formed by this process is then carried to a 
separate chemiluminescence reaction chamber. A ‘needle valve’ is used to regulate the 
flow and ensure that no foam or bubbles get through. Additional measures to avoid 
aspiration of bubbles into the reaction chamber include the use of antifoaming agents 
and de-proteinising samples prior to analysis. Ozone (generated by electrical discharge) 
is then mixed with the gaseous NO in front of a PMT. The PMT should be red sensitive, 
as the light emission occurs between 660 and 900 nm, and should be cooled, since this 
improves the signal / noise ratio.291,301 The sensitivity threshold for detection of NO with 
chemiluminescence ranges between 20-50 pmol.67,302  
 
Method 
The NO assay was based on a method which has previously been published in detail.436 
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Sample preparation 
4.5ml citrated blood samples were taken from each patient at baseline and 60 minutes 
after treatment allocation. The samples were immediately centrifuged (Capricorn 
Laboratory Equipment, Hants, UK) at 3300 rpm for 12 minutes and the plasma was 
transferred to 5ml bijou bottles for storage at –80oC. When required, they were allowed to 
thaw at room temperature and vortexed (Vortex Genie 2, Scientific Industries Inc, New 
York, USA) to mix the contents. The plasma was then deproteinised by mixing 100µl with 
200µl of cold ethanol in microcentrifuge tubes. These were vortexed, allowed to stand at 
0oC for 30 minutes and then centrifuged at 13000 rpm (Biofuge Pico, Kendro Laboratory 
Products, Germany) for a further 15min. The deproteinised supernatant was then 
removed for NOx analysis. The three-fold dilution of each sample was accounted for in 
the final NO calculation. 
 
Preparation of the NO assay 
Plasma NO was measured by chemiluminescence using a Seivers 280 NO Analyser 
(Analytix Ltd, County Durham, UK). First the analyser was switched on and allowed to 
warm up for 20 minutes. The purge chamber (figure 2.9) was filled with 5ml filtered 
vanadium (111) chloride reducing agent and 100µl of antifoaming agent. The reducing 
agent was prepared by adding 0.8g of vanadium chloride (VCl3, Fischer Scientific, 
Leicester, UK) to a volumetric flask containing 1M hydrochloric acid (Fischer Scientific, 
Leicester, UK). The flask was inverted several times until the solution turned blue. Then 
the contents were filtered and stored in a refrigerator. The antifoaming agent (Seivers 
Instruments, Boulder, Colorado, USA) was prepared by adding 1ml to a volumetric flask 
containing 29 ml of double deionised water (1:30 dilution). This was also mixed 
thoroughly and stored in a refrigerator prior to use. For high conversion efficiency the 
purge chamber had to be heated to 90oC. This was done using a hot water bath that was 
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connected to a heating jacket surrounding the purge chamber. Hose clamps were used 
to secure the rubber tubing to the heating jacket and the fittings on the water bath. To 
minimise damage to the NO analyser from hydrochloric acid vapour the purge vessel 
outlet was connected to a condenser and a gas bubbler filled with 20ml 1M sodium 
hydroxide (Fischer Scientific, Leicester, UK). Nitrogen (Air Products Plc, Crewe, UK) at 
0.2 – 0.5 psi was then connected to the gas inlet of the purge vessel and the needle 
valve was adjusted until the ‘purging conditions’ were considered acceptable (when the 
‘reaction cell pressure’ on the NO analyser was approximately 6 – 7 torr).  
 
Calibration of the NO analyser 
85mg of sodium nitrate (Fischer Scientific, Leicester, UK) and 10ml double deionised 
water were added to a volumetric flask to make 100mM of stock solution. 1:10 
progressive serial dilutions were then performed to prepare a series of 1µM to 100µM 
standard solutions. A calibration curve was constructed by injecting 10µL of the 
standards into the purge vessel. 
 
Sample analysis 
A micro-syringe (Exmire Micro-syringe, Analtix Ltd, Co Durham, UK) was used to draw 
up 10µL of the sample and ‘pumped’ several times to remove any air bubbles. A paper 
towel was then used to wipe the outside of the needle before it was inserted into the 
purge vessel through an airtight septum. The plunger was then rapidly depressed to 
transfer the sample into the vessel. Before the next sample was inserted the syringe was 
removed, wiped and rinsed 2-3 times with de-ionised water.  
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2.3.2 P-selectin ELISA 
A commercially available P-selectin immunoassay kit was used (Parameter, Human 
soluble P-selectin immunoassay, R&D systems, Oxfordshire, UK). The kit’s instruction 
book was followed. 
 
Sample preparation 
7ml clotted blood samples were taken from each patient at baseline and 60 minutes after 
treatment allocation. The samples were immediately centrifuged (Capricorn Laboratory 
Equipment, Hants, UK) at 3300 rpm for 12 minutes and the serum was transferred to 5ml 
bijou bottles for storage at –80oC. When required, these were allowed to thaw at room 
temperature and vortexed to mix the contents. 15µl from each sample was transferred to 
appropriately labelled polypropylene tubes and diluted 20-fold with 285µl of Sample 
Diluent (containing buffered protein base with blue dye and preservative). 
 
Reagent preparation 
500ml of wash buffer was prepared by combining 20ml of buffer concentrate (containing 
buffered surfactant, with preservative) with 480ml of distilled water in a measuring 
cylinder. The six vials containing p-selectin standards (lypophilised recombinant human 
p-selectin with blue dye and preservative) were then reconstituted by adding 1.0ml of 
distilled water and mixed by gentle inversion to give a series of concentrations ranging 
from 0.0 – 46.0ng/ml. Next, the p-selectin control (lypophilised human serum containing 
p-selectin) was reconstituted by combining it with 500µl distilled water. This was left at 
room temperature for 10 minutes before a 20-fold dilution was prepared by combining 
15µl with 285µl of Sample Diluent. Finally, 250µl of Conjugate Concentrate (containing 
sheep polyclonal antibody to recombinant human p-selectin conjugated to horseradish 
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peroxidase in buffer, with preservative) was transferred into the bottle containing 
Conjugate Diluent. This was mixed thoroughly by gentle inversion. All reagents were 
brought to room temperature before use. 
 
Preparation of microtitre plate 
A microtitre plate, coated with mouse monoclonal antibody to human p-selectin, was set 
up with 96 wells. 100µL of the solution from the standards, samples and the p-selectin 
control was transferred (in duplicate) to each of the wells. 100µL aliquots of the diluted p-
selectin conjugate was then added to each well with sufficient force to ensure mixing. 
Next, the plate was covered with the lid provided and incubated at room temperature. 
After 1 hour the wells were rinsed three times with wash buffer using a multi-channel 
pipette. Residual buffer was removed by blotting the plate on tissue. Next, 100µL of 
substrate (containing tetramethylbenzidine) was transferred to all the wells and the plate 
was incubated at room temperature on a microtitre plate shaker (Ika Schuttler MTS 4, 
Germany). The reaction was halted at 15 minutes by the addition of 100µL of stop 
solution (containing acid) and the optical density was read at 450nm (Dynatech mr5000 
Plate Reader, Gurnsey, Channel Islands). 
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2.4 Statistical Methods 
 
2.4.1 General statistical methods 
Various parametric and nonparametric techniques were chosen according to the 
distribution and type of data to be examined. Microsoft Excel 2001 and SPSS v10.0 
computer packages were used to perform the analyses and generate figures. 
Significance was set at p<0.05. Precise details of statistical methods are highlighted in 
each relevant chapter. 
 
2.4.2 Systematic Review Methods 
Background 
A systematic review begins with a search for studies that are relevant to the topic of 
interest. Since only 30-80% of all known published randomised controlled trials can be 
found on MEDLINE303 it is important to use more than one search method. Studies that 
do not meet pre-specified inclusion criteria are then discarded. More than one reviewer at 
this stage will reduce the possibility that relevant reports are lost.304  
 
The statistical methods used to combine the results of the included studies are known as 
meta-analysis. This is a two-stage process. First a summary statistic is calculated for 
each study. For continuous data the mean difference (also known as weighted mean 
difference, WMD) and the standardised mean difference (SMD, also known as the ‘effect 
size’) are used. The former is required when the outcome measurements are made on 
the same scale and the latter is required when different measurement scales are used for 
the same outcome. Alternatively, for categorical data the risk ratio (RR), odds ratio (OR), 
risk difference (RD, also known as the absolute risk reduction) and number needed to 
treat305 are used as measures of effect.  
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In the second stage of a meta-analysis a summary (pooled) effect estimate is calculated 
as a weighted average of the effects in the individual studies. Several statistical methods 
exist that can be used to pool data. The approach that is chosen is determined, in part, 
by whether heterogeneity is expected. Heterogeneity is present when the differences in 
effect between the individual studies are more than can be explained by sampling 
variation (i.e. chance) alone. Common sources of variability are clinical diversity 
(differences in participants, interventions and outcomes studied) and methodological 
diversity (differences in trial design and quality).305 If heterogeneity is thought to be 
present then a ‘random effects model’ is used. Alternatively, if it can be assumed that 
differences in effect are purely a result of sampling variation, then a ‘fixed effect model’ is 
used. This assumption can be checked by performing a χ2 test on the effect 
measurements of the included studies. There are four widely used methods of meta-
analysis for dichotomous (categorical) data. Three of these use fixed effect models; the 
Mantel-Haenszel306, Peto307 and Inverse variance methods.308 The other, the 
DerSimionian and Laird method309, uses a random effects model. The Peto method can 
only pool OR whilst the other three methods can combine OR, RR and RD. When 
continuous measures of effect are pooled with a fixed effect model the inverse variance 
method is commonly used. By contrast, if a random effect model is needed the 
DerSimionian and Laird method can be applied. Alternative methods to the above exist, 
however they require advanced statistical software.  
 
Finally, a meta-analysis is displayed in a standard way known as a ‘forest plot’ (figure 
3.2a, b). The horizontal lines correspond to the 95%CI for each study, with the central 
box drawn proportional to the relative size (‘weight’) of the study. The diamond at the 
bottom of the figure is the summary estimate of all the individual studies combined. A 
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result to the left or right of the unbroken vertical line represents an overall positive or 
negative effect. By contrast, if the diamond crosses the line then this means that the 
systematic review is neutral.  
 
Method 
A protocol was designed for each systematic review. This defined the question being 
addressed, study inclusion / exclusion criteria, quality scales and the subgroups of 
interest. Studies matching the pre-specified criteria were then identified by me through 
systematic searches of two or three electronic databases; ‘Pubmed’, ‘EMBASE’ and 
‘Web of Science’. In addition, articles were found from review papers and reference lists. 
The abstracts from these were used to select relevant studies for a re-examination of the 
full publication against the review criteria. Final decisions on inclusion or exclusion were 
taken be me and independently by another researcher to limit bias. Discrepancies were 
resolved by the project supervisor. Articles included in the NO donor and NOS inhibitor 
reviews were also assessed for methodological quality on an 8 point scale.310  
 
Study data were grouped according to the protocol prior to analysis. Where numerical 
values were not available for extraction, data were taken directly from enlarged graphs 
using a ruler. All data extraction was performed independently and in duplicate by me 
and another researcher. Any discrepancies were resolved by the project supervisor. The 
Cochrane Collaboration Review Manager (RevMan version 4.1) software was used to 
analyse the data as forest plots. Dichotomous data were analysed as OR and continuous 
data were analysed as WMD or SMD with 95% CI. A random effects model was used 
since statistical heterogeneity, assessed with a χ2 test, was expected in view of the wide 
range of study protocols. Subgroup analyses were performed to look at suspected 
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sources of heterogeneity. Publication bias was assessed using funnel plots and Egger’s 
asymmetry test311 (Stata function ‘metabias’).Significance was set at P<0.05. 
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Figure 2.0 Omron HEM-705CP, Omron Corp, Tokyo, Japan 
 
 
 
 
 
 
 
Figure 2.1 Portapres, TNO-TPD Biomedical Instrumentation 
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Figure 2.2 Finger cuff applied to the middle phalanx of the middle finger  
 
 
 
 
 
 
 
Figure 2.3 Typical waveforms of aortic and brachial pulse 
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Figure 2.4 Applanation tonometry at the radial pulse 
 
 
 
 
 
 
Figure 2.5 Nicolet EME Companion TCD system.  
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Figure 2.6 A typical MCA waveform   
 
 
 
 
 
 
 
 
Figure 2.7 XeCT head showing right MCA infarct 
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Figure 2.8 Diversified Diagnostic Products XeCT system 2, Houston, USA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 NO analyser purge chamber 
 
 
 
 
 Table 2.1 Typical TCD findings in Elderly Patients 
 
Artery Window Artery 
 
Direction of 
blood flow 
Depth 
(mm) 
MFV, cm/sec 
(95%CI) 
PI 
(95%CI) 
RI 
(95%CI) 
Transtemporal MCA Towards 45-55 58 (55 – 61) 0.97 (0.93 – 1.02) 0.62 (0.60 – 0.64) 
 ACA Away 55-75 51 (48 –54) 0.92 (0.87 – 0.97) 0.59 (0.57 – 0.62) 
 PCA Towards 65-80 42 (40 – 45) 0.97 (0.91 – 1.02) 0.60 (0.58 – 0.62) 
       
Transforaminal VA Away 65-85 33 (30 - 36) 0.94 (0.89 – 0.99) 0.59 (0.57 – 0.61) 
 BA Away >85 35 (31 – 40) 0.95  (0.86 – 1.03) 0.60 (0.56 – 0.64) 
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Chapter 3. 
High BP in acute stroke and subsequent outcome: a 
systematic review 
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3.1 Abstract 
Background: High BP is common in acute stroke and might be associated with a poor 
outcome although observational studies have given varying results. Method: In a 
systematic review articles were sought which reported both admission BP and outcome 
(death, death or dependency, death or deterioration, stroke recurrence, haematoma 
expansion) in acute stroke. Data were analysed using the Cochrane Review Manager 
software and are given as OR or WMD with 95% CI. Result: Altogether, 32 studies were 
identified involving 10,892 patients. When including all data, death was significantly 
associated with an elevated mean arterial BP (OR 1.61, 95% CI 1.12, 2.31), and high 
diastolic BP (OR 1.71, 95% CI 1.33, 2.48). Combined death or dependency was 
associated with high systolic BP (OR 2.69, 95% CI 1.13, 6.40) and diastolic BP (OR 4.68 
95% CI 1.87, 11.70) in PICH. Similarly, high systolic BP (+11.73 mmHg, 95% CI 1.30, 
22.16), mean arterial BP (+9.00 mmHg, 95% CI 0.92, 17.08) and diastolic BP (+6.00 
mmHg, 95% CI 0.19, 11.81) were associated with death or dependency in IS. Combined 
death or deterioration was associated with a high systolic BP (OR 5.57, 95% CI 1.42 to 
21.86) in patients with PICH. Conclusion: High BP in acute IS or PICH is associated with 
subsequent death, death or dependency, and death or deterioration. Moderate lowering of 
BP might improve outcome. Acute BP lowering needs to be tested in one or more large 
randomised trials.  
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3.2 Background 
High BP (BP >140/90 mmHg, as defined by the WHO) occurs in acute stroke in up to 75% 
of cases.116,117 Subsequently, BP settles over a period of about a week although around 
40% of patients remain hypertensive. The causes of this pathophysiological response are 
multifactorial and relate to pre-existing high BP, activation of the neuroendocrine systems 
(sympathetic nervous system, renin-angiotensin axis, glucocorticoid system), increased 
CO, and ‘white coat hypertension’.118-122 
 
It has been suggested that high BP is associated with a poor outcome after acute stroke, 
although the results of observational studies have given conflicting results. Some authors 
have even demonstrated better outcome in patients with high initial BP.144,312 Data from 
the International Stroke Trial confirmed that the risk of early death and late death or 
dependency was independently associated with increasing systolic BP in 17,398 
patients.138 This chapter reports a systematic review of observational studies of BP and 
outcome, and assesses the relationship between the two. 
 
3.3 Methods 
Study identification 
Published observational studies which reported baseline BP and outcome (death, death or 
dependency, death or deterioration) or mechanisms for poor outcome (recurrent stroke, 
haemorrhagic transformation, development of cerebral oedema, haematoma expansion) in 
acute (<7 days) stroke were sought. Systematic searches of ‘EMBASE’ and ‘Pubmed’ 
were made. The search strategy employed 10 keywords: blood pressure, hypertension, 
outcome, prognosis, death, mortality, recovery, stroke, cerebr*, acute. Additional studies 
were found from reference lists of identified articles and review papers.139,313,314 Disability 
or dependency were typically measured using the Barthel Index or Rankin Scale; 
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deterioration was defined as worsening on a stroke neurological impairment scale, e.g. 
NIH stroke scale, or where an ordinal scale (e.g. ‘improved’, ‘unchanged’, ‘worse’) was 
used. Publications were excluded if they were a randomised trial (these tend not to enrol 
consecutive patients and may have a less representative sample), gave insufficient data, 
used other outcomes, or were duplicate articles. Decisions on inclusion and exclusion of 
studies were made by two researchers. 
 
Data extraction 
Two researchers independently extracted data; discrepancies were resolved by the project 
supervisor. Studies with dichotomous data were analysed separately from those with 
continuous data. Within both types, the studies were subdivided by outcome measurement 
(death, death or dependency, death or deterioration, stroke recurrence, cerebral oedema, 
haematoma expansion) and by BP measurement (systolic BP, diastolic BP, mean arterial 
BP). The articles were then arranged by stroke type (PICH, IS, or mixed). Figures 3.2a and 
3.2b show typical forest plots and illustrate the layout of studies. 
 
Where articles quoted several BP measurements the earliest readings were used. 
Outcomes after the longest follow-up period were used where they were present at 
multiple time points. Some articles gave outcome data for several BP strata (e.g. mortality 
with systolic BP <140 mmHg, 141–180 mmHg and >180 mmHg).315 In such instances the 
data were dichotomised into a high BP and a combined normal / low BP group using a cut 
nearest to 150 mmHg since outcome may be best at this level.138 Likewise, publications 
with diastolic BP or mean arterial BP in several strata were dichotomised as close as 
possible to 90 mmHg and 110 mmHg respectively. Additionally, some articles gave 
continuous BP data in more than two groups (e.g. systolic BP for patients with ‘improved’, 
‘unchanged’ or ‘worse’ neurological status). These studies were incorporated in the review 
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after the data were transformed into two groups (e.g. combined ‘improved’ / ‘unchanged’ 
and ‘worse’). This was achieved by generating pseudo-random BP data (assuming a 
normal distribution for BP) and then merging this before recalculating an overall combined 
mean BP and standard deviation.  
 
Analysis 
Data were analysed using the Cochrane Collaboration Review Manager (version 4.1) 
software. Dichotomous data are given as OR and 95% CI, and WMD with 95% CI for 
continuous data. These were calculated with a random effects model and statistical 
heterogeneity was assessed with a χ2 test. The causes of heterogeneity were examined 
using sensitivity analyses based on type of stroke. Publication bias was assessed using 
Egger’s asymmetry test311 (Stata function ‘metabias’) on dichotomous outcome data. 
Significance was set at P<0.05. 
 
3.4 Results 
A flow diagram illustrating the search process is given in figure 3.1. Altogether, 32 studies 
with a total of 10,892 patients (median size 184) were included. Eleven of these focussed 
on PICH, five on IS, and the rest included patients with either type of stroke. A further 64 
studies were excluded; 35 did not provide BP and/or outcome data in a suitable form, 26 
did not assess BP within seven days of onset, and 3 were duplicate publications. 
 
BP was recorded at admission in 18 of the included articles. The method used was given 
in only nine studies; five used ‘clinic’ BP measurement, three used both ‘clinic’ BP 
measurement and ambulatory BP monitoring (ABPM), and one used ABPM alone. The 
criteria used to define high BP varied considerably; systolic BP thresholds ranged 
from150-200 mmHg,127,131,132 mean arterial BP levels 140-145 mmHg,129,132 and diastolic 
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BP between 90-115 mmHg.132,134,316,317 One article did not specify the criteria used for 
defining high BP;318 this study was analysed with the publications that dichotomised 
according to mean arterial BP. In addition, three studies allocated subjects to the high BP 
group if either systolic BP or diastolic BP or both exceeded certain threshold 
values.124,128,133 These articles were also analysed with publications that dichotomised 
according to mean arterial BP.  
 
Death was the most commonly reported outcome measure (survival status present in 7242 
patients, 66.5%). There were fewer data for combined death or dependency (1290, 11.8%) 
and combined death or deterioration (1196, 11.0%). These outcomes were assessed 
using validated stroke scales in 7 articles (Rankin score130,148,319-321, Scandinavian 
Neurological Stroke Scale320,322, Canadian Neurological Score323, National Institutes of 
Health Scale130). The other studies either used non-validated scales144 or qualitative 
assessments such as discharge disposition.124,127 Patient follow-up varied considerably 
between 6 days and 6 years, although most articles chose to measure outcome at 
discharge from hospital. Potential mechanisms of poor outcome were reported in four 
articles. Three looked at PICH (708, 6.5%) and assessed the relationship between BP and 
haematoma expansion; the other study investigated early recurrence in IS (1273, 11.7%). 
No studies assessed cerebral oedema or haemorrhagic transformation. 
 
There was no publication bias (Egger’s test p=0.21) in articles reporting systolic BP and 
mortality data. When assessing stroke as a whole, patients with high systolic BP or 
diastolic BP were at a 1.5-5.0 fold increased risk of dying or combined death or 
dependency / deterioration (table 3.2). Similarly, high mean arterial BP was associated 
with an increased odds for combined death and dependency. In patients with poor 
outcome, judged as death and death or dependency / deterioration, there was a trend for 
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higher systolic BP and diastolic BP levels of 5/3 mmHg. Heterogeneity was present in 
several of these analyses (table 3.2) and so the data were further examined by stroke 
type. 
 
PICH  
Increased odds of death, and death or disability / deterioration were found in patients with 
high BP (table 3.3). Additionally, mean arterial BP was higher in patients who died after 
PICH (table 3.4). The odds of haematoma expansion was increased for patients with high 
systolic BP (table 3.2).  
 
IS 
Limited data were available for studies specifically including patients with IS. Systolic BP 
and diastolic BP were higher by 12/6 mmHg in patients who died or became dependent 
(table 3.4). Similarly, IS patients had a twofold increase in the risk of stroke recurrence if 
their diastolic BP was elevated (table 3.2). 
 
Mixed stroke studies 
The odds of death were doubled in patients with high diastolic BP. Systolic BP was higher 
by 6.39 mmHg in patients who subsequently died (table 3.4). 
 
3.5 Discussion 
High systolic BP, mean arterial BP and diastolic BP in the acute phase of stroke are 
associated with a poor outcome, assessed either as death, or combined death or disability, 
and possibly combined death or early deterioration. This observation was present 
irrespective of stroke type. The result, based on 32 studies involving 10,892 patients, is 
similar to that found in IST where a high systolic BP (>140 mmHg) was independently 
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related to an increased risk of early death, and combined death or dependency in 17,398 
patients with acute IS.138 The individual studies that form the basis of this systematic 
review were generally either positive or neutral for the association between BP and 
outcome. The neutral findings in some studies probably reflect their small size, and 
therefore, limited statistical power. Three articles found improved outcomes for high 
systolic BP144,322 and diastolic BP135; however, when analysed with other studies there was 
no evidence of a protective effect for high BP. 
 
This review has found evidence for mechanisms that may link high BP to poor outcome. In 
IS high diastolic BP was associated with a two-fold increase in the risk of early recurrence. 
systolic BP was an important determinant of recurrent stroke in IST where an initial systolic 
BP of 200 mmHg or more conferred a >50% higher risk of recurrence than that for a 
systolic BP of 130 mmHg.138 No studies investigating the relationship between BP and 
haemorrhagic transformation or cerebral oedema in IS fulfilled the inclusion criteria. 
Nevertheless, evidence that was excluded from the review suggests that an acutely 
elevated systolic BP is associated with increased fatal cerebral oedema.138,141 Also, 
several studies have observed that high BP promotes haemorrhagic transformation in 
animal models324-326, although this was not found in IST.138 As far as PICH is concerned, 
patients with high systolic BP were almost twice as likely to have haematoma expansion. 
This could support the concept that high BP in the acute phase of haemorrhagic stroke 
leads to worse outcome at least in part by promoting continued intracerebral bleeding. 
However, this relationship may be confounded by timing of inclusion since patients with 
severe PICH tend to present earlier and are at greater risk of re-bleeding. 
  
Although this review has demonstrated a positive association between high BP and 
subsequent events in acute stroke, the findings are limited by several factors. First, there 
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were considerable differences in patient eligibility, case mix (including baseline BP), 
definition of high BP, measurement and timing of BP, and type and timing of outcome 
between the studies. This could be considered an advantage since it means the 
relationships observed are more likely to be generalisable. However it may also have led 
to statistical heterogeneity. To assess whether stroke type was a potential source of 
heterogeneity in the review IS and PICH were analysed separately. The relationship 
between outcome and BP tended to be stronger in patients with PICH (OR 2.26-5.57) as 
compared with those with IS. Similarly, patients who had a poor outcome had a higher BP 
if they had PICH (mean arterial BP 11 mmHg) than IS (systolic BP and diastolic BP 12/6 
mmHg, equivalent to a mean arterial BP of ~8 mmHg). Nevertheless, these comparisons 
are indirect and not precise. Other explanations for heterogeneity between the studies are 
likely but it was impossible to explore these due to the paucity of data. 
 
A second limiting factor is that it was impossible to judge whether the relationships that 
were observed were independent of other factors such as age, premorbid BP status and 
drug therapy, stroke severity or timing of BP measurement. A mega-analysis of the 
studies, based on individual patient data, would be required to investigate this further. This 
issue is important since some of the relationships might have been different if potential 
confounding factors had been accounted for. For example, the relationship between BP 
and re-bleeding in PICH is probably mostly explained by an interaction between timing of 
BP measurement and severity.142,327 Likewise, high premorbid BP contributes to elevated 
BP in acute stroke and could contribute, in part, to poor outcome through previous cerebral 
vascular damage. Third, the strategy of dichotomising BP, while clinically relevant, may 
create artificial strata for the analysis. For example, several articles have reported a ‘U’ 
shaped relationship between BP and outcome, with the least bad outcome at a systolic BP 
of 140-160 mmHg in IST (judged by the nadir of the ‘U’).136-138 Hence, studies including a 
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significant proportion of patients with BP below a cut of 160 mmHg might be expected to 
miss a relationship between high BP and poor outcome. Unfortunately, since only one 
article gave sufficient data on low BP in acute stroke it was not possible to examine how it 
influenced outcome. Last, it is worth noting a consistent weakness in the observational 
studies themselves, namely the lack of reporting how BP was measured. All studies 
assessing BP should give information on equipment (manufacturer, model, technique, 
validation), user (how trained, assessed and re-assessed) and patient (number and site of 
readings, position).178 
 
In summary this chapter assesses data from all available observational studies and shows 
that there is a positive association between high BP and poor outcome in acute stroke. 
This relationship may be mediated, at least in part, by early recurrence in patients with IS 
and, possibly, by early re-bleeding in those with PICH. Although these relationships 
suggest that high admission BP is directly causal it cannot be ruled out that this 
relationship was independent of other factors such as stroke severity or timing of 
measurements. Nevertheless, since lowering a high BP prevents first and recurrent stroke, 
it can be hypothesised that moderate lowering of a high BP in acute stroke might similarly 
reduce early death and deterioration, and late death and dependency. 
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Table 3.1 Included studies. 
 
Study N Stroke type BP timing BP method BP 
data 
Outcome measure Outcome timing 
Acheson  134 497 M Admission Not given D Death 4.6 years 
(mean) 
Allen 144 148 M Admission, 24 
hours 
Not given C Death or dependency 2 and 6 months 
Armario 319 49 IS Admission and 
daily 
Not given C Death or dependency Discharge 
Bhalla 320 72 M < 1 day, 7 days  Manual, ABPM C Death or dependency 1 week 
Britton 124 388 M Admission Manual D Death; Death or 
dependency 
Discharge 
Brott 328 103 PICH < 3 hours Not given C Haematoma growth < 4 hours 
Carlberg 315 916 M Admission Manual D Death 30 days 
Dandapani 132 87 PICH Admission  Not given D Death; death or 
dependency 
30 days 
Dawson 148 92 IS < 3 days Manual, ABPM C Death or dependency 30 days 
Dunne 127 40 Cerebellar 
PICH 
Admission Not given D Death or deterioration 6 days 
Fogelhol 329 141 IS 
(brainstem) 
< 24 hours Not given C Death 46.5 months 
(median) 
Fogelholm 330 282 PICH < 24 hours Manual C Death 28 days 
Fuji 327 419 PICH < 24 hours Not given D Haematoma growth < 2 days 
Fullerton 331 206 M 12- 48 hours Not given C Death; death or 
dependency 
6 months 
Harmsen 128 97 M Admission Manual D Death Discharge 
Jorgensen 322 868 M Admission Not given C Death or deterioration Day 2, weekly; 
at discharge 
Kazui 142 186 PICH < 24 hours Not given C Haematoma growth < 5 days  
Latorre 332 200 M Admission Not given D Death Discharge 
Longo-Mbenza 
135
 
1032 M Admission Not given C Death Discharge 
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Marquarsden 316 371 M Admission, day 1, 
day 7 
Not given D Death 5 years 
Marshall 317 251 M Admission Not given D Death 6 years 
Mbala-Mukendi 
333
 
388 M Admission Not given C Death Discharge 
Panayiotou 126 55 M < 24 hours ABPM C Death 2 years 
Portenoy 318 112 PICH Admission Not given D Death or dependency At last recorded 
follow up 
Qureshi 129 182 PICH Admission Manual D Death Discharge 
Rankin 133 247 M < 7 days  Not given D Death Discharge 
Robinson 130 136 M < 24 hours Manual, ABPM C Death or dependency; 
death or deterioration 
30 days 
Sacco 140 1273 IS < 7 days Not given D Recurrent stroke 30 days 
Tennent 334 107 PICH Admission Not given D Death Discharge 
Terayama 335 1701 PICH < 24 hours Not given C Death Discharge 
Toni 323 152 IS < 5 hours Not given C Death or deterioration Discharge 
Tuhrim 131 94 PICH Admission Not given D Death  30 days 
PICH: intracerebral haemorrhage; IS: ischaemic stroke; M: mixed; C: continuous; D: dichotomous
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Table 3.2 BP in acute stroke by outcome. 
 
Dichotomous BP  Continuous BP  
        
Outcome 
Studies / 
subjects 
OR (95% CI) P Heterogeneity Studies / 
subjects 
WMD (95% CI) P Heterogeneity 
          
SBP 6 / 1211 1.85 (1.17,2.93) <0.01* 0.03* 5 / 1799 4.81 (-0.98,10.60) 0.10 0.04* 
MABP 6 / 1912 1.61 (1.12,2.31) 0.01* 0.15 2 / 1983 11.40 (8.21,14.58) <0.01* 0.27 
Death 
DBP 6 / 1655 1.71 (1.33,2.18) <0.01* 0.38 5 / 1799 -0.05 (-2.56,2.47) 1.00 0.23 
          
SBP 1 / 87 2.69 (1.13,6.40) 0.03*  6 / 691 5.11 (-3.00,13.22) 0.20 <0.01* 
MABP 3 / 587 1.92 (0.83,4.44) 0.13 0.05* 1 / 92 9.00 (0.92,17.08) 0.03*  
Death / disability 
DBP 1 / 87 4.68 
(1.87,11.70) 
<0.01*  6 / 691 2.55 (-1.53,6.62) 0.20 0.04* 
          
SBP 2 / 891 1.86 
(0.28,12.50) 
0.50 <0.01* 3 / 1155 -1.04 (-7.59,5.50) 0.80 0.21 Death / 
deterioration 
DBP     3 / 1155 0.59 (-3.55,4.73) 0.80 0.12 
          
SBP 1/ 1273 1.52 (0.80,2.88) 0.20      Recurrent stroke 
DBP 1 / 1273 2.19 (1.16,4.14) 0.02*      
          
SBP 2 / 600 1.93 (1.22,3.06) <0.01* 0.43 2/ 284 7.24   
(-2.63,17.10) 
0.15 0.31 PICH enlargement 
DBP 1 / 180 1.14 (0.47,2.75) 0.80  2/ 284 0.81 (-4.57,6.19) 0.80 0.76 
 
80 
Table 3.3 Outcome by type of stroke for dichotomous data. 
 
 
PICH Infarct Mixed 
         
Outcome 
Studies / 
subjects 
OR 
 (95% CI) 
P Studies / 
subjects 
OR  
(95% CI) 
P Studies / 
subjects 
OR  
(95% CI) 
P 
           
SBP 3 / 244 3.55 
(1.80,7.00) 
<0.01*    3 / 967 1.40 
(0.85,2.30) 
0.18 
MABP 3 / 354 2.26 
(1.40,3.66) 
<0.01* 1 / 831 0.96 
(0.60,1.54) 
0.90 3 / 727 1.56 
(0.98,2.48) 
0.06 
Death 
DBP 2 / 162 1.74 
(0.88,3.46) 
0.11    4 / 1493 1.71 
(1.24,2.36) 
<0.01* 
           
SBP 1 / 87 2.69 
(1.13,6.40) 
0.03*       
MABP 2 / 199 2.90 
(1.57,5.36) 
<0.01*    1 / 388 0.87 
(0.40,1.91) 
0.70 
Death / 
disability 
DBP 1 / 87 4.68 
(1.87,11.70) 
<0.01*       
           
Death / 
deterioration 
SBP 1 / 40 5.57 
(1.42,21.86) 
0.01*    1 / 851 0.79 
(0.59,1.05) 
0.11 
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Table 3.4 Outcome by type of stroke for continuous data. 
 
 
 
PICH Infarct Mixed 
         
Outcome 
Studies / 
subjects 
WMD 
 (95% CI) 
P Studies / 
subjects 
WMD 
 (95% CI) 
P Studies / 
subjects 
WMD 
 (95% CI) 
P 
           
SBP    1 / 131 -2.04  
(-12.76, 8.68) 
0.70 4 / 1668 6.39  
(0.70, 12.09) 
0.03* 
MABP 2 / 1983 11.40 
(8.21,14.58) 
<0.01*       
Death 
DBP    1 / 131 2.22  
(-4.86,9.30) 
0.50 4 / 1668 -0.18  
(-3.04,2.68) 
0.90 
           
SBP    2 / 141 11.73 
(1.30,22.16) 
0.03* 4 / 550 2.95  
(-7.38,13.28) 
0.60 
MABP    1 / 92 9.00 
(0.92,17.08) 
0.03*    
Death / 
disability 
DBP    2 / 141 6.00 
(0.19,11.81) 
0.04* 4 / 550 1.32  
(-3.91,6.55) 
0.60 
           
SBP    1 / 152 3.00  
(-6.70,12.70) 
0.50 2 / 1003 -1.99  
(-11.83,7.85) 
0.70 Death / 
deterioration 
DBP    1 / 152 -0.60  
(-5.20,4.00) 
0.80 2 / 1003 4.44  
(-8.18,17.07) 
0.50 
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Figure 3.1 Search process 
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Figure 3.2a Forest plot of OR for death in ‘high’ verses ‘low/normal’ diastolic BP 
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Figure 3.2b Forest plot of WMD (mmHg) for systolic BP in dead or dependent 
patients compared with good outcome. 
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Chapter 4. 
A systematic review of NO donors and L-arginine in 
experimental stroke; effects on infarct size and CBF 
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4.1 Abstract 
Background: NO is a candidate treatment for acute IS, however published studies in 
experimental stroke have given conflicting results. Methods: A systematic review of 
published controlled studies of L-Arg (the precursor for NO) and NO donors in 
experimental stroke was performed. Data were analysed using the Cochrane Collaboration 
Review Manager software. SMD and 95% CI were calculated. Results: Altogether, 25 
studies (s) were identified. L-Arg and NO donors reduced total cerebral infarct volume in 
permanent (SMD -1.21, 95% CI -1.69 to -0.73, p<0.01, s=10) and transient models of 
ischaemia (SMD –0.78, 95% CI –1.21 to -0.35, p<0.01, s=7). Drug administration 
increased cortical CBF in permanent (SMD +0.86, 95% CI 0.52 to 1.21, p<0.01, s=8) but 
not transient models (SMD +0.34, 95% CI –0.02 to 0.70, p=0.07, s=4). Conclusions: 
Administration of NO in experimental stroke reduces stroke lesion volume in permanent 
and transient models. This may be mediated, in part, by increased cerebral perfusion in 
permanent models. These data support clinical trials in stroke patients, although the 
presence of a narrow therapeutic time window may be a limiting factor.  
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4.2 Background 
NO is a multimodal endogenous mediator that is synthesised from its precursor L-Arg by 
the action of NOS.108 It is implicated in the pathophysiology of acute IS, although its 
precise role remains to be determined.100,336 In stroke, NO produced by the neuronal and 
inducible isoforms of NOS (nNOS, iNOS) can be neurotoxic101,104, partly as a 
consequence of the formation of peroxynitrite, a free radical, which leads to direct damage 
to mitochondrial enzymes and DNA.86,88 In contrast, NO produced by the endothelial 
isoform of NOS (eNOS) is beneficial in acute stroke.99 Endothelial-derived NO may limit 
neuronal damage through effects in vascular beds or within the brain itself.337 In the 
intravascular space NO acts as a powerful vasodilator that can modulate blood flow. Also, 
NO inhibits leukocyte adhesion / migration to endothelium78,79 and has antiplatelet 
effects.75 In the brain NO may be neuroprotective through several mechanisms including: 
scavenging of reactive oxygen species338-340, anti-inflammatory effects78,79 and possibly 
through attenuation of NMDA receptors.341 Furthermore, in experimental stroke exogenous 
NO limits metabolic derangement211,342, reduces apoptosis199 and stimulates 
neurogenesis.195 Consequently, administration of NO has been considered to be a 
candidate treatment for acute stroke. 
 
Useful sources of NO for study in animal models are its essential amino acid substrate L-
Arg and pharmacological donors. Exogenous L-Arg appears to increase NO levels partly 
via the NOS pathway, but also by the release of other vasoactive substances and arginase 
enzyme.106,107 In contrast, NO donors are drugs that generate NO through mechanisms 
that are independent of NOS. Commonly used agents are the organic nitrates (e.g. GTN, 
ISDN), SNP , sydnonimines (e.g. molsidomine, SIN-1), S-nitrosothiols (e.g. s-
nitrosoglutathione), NONOates (e.g. SPERMINE-NONOate, DETA-NONOate), and hybrid 
donors (e.g. nitroaspirins, nicorandil). Pre-clinical studies of these agents have given 
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variable results for effects on lesion size and CBF in animal models of cerebral 
ischaemia.343 The aim of the present investigation was to determine systematically what 
effect NO donors have on these parameters. 
 
4.3 Methods 
Study identification 
Experimental studies of L-Arg and NO donors were sought and included if they reported 
the effect on infarct volume or CBF in IS models (transient or permanent, global or focal). 
Systematic searches of ‘Pubmed’, ‘EMBASE’ and ‘Web of Science’ were made for articles 
published from 1980 - 2002. The search strategy employed four primary keywords (nitric 
oxide, cerebro*, brain, ischaemia) combined with a fifth word chosen from a list of NO 
donors and L-Arg, and limited to animal studies. Additional articles were identified from 
previous non-systematic reviews336 and reference lists by three researchers. On the basis 
of title and abstract, articles of interest were selected for a review of the full publication. 
Decisions on inclusion or exclusion were then made by one researcher and the project 
supervisor. Exclusion criteria were: non-stroke model, NO donor not administered, 
outcomes other than infarct volume or CBF, no control group, insufficient data given, or 
duplicate publication. 
 
Data Extraction 
Data were extracted on infarct volume and CBF from the selected articles. Infarct volume 
was recorded in mm3 or as a % of normal brain. Measurements from the longest period of 
follow up were used. CBF was recorded as ml.min-1.g-1 or % of baseline readings or 
baseline control. In permanent models, the CBF measurement closest to one hour after 
onset of occlusion was used. For transient models CBF measurements were used after 
one hour of reperfusion. Where articles gave infarct volume or CBF readings for different 
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brain regions the data were classified as sub-cortical, cortical, or total. If the location was 
not specified then it was assumed to be total brain. When studies used multiple groups of 
animals to assess dose response relationships or optimal timing of administration, the data 
from each group were individually extracted for separate analysis. If the number of animals 
in a specific group was given as a range then the lowest figure quoted was used. 
Occasionally, numerical data were not available in print and it was necessary to extract 
data directly from enlarged, photocopied graphs. All discrepancies were resolved by the 
project supervisor. Methodological quality of studies was assessed according to published 
recommendations344 using an 8 point ‘ STAIR’ rating scale.310 One point was given for 
written evidence of each of the following factors; (i) presence of randomisation; (ii) 
monitoring of physiological parameters; (iii) assessment of dose response relationship; (iv) 
assessment of optimal time window; (v) blinded outcome measurement; (vi) assessment of 
outcome at day 1-3; (vii) assessment of outcome at day 7-30 and; (viii) combined 
measurement of infarct volume and functional outcome. 
 
Analysis 
Data were analysed using the Cochrane Collaboration Review Manager (RevMan version 
4.1) software. Figure 4.1 shows a typical forest plot and illustrates the layout of studies. 
Published recommendations suggest that candidate neuroprotectants should be effective 
in multiple brain regions, at different times of administration, and in permanent and 
transient stroke.344,345 Hence, infarct volume and CBF data were grouped ‘a priori’ for 
analysis in several ways: (i) by experimental model - permanent or transient; (ii) by 
outcome location - total brain, cortex, sub-cortex; and (iii) by timing of administration – NO 
administered before (pre-treated), 0 to 1 hour after (early treatment) or >1 hour after (late 
treatment) onset. Results are given as SMD (which allows data measured on different 
scales to be merged) with 95% CI. A random effects model was used since heterogeneity 
90 
was likely to be present due to the use of different protocols, animal species, drugs and 
administration timings. Statistical heterogeneity was assessed with a χ2 test. The likely 
causes of heterogeneity were explored using subgroup analyses based on drug type (L-
Arg, organic nitrates, SNP, sydnonimines, S-nitrosothiols, NONOates, and hybrid donors) 
and timing of administration. Publication bias was assessed using Egger’s asymmetry 
test311 (Stata function ‘metabias’) and visual assessment of a funnel plot. Significance was 
set at P<0.05. 
 
4.4 Results 
Design of studies 
The literature search identified 440 potential articles, although most of these were 
excluded (figure 4.2). The characteristics of the remaining 25 studies (median 41 animals) 
are given in table 4.1. Most of these studied NO administration in permanent / focal 
ischaemia (15 articles). Transient models utilised both focal (6 articles) and global (4 
articles) ischaemia. Rat species (Sprague Dawley, Wistar, Spontaneously Hypertensive, 
Long Evans) were used in 23 studies (table 1), whereas only 1 chose a rabbit model346 
and 1 used both.339 Methodological design was variable as far as drug administration was 
concerned. Several different routes (intra-venous, intra-arterial, intra-peritoneal) were used 
at timings ranging from 18 hours before to 24 hours after induction of ischaemia. Likewise, 
dosage regimens differed between studies, e.g. L-Arg 3.0 – 300 mg/kg, SNP 0.1 – 3.0 
mg/kg, SIN-1 0.1 – 10.0 mg/kg. In three studies188,189,337, the hypotensive effect of high 
doses of SNP and SIN-1 were countered by co-administration of phenylephrine. 
 
Study design was more consistent for outcome measures. Infarct volume was mostly 
measured in mm3, apart from two instances when it was given as percentage of total 
brain163 or hemisphere.195 Volumes were assessed by histological staining techniques and 
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image analysis of sequential coronal brain sections in all studies. Regional CBF was 
commonly measured as percentage of baseline values in the cerebral cortex using laser 
Doppler flowmetry.163,188,189,222,337,339,347-351 In addition, several studies analysed CBF as 
ml.min-1.g-1 using 14C-iodoantipyrine192,352 or hydrogen clearance211,342,346 techniques.  
 
The median STAIR rating for the included articles was 2 points (range 1-7 out of 8). 
Animals were allocated treatment by randomisation in 8 articles.114,191,195,199,339,346,351,352 In 
9 studies114,163,189,191,195,347,349,350,353 different dosage regimens were tested, but only 4 
assessed the optimal timing window for administration.114,195,337,348 Most studies examined 
outcome measures between days 1-3; only one did this blinded to treatment339 whilst two 
looked at functional outcome as well as infarct volume.114,195 
 
Infarct volume and CBF 
Overall, NO administration resulted in significant reductions in total, cortical and sub-
cortical infarct volume in permanent models of ischaemia (table 4.2). NO administration 
also reduced total infarct volume in transient models; data were limited to single studies for 
cortical and sub-cortical stroke. At approximately one hour of permanent occlusion CBF 
was significantly increased by NO donors in the cerebral cortex (table 4.2). There was no 
significant effect at 1 hour of reperfusion in transient stroke. Data were lacking for other 
comparisons. Publication bias was present for studies reporting the effect of NO 
administration on lesion volume in permanent (Egger’s test p=0.02), but not transient 
(Egger’s test p=0.39) models. Heterogeneity was present in several of the analyses and so 
infarct volume and CBF were further examined by drug type (table 4.3, Figure 4.1). 
Likewise, the effects of different timings of administration were examined separately in 
permanent and transient models (Table 4.4). 
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L-Arg (NO substrate) 
L-Arg did not significantly alter lesion volume in both permanent and transient stroke. This 
was despite evidence of a beneficial effect on cortical CBF in permanent models. 
 
SNP  
SNP reduced total infarct volume after permanent and transient stroke, although it did not 
appear to change cortical CBF.  
 
Organic nitrates 
GTN did not alter cortical CBF after permanent ischaemia, although this finding was based 
on one study. There were no studies examining the effect of GTN on infarct volume. 
 
NONOates 
The NONOates significantly reduced total infarct volume in transient, but not permanent, 
models. There was a non-significant trend to increased cortical CBF following reperfusion 
in transient models. 
 
Sydnonimines 
The sydnonimines were effective in both permanent and transient stroke models. In 
permanent models they reduced total infarct volume and increased cortical CBF. In 
transient models they significantly reduced total infarct volume. 
 
Hybrid donors 
Total infarct volume was reduced in one study.199 There were no data available for CBF 
outcomes. 
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Timing of treatment 
Pre-treatment with NO from any source reduced infarct volume in transient but not 
permanent models of ischaemia. Early administration of NO from 0 – 1 hour of onset was 
equally effective in both transient and permanent stroke. Later treatment with NO had no 
overall beneficial effect on infarct volume in either transient or permanent stroke. 
 
4.5 Discussion 
This systematic review has assessed the effect of NO donors on lesion size and CBF in 
experimental stroke models. With one exception354 most of the individual studies were 
positive or neutral; when combined, NO significantly reduced infarct volume and improved 
CBF after permanent stroke. NO similarly reduced lesion volume in transient stroke. One 
article noted that NO-induced changes in CBF preceded electroencephalographic brain 
recovery.348 Others found concomitant increases in pial vessel diameter.347,350,355 Taken 
together these findings suggest that vascular effects of NO are important for limiting 
neuronal damage, perhaps because they lead to improved collateral blood flow in areas of 
compromised cerebral perfusion. 
 
Source of NO 
In general, the NO donors (SNP, Sydnonimines, NONOates and hybrid donors) were all 
effective at reducing lesion volume in transient stroke, permanent stroke, or both. An 
exception was L-Arg, which increased cortical CBF after permanent occlusion but was 
otherwise ineffective. In addition, L-Arg significantly increased infarct volume in one 
article.354 Several factors may account for these findings: L-Arg stimulates hormones such 
as insulin, glucagon, growth hormone and catecholamines356 and can be converted to 
toxic by-products such as polyamines357 or agmatine.358 Alternatively, L-Arg may enhance 
the synthesis of potentially detrimental NO from iNOS since it countered the 
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neuroprotective effects of iNOS inhibitor in two studies.222,354 Hence, L-Arg is probably not 
an agent of first choice for testing in clinical stroke.  
 
Timing of treatment 
The timing of drug administration varied considerably from 18 hours prior to 24 hours after 
onset of ischaemia. Early treatment within 1 hour of ischaemia was effective in both 
transient and permanent models of stroke whereas later treatment was ineffective. This 
biphasic response can be explained by NO having neuroprotective activity. Further 
experimental studies with delayed NO administration are required in order to assess when 
the optimum time window closes. 
 
Types of models 
Reductions in lesion volume were present in both permanent and transient models of 
stroke. No direct comparisons of efficacy in these different models have been published. 
However, indirect assessment using the data in this review suggest that NO donors may 
be less effective after transient ischaemia. Reductions in total lesion volume for transient 
models were about half those seen for permanent ischaemia. Also, whilst there was 
evidence of benefit on infarct volume in permanent cortical and sub-cortical stroke there 
was none in transient stroke. It is difficult to interpret the findings in transient models since 
focal and global models of transient ischaemia differ neuro-pathologically359, and it was not 
possible to examine them separately because of lack of studies. Nevertheless, the most 
likely explanation is that since transient ischaemia was associated with less cerebral 
damage than seen with permanent models, there was a smaller lesion for NO donors to 
modify. Alternatively, the apparent differences may reflect chance, paucity of data and 
varied protocol design (e.g. timing of drug administration). Additionally, NO might induce 
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reperfusion injury after transient ischaemia,214 although NO has been proposed as a 
treatment for reducing reperfusion injury after thrombolysis.339 
 
Limitations 
Although this review has demonstrated an association between NO administration and 
reduction in infarct volume and improved CBF in experimental stroke, the findings are 
limited by several factors. First, there were considerable variations in animal species, 
physiological parameters (e.g. BP), drug administration (timing, dosage, route), surgical 
methodology, and duration of ischaemia between the studies, as highlighted above. 
Unfortunately, it is not possible to judge if the relationships that were observed are 
independent of these factors. Inevitably, the variety of protocols will have made the results 
more heterogeneous although this was accounted for by using a random effects statistical 
model. Second, since Egger’s asymmetry test suggested publication bias was likely, it is 
possible that the extensive search strategy did not identify all studies. Publication bias 
could have resulted from both the lack of reporting of some neutral or negative studies, 
and through commercial pressures not to publish positive studies involving patented drugs 
in development. Consequently, the benefits of NO on infarct volume and CBF might have 
been either over or underestimated.  
 
Third, when numerical data were not available the information on volume and blood flow 
was extracted from published figures. This can be imprecise, although graphs were 
enlarged and two independent authors extracted the data. Fourth, a few articles 
administered phenylephrine in order to counter hypotension induced by high doses of SNP 
and sydnonimines.189,337,360 These studies are complex to assess, in part because 
phenylephrine could itself be beneficial after stroke.361 Fifth, the studies came from a 
relatively small number of research groups and involved a limited number of animals. Both 
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of these factors could have influenced the outcome of the analysis. The extraction of 
multiple pieces of information from a limited number of sources further risks introducing 
bias into the review. Finally, it is worth noting that the median STAIR rating was only 2 out 
of a maximum of 8. Several key concerns exist when considering study quality: few studies 
stated that they used randomisation to treatment; only one study reported using a blinded 
observer to assess outcome339; and functional outcomes were only assessed in two 
studies.114,195 Future studies evaluating neuroprotective agents in experimental stroke 
models should follow published recommendations on preclinical drug development.344 
 
In summary, administration of NO in experimental stroke is associated with a reduction in 
infarct size. This effect may be mediated, at least in part, through beneficial effects on CBF 
in areas of compromised perfusion. NO administration was also effective in multiple brain 
regions in permanent and, to a lesser extent, transient stroke. This would support the 
continued development of NO sources for treatment of human stroke, as has been started 
in phase II clinical trials.166,362 However, the potentially narrow time window for efficacy 
with NO donors might be a limiting factor. The potential of NO administration in acute 
stroke will remain uncertain until the results of a large ongoing RCT is available.363 
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Table 4.1 Included studies 
 
Drug Studies Species STAIR 
rating 
Total 
N 
Model 
P/T 
Occlusion 
G/F 
1st dose timing 
(min) 
Route Measures 
         Infarct 
vol 
CBF 
L-Arg Bednar, 1997 346 NZR 2 27 P F +30 i.v  ml.min-1.g-1 
 Buisson, 1993 355 SDR 2 31 P F -30 i.p mm3  
 Dalkara, 1994 348 SHR 2 28 P F +5, +15, +30 i.v  % 
 Escott, 1998 114 SDR 6 55 T F +5 i.p. mm3  
 He, 1995 342 SHR 2 43 P F -20 i.p mm3 ml.min-1.g-1 
 Humphreys, 
1998349 
SDR 2 63 T G -30 i.v  % 
 Iadecola, 1995 222  SHR 2 53 P F +1440 i.p mm3  
 Morikawa, 1992a364  SHR 2 60 P F -960 i.p mm3  
 Morikawa, 1992b 
350
  
SHR 2 36 P F +5 i.v  % 
 Morikawa, 1994 347 SHR, 
SDR 
3 53 P F +5 i.v mm3 % 
 Prado, 1996 352  SHR 3 31 P F -1080 i.p mm3 ml.min-1.g-1 
 Sadoshima, 1997 
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SHR 1 34 T G +60 i.v  ml.min-1.g-1 
 Zhang, 1996 354 SDR 1 71 T F +1440 i.p mm3  
 Zhao, 1999 351 WR 2 12 T G -30 i.p  % 
           
GTN Bednar, 1997 346 NZR 3 27 P F +30, +150 i.v  ml.min-1.g-1 
           
SNP Bednar, 1997 346 NZR 3 27 P F +30, +150 i.v  ml.min-1.g-1 
 Chi, 1995 192 LER 1 28 P F +40 i.v  ml.min-1.g-1 
 Salom, 2000 163 WR 3 56 T F 0 i.v % % 
 Zhang, 1993 188  SDR 2 31 P F +3 i.a mm3 % 
 Zhang, 1994a 189 SHR, 
SDR 
3 74 P F +3 i.a mm3 % 
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Sydnonimines Chi, 1995 192  LER 1 28 P F +40 i.v  ml.min-1.g-1 
 Coert, 1999 191 WR 3 92 T F -30 i.v mm3  
 Coert, 2002 353 WR 4 60 T F -30 i.v mm3  
 Zhang, 1994a 189 SHR, 
SDR 
3 74 P F +3 i.a mm3 % 
 Zhang, 1994b 337 SHR 2 39 P F +3, 15, 30, 60, 120 i.a mm3 % 
           
NONO-ates Coert, 1999 191 WR 3 92 T F -30 i.v mm3  
 Mason, 2000 338 WR 2 12 T G +5 i.v mm3  
 Pluta, 2001 339 SDR, 
NZR 
2 41 T F +60 i.a mm3 % 
 Salom, 2000 163 WR 3 56 T F 0 i.v % % 
 Zhang, 2001 195 WR 7 ? P F +1440, 2880 i.p %  
           
Hybrid donors Fredduzzi, 2001 199 SHR 2 40 P F +10 i.p mm3  
Abbreviations: Spontaneously Hypertensive rat (SHR); Sprague-Dawley rat (SDR); Wistar rat (WR); Long-Evans rat (LER); New-Zealand 
rabbits (NZR); male (M); female (F); permanent (P); transient (T); global (G); focal (F); intra-venous (i.v.); intra-arterial (i.a.); intra-
peritoneal (i.p.); infarct volume (infarct vol.); cerebral blood flow (CBF) 
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Table 4.2 Effect of no donors on lesion volume and CBF by brain region; data are SMD (95% CI) 
 
Outcome  Permanent models   Transient 
models 
 
 
 Total 
 
Cortical Sub-cortical Total Cortical Sub-cortical 
Lesion volume -1.21*  
(-1.69, -0.73) 
S=10, n=235 
 
-1.40*  
(-1.94, -0.86) 
S=6, n=181 
-0.55*  
(-0.86, -0.24) 
S=5, n=131 
-0.78*  
(-1.21, -0.35) 
S=7, n=228 
+2.35*  
(0.97, 3.72) 
S=1, n=16 
+0.54 
 (-0.49, 1.58) 
S=1, n=16 
CBF +0.66 
(-0.02, 1.35) 
S=1, n=24 
 
+0.86*  
(0.52, 1.21) 
S=8, n=220 
+0.48  
(-0.18, 1.14) 
S=3, n=42 
 
 
No data 
+0.34  
(-0.02, 0.70) 
S=4, n=108 
+0.64 
(-0.18, 1.47) 
S=1, n=24 
Abbreviations: number of studies (S); number of animals (n); *p<0.05 
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Table 4.3 Effect of different NO donors infarct volume and CBF; data are SMD (95% CI) 
 
 Permanent Transient 
 Total infarct volume Cortical CBF Total infarct volume Cortical CBF 
L-Arg -0.59, (-1.33, 0.16) 
S=5, n=118 
 
+0.82*, (0.42, 1.23)  
S=4, n=101 
+0.96, (-2.15, 4.07) 
 S=2, n=36 
+0.52, (-0.16, 1.20) 
S=2, n=35 
SNP -2.23*, (-3.27, -1.20) 
S=2, n=41 
 
+0.60, (-0.44, 1.64)  
S=4, n=45 
-1.14*, (-2.08, -0.20) 
S=1, n=25 
-0.04, (-0.76, 0.67) 
S=1, n=22 
GTN  
No data 
-0.35, (-1.60, 0.91) 
S=1, n=10 
 
 
No data 
 
No data 
NONOates -0.42, (-1.24, 0.40) 
S=1, n=16 
 
 
No data 
-0.79*, (-1.39, -0.20) 
 S=4, n=83 
+0.43, (-0.09, 1.28) 
S=2, n=51 
Sydnonimines -2.06*, (-3.06, -1.07) 
S=2, n=50 
 
+1.26*, (0.56, 1.95)  
S=3, n=64 
-1.03*, (-1.54, -0.52) 
 S=2, n=84 
 
No data 
Hybrid donors -1.09*, (-2.04, -0.14) 
S=1, n=20 
 
 
No data 
 
No data 
 
No data 
Abbreviations: number of studies (S); number of animals (n); *p<0.05 
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Table 4.4 Effect of timing of administration (within 1 hour versus >1 hour) on total 
infarct volume; data are SMD (95% CI) 
 
Timing 
 
 
Pre-treatment Early 
Treatment 
 
Late 
Treatment 
Permanent 
models 
 
-0.08  
(-1.78, 1.61) 
S=2, n=35 
 
-1.77*  
(-2.23, -1.30) 
 S=6, n=158 
-0.17 
 (-0.73, 0.38) 
S=3, n=46 
Transient 
models 
 
-0.75*  
(-1.21, -0.29) 
S=2, n=102 
-1.15*  
(-1.58, -0.73) 
S=4, n=86 
+2.60*  
(1.15, 4.05) 
S=1, n=16 
Abbreviations: number of studies (S); number of animals (n); *p<0.05 
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Figure 4.1 Effect on total lesion volume by different no donor classes for permanent 
models of ischaemia 
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Figure 4.2 Search process showing identified trials 
 
 
 
 
 
Ischaemia not induced
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Chapter 5. 
NOS inhibitors in experimental IS and their effects on infarct 
size and CBF; a systematic review 
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5.1 Abstract 
 
Background: NO produced by the neuronal or inducible isoforms of NOS (nNOS, iNOS) is 
detrimental in acute IS , whilst that derived from the endothelial isoform (eNOS) is 
beneficial. However, experimental studies with NOS inhibitors have given conflicting 
results. Method: Relevant studies were found from searches of EMBASE, PubMed and 
reference lists; of 456 references found, 73 studies involving 2321 animals were included. 
Data on the effect of NOS inhibition on lesion volume (mm3, %) and CBF (%,ml.min-1.g-1) 
were analysed using the Cochrane Review Manager software. Result: NOS inhibitors 
reduced total infarct volume in models of permanent (SMD -0.56, 95% CI, -0.86, -0.26) 
and transient (SMD -0.99, 95% CI -1.25, -0.72) ischaemia. Cortical CBF was reduced in 
models of permanent but not transient ischaemia. When assessed by type of inhibitor, 
total lesion volume was reduced in permanent models by nNOS and iNOS inhibitors, but 
not by non-selective inhibitors. All types of NOS inhibitors reduced infarct volume in 
transient models. Conclusion: NOS inhibition may have negative effects on CBF but 
further studies are required. Selective nNOS and iNOS inhibitors are candidate treatments 
for acute IS. 
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5.2 Introduction 
NO is synthesised from its precursor L-Arg by the action of NOS. NO is produced in the 
brain following the onset of cerebral ischaemia, although it’s precise role in the 
pathophysiology of IS is unclear. Gene knockout studies have determined that NO derived 
from the eNOS is beneficial in acute IS.99 This may be due, in part, to antiplatelet effects75 
and preservation of CBF.336 In contrast, NO produced by nNOS and iNOS can be 
neurotoxic.101,104 This probably occurs through NO induced formation of peroxynitrite365 
and toxic free radicals leading to damage by lipid peroxidation.366 NO further potentiates 
damage by inhibiting enzymes needed for mitochondrial respiration (cytochrome oxidase), 
glycolysis (GAPDH) and DNA replication (ribonucleotide reductase).367-370 Moreover, NO 
has been reported to stimulate the release of the neurotransmitter glutamate and could 
contribute to excitotoxicity.371,372 Consequently, inhibition of NO production has been 
considered to be a candidate treatment for acute IS. 
 
The first NOS inhibitors were the guanidino aminoacids, many of which act competitively 
at the NOS active site, e.g, L-NNA, L-NAME (a methyl ester pro-drug that is activated to 
become L-NNA) and L-NMMA. Both L-NAME and L-NNA exhibit greater in-vitro potency 
than L-NMMA in inhibiting nNOS and eNOS versus iNOS (table 5.1)373 However, none of 
the guanidino aminoacids discriminate sufficiently to enable them to be used to target a 
single NOS isoform. By contrast, some inhibitors possess higher affinity against one 
isoform and are commonly referred to as ‘selective’, although this term is used rather 
indiscriminately.108 Agents used to target iNOS include: aminoguanidine, NG-iminoethyl-L-
lysine (L-NIL), the bis-isothioureas (PBITU)109, 1400W (N-[3-
(aminomethyl)benzyl]acetamidine), GW273629 and GW274150.110 Other agents are used 
to target nNOS and include: 7-NI, tri(fluoromethylphenyl)imidazole (TRIM)111, ARL 17477, 
AR-R18512112, BN 80933113, S-ethyl and S-methyl thiocitrulline and vinyl L-NIO. Recent 
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in-vitro studies have suggested that in some cases the distinction between selective iNOS 
and selective nNOS inhibitor may not be straightforward. For example, aminoguanidine is 
only mildly selective against iNOS in-vitro (~5 fold) and probably affects other molecular 
targets.108 Similarly, 7-NI has been found to be an equipotent inhibitor of all three isoforms 
of NOS at the isolated enzyme level (table 5.1)108,114 although it has more selectivity for 
nNOS in vivo, possibly a consequence of cell specific effects (neuronal verses 
endothelial).108  
 
Studies of NOS inhibitors in IS models have given contradictory results for effects on 
lesion size and CBF, with many demonstrating beneficial effects113,204,215,218,226 whilst 
others report contradictory findings.188,210,374-377 Hence, the aims of the present 
investigation were to undertake a systematic review to determine the efficacy of NOS 
inhibitors to decrease brain injury following cerebral ischaemia, and to assess whether 
their effects may be influenced by changes in CBF, timing of administration, type of model 
and animal species.  
 
5.3 Methods 
Study identification 
Experimental studies assessing the effects of NOS inhibitors on IS lesion volume and CBF 
in IS models (transient or permanent, global or focal, any species) were identified. 
Searches were made of ‘EMBASE’ and ‘Pubmed’ for articles published from 1980 - 2002. 
For the EMBASE search four primary keywords (nitric oxide, brain, ischaemia, non-
human) were chosen combined with a fifth chosen from a list of NOS inhibitors. Different 
primary keywords were used in the Pubmed search (nitric oxide, cerebro*, ischaemia) 
which was then limited to animal studies. Other publications were found from reference 
lists and review articles. Abstracts were then used to select relevant articles for an 
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examination of the full publication. Final decisions on inclusion or exclusion were made by 
two researchers. Pre-specified exclusion criteria were used to minimise the potential for 
bias, namely; (i) not an IS model; (ii) NOS inhibitor not administered; (iii) No infarct volume 
or CBF data reported; (iv) no control group; (v) incompatible data (for instance, standard 
deviations omitted); or (vi) duplicate publication. 
 
Data Extraction 
Infarct volume data (mm3 or % of normal brain) and CBF data (ml.min-1.g-1 or % of 
baseline readings or baseline control) were extracted for analysis. Infarct volume 
measurements from the longest period of follow-up were used. CBF measurements after 
one hour of occlusion or reperfusion were used in models of permanent and transient 
ischaemia respectively. Where possible, regional infarct volume and CBF data were 
obtained separately for total brain, cortex and sub-cortex. In cases where region was not 
specified then the measurements were classified as total brain. If an article investigated 
dose response relationships or optimal timing of administration then data from each 
individual experimental condition were included separately. In cases where the number of 
animals in each experiment was given as a range then it was assumed to be the lowest 
figure. Where numerical values were not available, data were estimated directly using a 
ruler from graphs that were enlarged twofold. All data extraction was done by two 
independent researchers; discrepancies were resolved by the project supervisor. Finally, 
the methodological quality of the included articles was assessed as an 8 point ‘STAIR 
rating’310 based on published recommendations for investigating new agents in 
experimental IS344; one point was given for written evidence of each of the following 
factors; (i) randomisation; (ii) monitoring of physiological parameters; (iii) assessment of 
dose response relationship; (iv) assessment of optimal time window; (v) blinded outcome 
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measurement; (vi) assessment of outcome at day 1-3; (vii) assessment of outcome at day 
7-30 and; (viii) combined measurement of infarct volume and functional outcome. 
 
Analysis 
Study data were grouped by protocol prior to analysis: (i) experimental model - permanent 
or transient; (ii) outcome location - total brain, cortex, sub-cortex; (iii) outcome measure - 
infarct volume (mm3, %), and CBF (ml.min-1.g-1, %). Data from each of these groups were 
analysed as forest plots using the Cochrane Collaboration Review Manager (RevMan 
version 4.1) software. Figures 5.1A and 5.1B illustrate the general layout of the forest 
plots. Publication bias was assessed using Egger’s asymmetry test311 (Stata function 
‘metabias’). Results are given as SMD (reported in units of standard deviation), which 
allows data measured on different scales to be merged, and 95% CI. A random effects 
model was used since statistical heterogeneity, assessed with a χ2 test, was expected in 
view of the wide range of protocols. Sensitivity analyses were performed to look at likely 
sources of heterogeneity, including study quality, NOS inhibitor type (grouped as non-
selective inhibitors, iNOS inhibitors, nNOS inhibitors), animal species and timing of 
administration. For the latter, articles were divided into those that administered NOS 
inhibitors before (pre-treated), 0 to 1 hour after (early treatment) or >1 hour after (late 
treatment) onset. Meta-regression (STATA, version 7.0) was used to analyse the 
relationship between timing of administration and the effect on total infarct volume (SMD) 
in order to try and determine the size of the therapeutic window. Studies were weighted by 
sample size and only those that administered NOS inhibitors after onset of ischaemia were 
included. Significance was set at P<0.05. 
 
5.4 Results 
Design of studies 
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Altogether 456 articles were found in the literature search (figure 5.2). A large proportion 
did not qualify for the review, leaving 73 studies (s). Data from a total of 2321 experimental 
subjects were used in the analysis. Table 5.2 summarises the characteristics of the 
included articles. The most commonly used agents were non-selective inhibitors such as 
L-NAME (s=38) and L-NNA (s=15). In addition, several compounds were used to target 
nNOS, including: 7-NI (s=9), AR-R 17477 (s=4), BN 80933, PPBP and TRIM. In contrast, 
only two types of iNOS inhibitor were represented: aminoguanidine (s=12) and 1400W 
(s=1). NOS inhibitors were administered to 22 permanent / focal models and to one 
permanent / global model. More articles assessed the effect of NOS inhibition in transient 
ischaemia (30 focal, 14 global and 2 using both). In addition, 2 studies were included 
which compared a combination of permanent and transient models.220,378 Rats were the 
animal models used in the majority of studies (24 Sprague Dawley, 21 Wistar, 8 
spontaneously hypertensive, 1 Long Evans, 1 Lewis, 1 Fischer). Other studies used 
diverse species, including; rabbits379,380, cats381-383, mice210,212,214,226,384-387, gerbils113,388,389, 
pigs390-393, and lambs.394 
 
Variable methods of drug administration were utilised, e.g. different routes (oral, intra-
venous, intra-ventricular, intra-arterial, intra-peritoneal), different timings (1st dose ranging 
from 6 weeks before to 48 hours after induction of ischaemia) and different dosage 
regimens (e.g. total administered dose of L-NNA 0.06 – 40.0 mg/kg, L-NAME 0.1mg/kg – 
4.2 g/kg, aminoguanidine 100 – 800 mg/kg, ARL-17477 1.0 – 10.0 mg/kg and 7-NI 0.1 – 
100 mg/kg). Study design was more consistent for outcome measures. Infarct volumes 
were assessed by histological staining techniques and image analysis of sequential 
coronal brain sections in nearly all of the studies. An exception to this were 3 articles that 
used serial MRI techniques to monitor lesion progression.395-397 Regional CBF after IS 
onset was commonly measured as percentage (of baseline or control values) using laser 
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doppler flowmetry.188,214,220,222,226,349,351,376,392,398-404 In addition, one article indirectly 
assessed total CBF using an ultrasonic flow transducer.394 Alternatively, several studies 
analysed CBF as ml.min-1.g-1 using 14C-iodoantipyrine204,209,405, hydrogen 
clearance211,393,406,407, radio labelled microsphere381-383,390,391 or umbelliferone 
fluorescence379,380 techniques.  
 
The median STAIR rating for the included articles was 3 points (range 1-6/8). Treatment 
was allocated by randomisation in only 17 articles whilst 26 studies assessed dose 
response; just 14 studies assessed the optimal timing of administration. Most studies 
examined outcome measures between days 1-3; only 9 did this blinded to treatment whilst 
11 looked at functional outcome as well as infarct volume. Classifying studies by STAIR 
score accounted for a significant part of the between group heterogeneity (Figure 5.3). 
There was no evidence of a beneficial effect on infarct volume in studies with a STAIR 
rating of 1 point.  
 
Infarct volume and CBF 
Collectively, NOS inhibitors caused a significant reduction in total, cortical and sub-cortical 
infarct volume of magnitude 0.5 to 1.0 standard deviations (table 5.3, figure 5.1A). 
Paradoxically, detrimental effects on CBF were observed in the cerebral cortex of 
permanent models. Most CBF data came from studies administering non-selective 
inhibitors. There was no evidence of publication bias for articles reporting the effect of 
NOS inhibition on total lesion volume in permanent (Egger’s test p=0.33), or transient 
(Egger’s test p=0.65) models. Since heterogeneity was observed in several of the 
analyses, infarct volume and CBF were further examined by type of NOS inhibitor (figure 
5.4), in different animal models and by different timings of administration (figure 5.5). 
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Type of NOS inhibitor 
 
Non-selective inhibitors 
In permanent models non-selective inhibitors did not significantly alter infarct volume but 
did reduce cortical CBF (figures 5.1A, 5.4A and 5.4B). By contrast, after transient 
ischaemia non-selective inhibitors reduced total infarct volume and did not affect CBF 
(figures 5.1B, 5.4C and 5.4D). 
 
iNOS inhibitors 
Aminoguanidine and 1400W significantly reduced infarct volume in both permanent and 
transient models. No studies of selective iNOS inhibitors on CBF were included. 
 
nNOS inhibitors 
nNOS inhibitors significantly reduced infarct volume in both permanent and transient 
models (figures 4A and 4C). At 1 hour of reperfusion there was no overall effect on cortical 
CBF in transient models. However, reduced cortical CBF was seen in one small (n=8) 
study involving a model of permanent ischaemia. 
 
Timing of treatment 
Treatment before IS onset was effective at reducing infarct volume in transient models 
(figure 5B) whilst early administration of NOS inhibitors (within 1 hour of onset) was 
effective in permanent ischaemia (figure 5A). Later treatment after 1 hour of onset had a 
beneficial effect on infarct volume in both types of IS model. Meta-regression analysis 
found no evidence of a relationship between total infarct volume (SMD) and timing of 
administration in permanent (p=0.08) or transient (p=0.18) models (figure 6).  
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Animal Model 
Overall, NOS inhibitors appeared to reduce total brain lesion size in agyrencephalic 
species (figure 5C and D) but not in cats. Surprisingly, NOS inhibition in Wistar rat IS 
models increased infarct volume after permanent ischaemia and decreased infarct volume 
after transient ischaemia. Limited data were available on the effects of NOS inhibitors in 
higher animals. 
 
5.5 Discussion 
This chapter has examined systematically the effects of NOS-inhibitors on infarct size in 
experimental IS models. Apart from 7 studies188,208,210,374,375,377,408, most of the individual 
articles were either positive or neutral for this outcome. However, when considered 
together there was an overall beneficial effect, such that NOS-inhibitors significantly 
decreased lesion size by about 0.5 to 1.0 standard deviations. Several mechanisms are 
likely to be involved, including; reduced formation of peroxynitrite and reactive oxygen 
species409-412, inhibition of brain oedema395,413, reduced vascular damage214,386, and 
inhibition of apoptosis and necrosis.413,414 Furthermore, NOS inhibitors increase 
hippocampal neuronal survival in experimental IS113,388,415-420 and improve functional 
outcome.113,214,224,225,386 
 
The findings are limited by several factors. First, there were differences between study 
protocols in terms of animal species, physiological parameters (e.g. BP), drug 
administration (dosage, route), surgical methodology, and duration of ischaemia. 
Unfortunately, it is not possible to judge whether the relationships that were observed were 
independent of these factors. In addition, protocol variations can lead to statistical 
heterogeneity and make the analysis less reliable. To take account of this a random 
effects model was used and sensitivity analyses were performed to identify sources of 
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heterogeneity. Second, some relevant articles may not have been identified for inclusion in 
the review. Publication bias can contribute to this, either through of lack of reporting of 
neutral or negative studies or through suppression of positive studies for commercial 
reasons, e.g. intellectual property rights. This could mean the benefits of NO on infarct 
volume and CBF have been either over or underestimated. Statistical assessment using 
Egger’s asymmetry test did not suggest the presence of publication bias but the possibility 
that some relevant data was omitted cannot be ruled out. Third, there were several 
instances when numerical data were not readily available and it had to be derived directly 
from published figures. This can be imprecise, although graphs were enlarged and two 
authors extracted data. Fourth, some NOS inhibitors work though additional 
neuroprotective mechanisms that do not involve inhibition of NO synthesis. Moreover, 
some of the ‘selective’ inhibitors only discriminate moderately between iNOS and 
nNOS.108 Hence, it is not possible to ascertain whether the relationships observed in each 
sub-group are independent of either of these factors. Fifth, the technique of extracting 
multiple pieces of information from single publications has a potential to introduce bias into 
the review since the results would have been generated by the same investigators and 
laboratories. Sixth, female animals may be resistant to the damaging effects of iNOS 
derived NO, perhaps because of modulation by hormones like progesterone.421 Since the 
findings in this review are based almost entirely on male animals it is impossible to say 
whether iNOS inhibitors would work as therapeutic agents in females. Further studies 
using female animals are required. Finally, since the median STAIR rating of the studies 
was only 3 out of a total of 8, there are likely to be methodological weaknesses in the 
included studies. Two key areas of concern are that studies are not reporting that they 
randomised animals to active and control treatment or performing blinded outcome 
assessments. All studies evaluating agents in experimental IS models should follow 
published recommendations on preclinical drug development.344 
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Despite the limitations, the present investigation has shown that NOS inhibitors can 
decrease brain injury following cerebral ischaemia. Not all published experimental studies 
agree with this finding, possibly because of differences in drug pharmacology, dosage, 
route of administration, timing of treatment, animal model and type of ischaemia. Hence, 
the impact of some of these factors was examined further. 
 
Type of experimental model 
Indirect assessment of the pooled data in table 5.3 suggests that NOS inhibitors were 
equally effective in models of transient and permanent ischaemia. However, the sub-group 
analysis in figure 5.4 revealed that non-selective inhibitors did not work in permanent 
ischaemia but did in transient ischaemia models. This discrepancy could be attributed to 
the presence of additional beneficial effects after transient ischaemia, such as limitation of 
reperfusion injury caused by eNOS-derived NO.214 Alternatively, the beneficial effects of 
non-selective inhibitors may have been limited in models of permanent ischaemia because 
they inhibit eNOS to a similar degree as nNOS or iNOS. Consequently, they may 
aggravate brain ischaemia by increasing platelet aggregation and white cell activity, 
raising BP, and by restricting penumbral blood supply. Evidence of reduced CBF after 
administration of non-selective inhibitors to permanent models is consistent with this 
hypothesis. Hence, the non-selective inhibitors are not agents of first choice for testing in 
clinical IS. 
 
Timing of treatment 
The administration of 1st dose varied considerably from 6 weeks prior to 24 hours after 
onset of ischaemia. Treatment with NOS-inhibitors was effective prior to onset of transient 
ischaemia, within 1 hour of permanent ischaemia, and even beyond 1 hour of onset in 
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both transient and permanent ischaemia models. The neutral findings seen with pre-
treatment of permanent models and early treatment of transient models probably 
represents the use of non-selective agents and paucity of data rather than lack of 
response to NOS inhibitors. More important is the confirmation that these agents reduce 
infarct volume even when administered beyond 1 hour after IS onset. Beneficial activity 
several hours after IS suggests that the NOS inhibitors might be useful in clinical IS. Meta-
regression analysis did not provide evidence of a therapeutic time window. More 
experimental studies with delayed administration are required to assess when the 
optimum window of opportunity closes. 
 
Animal model 
Significant infarct reductions after either transient or permanent ischaemia were seen in 
almost all rat strains. Surprisingly, in Wistar rats (WR), the NOS inhibitors decreased 
infarct volume after transient ischaemia, but they increased infarct volume in models of 
permanent ischaemia. This probably reflects the use of non-selective agents in permanent 
models, rather than being evidence of a different response to NOS inhibition by WR. Only 
spontaneously hypertensive rats (SHR) responded to NOS inhibitors in both models of 
transient and permanent ischaemia. This could arise partly because normotensive strains 
(SDR, WR, FR) suffer smaller and more variable infarcts than SHR.359 In mice, NOS 
inhibitors worked in permanent but not transient ischaemia models. This inconsistency is 
most likely due to lack of data, although these studies are complex to assess because 
different transgenic mouse strains were used. Unfortunately, paucity of data prevents any 
definitive statements about the role of NOS inhibitors in rabbits and cats. More studies 
need to be performed in lissencephalic and/or gyrencephalic species before clinical trials 
are commenced, as per the STAIR recommendations.344 
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Overall, this chapter brings together data from all published studies and confirms that NOS 
inhibitors, especially if ‘selective’ to nNOS or iNOS, reduce infarct volume in experimental 
IS. The data support the development of selective NOS inhibitors as treatments for clinical 
IS, assuming that side effects are tolerable. Unfortunately, many compounds that provide 
effective neuroprotection in animal models have progressed to full human studies, and yet 
none is clinically efficacious. Systematic reviews of animal data can help in the transition 
to clinical trials and are increasingly recognised as an important prerequisite to human 
studies.422-425  
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Table 5.1 In-vitro potency (IC50, µM) of commonly recognised inhibitors against 
NOS isoforms (based on published data108,110-112,373) 
 
Inhibitor iNOS nNOS eNOS 
1400W 0.2 7.3 1000.0 
7-NI 6.9-9.7 1.1-8.3 2.1-14.8 
Aminoguanidine 27.2-31.0 20.3-170.0 330.0 
ARR18512 5.5 0.1 24.0 
ARL17477 0.3-5.0 0.04-0.1 1.6-3.5 
GW273629 8.0 630.0 1000.0 
GW274150 1.4 145.0 466.0 
L-NAME 13.5 0.1 1.0 
L-NIL 1.6 37.0 49.0 
L-NMMA 3.5-6.6 0.3-4.9 1.0-3.5 
L-NNA 3.1-6.0 0.02-0.3 0.09-0.6 
TRIM 27.0 28.2 1057.5 
 
Abbreviations: 50% inhibition (IC50)
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Table 5.2 Included studies 
 
Drug Studies Species STAI
R 
rating 
Total 
N 
Model 
P/T 
Occlusion 
G/F 
1st dose timing 
(min) 
route Measures 
         infarct 
vol 
CBF 
           
Non specific 
inhibitors 
          
L-NAME  Anderson, 1996 380 R 3 42 T F -20 i.v.  ml.min-1.g-1 
   Anderson, 2000 379 R 3 15 P F -30 i.v. % ml.min-1.g-1 
   Ashwal, 1993 206 SHR 2 14 T F -60 i.v.  mm3  
   Ashwal, 1994 204 SHR 3 ? T F +0, +120, +150 i.v. mm3, % ml.min-1.g-1, % 
  Ashwal, 1995 205 SHR 3 14 T F -60 i.p. % , mm3  
  Batteur-Parmentier, 
2000 376 
SDR 3 110 T F +5 i.p. mm3 % 
   Buisson, 1992 426 SDR 2 ? P F +5 i.p.  mm3  
   Buisson, 1993 355 SDR 2 50 P F -30 i.p.  mm3  
   Charriaut-Marlangue, 
1996 414 
SDR 1 42 T F +5 i.p.  mm3, %  
   Clavier, 1994 381 C 3 24 T G +180 i.v.  ml.min-1.g-1 
   Coert, 1999 191 WR 3 92 T F -30 i.v. mm3  
   Dawson, 1992 427 SDR 3 18 P F -30  s.c mm3  
   Dawson, 1994 378 SDR 3 67 P, T F -30 i.p.  mm3  
   Ding-Zhou, 2002 386 M 4 ? T F +180 i.p.  mm3  
   Greenberg, 1995 392 P 4 20 T G -60 i.v.  ml.min-1.g-1 
  Hamada, 1995 408 WR 4 77 P F -20 i.c.v. mm3  
  Hiramatsu, 1996 390 P 2 40 T G -? i.v.  ml.min-1.g-1 
   Humphreys, 1998 349 SDR 3 63 T G -30 i.v.  % 
   Iuliano, 1995 207 WR 4 78 T F -30 i.v. mm3  
   Kamii, 1996 210 M 2 ? T F +5 i.p. mm3  
   Kuluz, 1993 208 WR 4 24 T F -15 i.v. mm3  
   Margaill, 1997 203 SDR 4 ? T F +5, 180, 360, i.p. mm3  
  
120 
540,720 
   Nishikawa, 1993 382 C 4 20 P F -30 i.v. % , mm3 ml.min-1.g-1 
   Nishikawa, 1994 383 C 2 49 T F -60, +45 i.v. % ml.min-1.g-1 
   Prado, 1993 404 WR 2 14 T G -5 i.v.  % 
  Puisieux, 2000 428 WR 2 52 T F -4320 i.p. mm3  
   Quast, 1995 395 SDR 2 36 T F -1 i.v. mm3  
  Schleien, 1998 391 P 3 18 T G -? i.v.  ml.min-1.g-1 
   Segawa, 1998 393 P 4 12 T G +90 i.v.  ml.min-1.g-1 
   Sercombe, 2001 429 SDR 1 37 P F -20160, -60480 p.o. mm3  
  Stagliano, 1997 209 WR 3 29 P F +5 i.v.  ml.min-1.g-1 
  Sugimura, 1998 400 WR 3 18 T G -? ?  % 
  Uetsuka, 2002 406 WR 3 40 T G -120 i.v.  ml.min-1.g-1 
   Wei, 1994 405 LER 2 28 P F +15 i.v.  ml.min-1.g-1 
   Wei, 1998 396 SDR 2 22 T F -1 i.p.  mm3  
  Zhang, 1993 188 SDR 2 31 P F +3 i.a. mm3 % 
 Zhang, 1995 430 SHR 4 37 P F +5, 120, 180, 360 i.a. mm3  
   Zhao, 1999 351 WR 2 36 T G -30 i.p.   % 
           
 L-NNA  Buchan, 1994 220 WR, 
SHR 
6 ? T, P G, F -30 , +5 i.p.  mm3 % 
  Carreau, 1994 212 M 3 ? P F +5 i.p.  mm3, %  
   Dorrepaal, 1997 394 L 3 18 T G +35 i.v.  % 
   Gursoy-Ozdemir, 2000 
214
 
M 4 65 T F +105 i.p.  mm3  
   Hashimoto, 1999 402 WR 2 ? T F -10 i.p., 
i.a.. 
% % 
   Matsui, 1997 407 SDR 4 148 T F -5, +5 i.p.  mm3 ml.min-1.g-1 
   Nakashima, 1999 374 WR, FR 1 ? T F +120 i.p., i.v. mm3  
   Nowicki, 1991 384 M 1 31 P F +5 i.p.  mm3  
   Sadoshima, 1997 211 SHR 2 34 T G +60 i.v.   ml.min-1.g-1, % 
  Santizo, 2000 398 SDR 2 26 T G -45 i.v.  % 
  Spatz, 1995 389 MG 2 ? T G -240 i.p.  % 
   Spinnewyn, 1999 215 SDR 3 88 T F +240 i.v.  mm3  
  Xu, 2000 377 SDR 1 24 P F -30 i.p. mm3  
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   Yamamoto, 1992 375 WR 2 37 P F +5 i.v.  mm3  
   Zhang, 1996 218 WR 3 73 T F +120 i.v.  % % 
           
L-NMMA  Sakashita, 1994 401 WR 1 30 T G -5 i.p.  % 
           
nNOS inhibitors           
           
  7NI  Coert, 1999 191 WR 3 92 T F -60 i.p. mm3  
   Escott, 1998 114 SDR 6 55 T F +5, +90 i.p. %, mm3  
   Goyagi, 2001 226 WR, M 5 115 T F -30  i.p. %  
  Gursoy-Ozdemir, 2000 
214
 
M 4 65 T F -30, +90 i.p. mm3  
   Humphreys, 1998 349 SDR 3 63 T G -30 i.v.   % 
  Jiang, 1999 399 WR 3 18 T G -20 i.p.  % 
   Kamii, 1996 210 M 2 ? T F +5 i.p. mm3  
  Uetsuka, 2002 406 WR 3 40 T G -60 i.p.  ml.min-1.g-1 
   Yoshida, 1994 227 SDR 3 55 P F +5 i.p. mm3  
           
 AR-R 17477  Harukuni, 1999 431 WR 5 53 P F -30, +60 i.v.  mm3  
  O'Neill, 2000 388 MG, 
WR 
4 ? T F, G 0, +30, +120 i.v. mm3  
  Santizo, 2000 398 SDR 2 26 P F -45 i.v.  % 
   Zhang, 1996 218 WR 3 48 T F +120 i.v.  % % 
           
 BN 80933  Chabrier, 1999 113 SDR, 
MG 
6 ? T F, G +5, 240, 360, 480, 
1440 
i.v. mm3  
           
 PPBP  Goyagi, 2001 226 WR, M 5 115 T F -30 i.p, i.v. %  
           
 TRIM  Escott, 1998 114 SDR 6 55 T F +5 or 90 i.p. %, mm3  
           
           
iNOS inhibitors           
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1400W  Parmentier, 1999 225 SDR 3 ? T F +1080 s.c. mm3  
           
Aminoguanidine  Cash, 2001 397 SDR 3 ? T F +360  i.p. mm3  
  Cockroft, 1996 223 LR 4 ? P F +15, 60, 120, 180 i.p. %  
  Han, 2002 432 SDR 3 ? T F +0 i.p. %  
  Iadecola, 1995 222 SHR 2 53 P F +1440 i.p. mm3 % 
  Iadecola, 1996 403 SDR 2 79 T F +360 i.p. mm3  
  Nagayama, 1998 224 SHR 4 60 P F +1440 i.p. mm3, %  
  Sugimoto, 2002 385 M 3 58 P F +1080 i.p. mm3  
  Tsuji, 2000 433 WR 3 31 P G -60 i.p. %  
  Xu, 2000 377 SDR 1 24 P F -30 i.p. mm3  
  Zhang, 1996 354 SDR 1 71 T F +1440 i.p. mm3, %  
  Zhang, 1998 434 SHR 3 47 P F +0 i.p. mm3  
  Zhu, 2002 387 M 2 75 T F +360 i.p. %  
 
Abbreviations: Mice (M); Mongolian Gerbil (MG); Piglets (P); Lambs (L); Cats (C); Spontaneously Hypertensive rat (SHR); Sprague-
Dawley rat (SDR); Wistar rat (WR); Long-Evans rat (LER); Lewis Rats (LR); Fischer Rats (FR); Rabbits (R); male (M); female (F); 
permanent (P); transient (T); global (G); focal (F); intra-venous (i.v.); intra-arterial (i.a.); intra-peritoneal (i.p.); infarct volume (infarct vol.); 
cerebral blood flow (CBF); value not reported (?) 
  
123 
Table 5.3 Effect of NOS inhibitors on lesion volume and CBF (SMD, 95% CI) by brain region in models of permanent and 
transient ischaemia 
 
Outcome  Permanent   Transient 
 
 
 Total 
 
Cortical Sub-cortical Total Cortical Sub-cortical 
Lesion 
volume 
-0.56*  
(-0.86, -
0.26) 
S=18, 
n=554 
 
-0.89*  
(-1.31, -
0.47) 
S=16, 
n=409 
-0.47*  
(-0.78, -
0.16) 
S=13, 
n=361 
-0.99*  
(-1.25, -
0.72) 
S=25, 
n=927 
-0.71*  
(-0.95, -
0.46) 
S=13, 
n=543 
-0.45* 
 (-0.76, -
0.14) 
S=12, 
n=418 
CBF  
No data 
 
-0.80*  
(-1.34, -
0.27) 
S=6, n=87 
-0.73  
(-1.83, 
0.36) 
S=1, n=14 
 
-0.57 
(-1.26, 
0.11) 
S=8, n=120 
-0.22  
(-0.52, 
0.07) 
S=15, 
n=320 
-0.38 
(-1.03, 0.26) 
S=3, n=66 
 
Abbreviations: Standardised mean difference (SMD); cerebral blood flow (CBF); 95% confidence intervals (95% CI); number of studies 
(S); number of animals (n); *p<0.05 
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Figure 5.1a Total lesion volume by different NOS inhibitor types for permanent 
models of ischaemia 
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Figure 5.1b Cortical CBF by different NOS inhibitor types for transient models of 
ischaemia 
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Figure 5.2 Search process showing reasons for exclusion of studies 
 
 
 
 
 
 
 
 
 
 
Identified studies 
n=456 
Ischaemia not induced 
n=276 
Ischaemia induced 
n=180 
No NOS inhibitor given 
n=10 
NOS inhibitor administered 
n=170 
No Infarct/CBF measurements 
n=82 
Infarct volume / CBF measured 
n=88 
Other exclusion criteria 
n=15 
Included studies 
n=73 
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Figure 5.3 SMD and 95%CI by reported STAIR score for (A.) Permanent models; (B.) 
Transient models 
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Figure 5.4 SMD and 95%CI by type of NOS inhibitor for (A.) Total lesion volume in permanent models; (B.) Cortical CBF in 
permanent models; (C.) Total lesion volume in transient models; (D.) Cortical CBF in transient models. 
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Figure 5.5 SMD and 95%CI by timing of treatment (A.) in permanent models; (B.) in transient models; and by animal species (C.) 
in permanent models; (D.) in transient models. 
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Figure 5.6 Effect of delay until first dose (minutes) on total infarct volume (SMD) in transient ischaemia. Size of circle 
proportional to size of study. 
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Chapter 6. 
Haemodynamic and plasma effects of transdermal GTN, a NO 
donor, given <48 hours after stroke 
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6.1 Abstract 
Background: High BP is a potential therapeutic target in acute stroke because it is 
independently associated with a poor outcome. Hence, the effect of GTN on 
haemodynamics and platelet activation was investigated in patients with acute (< 48 
hours) stroke. Methods: 42 patients with ischaemic or haemorrhagic stroke were 
randomised within 48 hours to transdermal GTN (5 mg) or control. Peripheral BP 
measurement (Omron 705CP), pulse wave analysis (Sphygmocor), non-invasive CO 
monitoring (Portepres), TCD (Nicolet EME Companion TCD system), NO analysis (Seivers 
280 NO Analyser) and P-selectin ELISA (Parameter, Human soluble P-selectin 
immunoassay) were performed before and 1hour after treatment. Daily GTN was 
continued for 7 days. The effect of GTN on the measurements were adjusted for baseline 
(ANCOVA); mean and 95% CI are given. Results: GTN lowered peripheral and central 
systolic BP by -15.1 (95% CI -26.6, -3.5, p=0.01) and -15.6 (95% CI -24.2, -7.0, p<0.01) 
mmHg respectively. GTN also lowered PP, mean arterial BP (central and peripheral) and 
AI. Heart rate, diastolic BP, MCA velocity, PI, BI, plasma NO metabolites and p-selectin 
were unaffected. Conclusions: It is feasible to lower BP <48 hours from stroke onset with 
transdermal GTN. The absence of any detrimental effect on MCA velocity and PI suggests 
that cerebral perfusion was not compromised, although further studies are required. 
Neutral effects on platelet activation imply that GTN patches can continue to be 
investigated in haemorrhagic stroke.  
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6.2 Background 
BP is raised in three quarters of IS patients and is associated with poor outcome.138 
Therefore, it may be possible to improve outcome by lowering BP as long as CBF is not 
compromised. NO , given as GTN, is a potent endogenous vasodilator that lowers BP and 
increases CBF in normal subjects.435 Moreover, in animal models NO is neuroprotective, 
possibly due to scavenging of reactive oxygen species338-340, inhibition of platelets and 
leucocytes78,79, and attenuation of NMDA receptors.341 Two trials have previously studied 
the effects of GTN in patients with recent stroke on BP. The first demonstrated a 
significant (~8%) reduction in 24 hour ambulatory systolic BP on day 1. However there 
was evidence of tolerance at day 8, a known property of organic nitrates.166 The second 
found that GTN lowered 24 hour ambulatory mean arterial BP by 5 - 7% on day 1 in a 
dose dependent manner.167 Tolerance was overcome by increasing the GTN on day 4. In 
addition, GTN had no effect on cerebral blood velocity in the affected hemisphere, 
suggesting that CBF did not change.   
 
The optimum therapeutic time window for GTN administration is not known, however it is 
likely that the sooner it is given the better. For instance, the NO donor SIN-1 was effective 
at reducing infarct volume up to, but not beyond 1 hour in one study, suggesting that 
neuroprotective effects of NO are short-lived.337 The median time to treatment was 4.4 
days in the first GTN trial166 and 51 hours in the second.167 Hence, there is a rationale for 
initiating treatment with GTN earlier than was accomplished in the previous trials. 
Therefore, the aim of the present study was to undertake a fuller assessment of the effect 
of GTN on BP when administered <48 hours after onset of ischaemic or haemorrhagic 
stroke. Effects on plasma NO, platelet adhesion systemic and cerebral haemodynamics 
were also studied.  
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6.3 Methods 
Design 
A single centre sub-study forming part of an ongoing, prospective, international, 
multicentre, randomised, parallel-group, double-blind, placebo-controlled, trial was 
performed. The Efficacy of Nitric Oxide in Stroke (ENOS) trial is designed to test the safety 
and efficacy of NO, given as transdermal GTN, and of continuing or stopping prior anti-
hypertensive medication, in 5000 patients with acute ischaemic or haemorrhagic stroke.363 
The ENOS trial database was not interrogated for the purposes of the sub-study; instead 
data were collected from the ENOS case report forms and prescription charts. Ethical 
approval was obtained from the local ethics committee (EC01/53) and patients gave 
written informed consent to participate. The study conformed to the Declaration of Helsinki 
and International Conference on Harmonisation guidelines. Enrolment took place between 
September 2001 and September 2004. 
 
Subjects 
Previously independent (Rankin score < 3) adult patients with a clinical stroke syndrome, 
including limb weakness (defined as Scandinavian Neurological Stroke Scale, SNSS Arm 
and /or leg<6), were recruited within 48 hours of ictus. All subjects had elevated systolic 
BP (140–220mmHg) on at least one of three consecutive measurements at baseline. 
Subjects with a requirement for, or a contraindication to nitrate therapy, were excluded. 
Similarly, those who had a definite need for prior antihypertensive therapy or vasoactive 
drugs were disqualified.  
 
Treatment 
Subjects were randomised to receive either a 5mg GTN patch (Transiderm-Nitro 5, 
Novartis Pharmaceuticals UK Limited, West Sussex, UK) or nothing once daily for 7 days. 
  
135 
In contrast to a previous study166 no manufacturer was willing to provide placebo patches, 
hence a large dressing was used to conceal treatment status from patients (‘single blind’) 
and enable blinded outcome assessment. GTN patches were changed at 08:00 every 
morning by a ward nurse and kept on for a full 24 hours. Subjects taking prior 
antihypertensive medication were also randomised 1:1 to either stop or continue 
treatment.  
 
Systemic haemodynamics 
Peripheral BP was measured in the non-hemiparetic arm with a validated digital readout 
oscillometric device (Omron HEM-705CP, Omron Corp, Tokyo, Japan).235 Average systolic 
and diastolic BP was determined at baseline, 1 hour after treatment allocation and on day 
4 and day 7 of the treatment period. CO and total peripheral resistance (TPR) were 
assessed using Portapres model-2 (TNO-TPD Biomedical Instrumentation). 
Measurements were taken for 5 minutes at baseline and at 1 hour after allocation to 
treatment using the normal hand. BeatScope 2 software (TNO-TPD Biomedical 
Instrumentation) was used to calculate CO by the Modelflow method.240 Central systolic 
BP, diastolic BP and AI were assessed by applanation tonometry at the radial pulse 
(Sphygmocor Pulse Wave Analysis System, Sydney, Australia). PWV was not determined 
because measurements from the carotid artery could be dangerous in the presence of un-
diagnosed carotid stenosis. Measurements were taken from the non-hemiparetic wrist until 
two satisfied the quality control system built in to the software. Mean values were then 
determined at baseline and 1 hour after treatment allocation.  
 
Cerebral haemodynamics 
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Bilateral MCA blood velocity and PI were measured using a Nicolet EME Companion TCD 
system connected to a 2 Mhz probe. The highest attainable velocities from the M1 
segment of the MCA were recorded at baseline and 1hour after treatment allocation. 
 
Laboratory analyses 
Plasma and serum was collected at baseline and 1hour after randomisation to treatment. 
Samples were analysed in batches blinded to treatment. Plasma NO was measured by 
chemiluminescence using a Seivers 280 NO Analyser (Analytix Ltd, County Durham, UK). 
Detailed methods have been published previously.436 In addition, a commercially available 
enzyme immunoassay kit was used to assess the effect of GTN on soluble p-selectin 
(Parameter, Human soluble P-selectin immunoassay, R&D systems, Oxfordshire, UK).  
 
Functional outcome 
Data on modified Rankin are collected centrally for ENOS patients and were not available 
for this study.  
 
Statistical methods 
Patients were randomised with minimisation on age, stroke type, stroke severity (SNSS), 
history of stroke, history of hypertension, and history of nitrate use within previous two 
days. Data were entered and analysed by received treatment using SPSS (Macintosh 
version 10.0, SPSS Inc, Chicago, IL). Mean (standard deviation [SD]), median 
(interquartile range [IQR]) or frequencies (%) are given. All comparisons of BP and 
haemodynamic data between the treatment groups were analysed with adjustment for 
baseline values using analysis of covariance (ANCOVA). Data from subjects who were 
randomised to continue prior antihypertensive medication were excluded from the 
analysis. Significance was set at p<0.05.  
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6.4 Results 
Sample characteristics 
Consent or assent was obtained for 51 subjects; 9 of these were randomised to continue 
prior antihypertensive drugs and hence were excluded from the analysis (figure 6.1). The 
patients in the control and GTN groups were well matched for age, gender, time to 
randomisation, previous strokes, smoking, hypertension and antihypertensive usage (table 
6.1). However, baseline central (not peripheral) systolic BP, was significantly lower in the 
GTN group. The sample included a representative mixture of both ischaemic (n=35, 83%) 
and haemorrhagic strokes (n=7, 17%), however cortical strokes were under-represented 
(n=14, 33%). The mean delay from stroke onset to randomisation was 32 hours.  
 
BP and pulse 
Systolic BP tended to fall over the course of the study in both treatment arms (figure 6.2a). 
Compared with baseline, significant reductions in systolic BP were observed in the GTN 
group at 1 hour (-12mmHg, 95%CI -19, -5) and at day 7 (-11mmHg, 95%CI -20, -2). By 
contrast, there were no significant changes in systolic BP for the control group. After 
adjustment for baseline values, peripheral and central systolic BP were lower at 1 hour in 
the GTN group than in the control group by 15 mmHg (9%) and 16 mmHg (10%) 
respectively (p=0.01, p<0.01, table 6.2). Similarly, peripheral and central mean arterial BP 
were lower than in the control group by 10mmHg (p=0.03) and 9mmHg (p<0.01) 
respectively. Diastolic BP tended to remain lower than at baseline in the GTN group and 
rise in the control group over the course of the study (figure 6.2b). In the GTN group 
significant reductions in diastolic BP compared with baseline were observed at 1 hour 
(mean change -10mmHg, 95%CI -16, -5) and at day 7 (mean change -5mmHg, 95%CI -
10, -0). By contrast, there were no significant changes in diastolic BP for the control group. 
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Also, after adjustment for baseline values GTN did not significantly lower peripheral 
(7mmHg, p=0.10) or central diastolic BP (5mmHg, P=0.07) compared with the control 
group. Finally, GTN had no effect on heart rate.  
 
Other systemic haemodynamic measures 
AI at 1 hour was significantly lower by -20% (p<0.01) in those who received GTN as 
compared with the control subjects (table 6.2). GTN had no effect on CO, TPR or BI. 
 
Cerebral haemodynamic measures 
MCA velocity and PI did not change with GTN in either the affected or unaffected 
hemispheres at 1 hour. 
 
Laboratory measures 
GTN had no significant effect on 1 hour plasma NOx levels. Similarly, GTN did not affect 
expression of soluble p-selectin.  
 
6.5 Discussion 
This chapter has shown that transdermal GTN lowers systolic and mean arterial BP in 
acute ischaemic or haemorrhagic stroke. This finding is compatible with 2 previous studies 
which demonstrated a similar (~5-8%) reduction in 24 ambulatory systolic166 or mean 
arterial BP.167 The effect on BP was modest and beneath the maximum limit suggested by 
published guidelines, which recommend that BP should not be lowered by more than 20% 
in acute stroke.153,437 Importantly, the study extends the information available and 
demonstrates the feasibility of administering GTN < 48 hours from onset. 
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Effects on plasma NO metabolites and central haemodynamics were examined to gain 
insight into the mechanisms by which GTN lowers BP. Interestingly, GTN did not alter 
plasma nitrate / nitrite (NOx) levels, the metabolic product of NO. This corresponds with 
previous studies involving stroke patients167 and normal humans.438 Possible explanations 
include; confounding by the effects of recent food intake,439 contamination with inorganic 
nitrites and nitrosamines300 or inadequate sample size. In contrast, GTN did lower 
peripheral and central systolic BP, mean arterial BP and PP. Significant effects on central 
haemodynamics are of importance because they may better indicate the effect of GTN on 
intracranial haemodynamics than peripheral measurements. BP might have been 
influenced, in part, by the increase in aortic compliance that was observed. Reduced AI 
following GTN is consistent with findings in normal subjects440,441 and in sub-acute 
stroke.167 Alternatively, GTN did not appear to influence BP through effects on TPR, which 
remained unchanged at 1 hour. Previous studies have also failed to detect changes in 
TPR, suggesting that any effect of GTN on peripheral arterioles is relatively small.442,443 
Similarly, GTN had no detrimental effect on CO at 1 hour, which is reassuring because the 
brain consumes 15-20% of total CO to maintain resting CBF.8 Effects of GTN on CO have 
been variable in published data with some studies reporting neutral results167,444, and 
others reporting negative results.445,446 Presumably, inconsistencies have arisen through 
differences in the route of administration, dosage, and cardiac status of the study subjects. 
Finally, GTN did not alter heart rate at 1 hour, contradicting data from several studies 
where reflex activation of the sympathetic nervous system was thought to be responsible 
for increases in heart rate.447,448 This inconsistency is also likely to reflect differences in 
drug formulation and dosage since 5mg transdermal GTN patches did not effect heart rate 
in either of the previous stroke trials.166,167 
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NO is known to have anti-platelet properties, in part through suppression of p-selectin 
expression on the surface of platelets and in the plasma.449 However, transdermal GTN 
did not alter plasma soluble p-selectin, suggesting that there was no alteration in platelet 
activation. Interestingly, this finding corresponds with data from two earlier studies using 
GTN patches,166,450 but it conflicts with studies using other NO donors, such as 
SNP.162,451,452 GTN does not have antiplatelet properties because platelets are unable to 
release NO from organic nitrates.79 The lack of observable effects on platelet function 
mean that GTN patches can continue to be studied in haemorrhagic as well as IS.   
 
Finally, GTN had no effect on MCA velocity and PI (an index of vascular resistance), 
implying that CBF was unaffected. This is reassuring since there are concerns that 
lowering BP might worsen outcome in acute stroke through reducing CBF.313 However, it 
is impossible to entirely rule out a detrimental effect on cerebral perfusion because the 
relationship between blood velocity and CBF remains unclear.261,453 Further studies 
involving quantitative CBF measurements with SPECT or XeCT are required. The findings 
are consistent with previous data involving GTN patches,362 however they disagree with 
studies using sublingual or intravenous GTN where velocities decreased 
significantly.161,454,455 The inconsistency probably arises because transdermal GTN 
produces a lower peak plasma concentration than other GTN formulations.456  
 
A number of methodological weaknesses may have influenced the findings. First, there 
was no placebo control due to lack of commercial availability of placebo patches. 
Consequently, attempts were made to limit bias by the using a gauze dressing to enable 
blinded outcome assessment. Second, central systolic BP was lower in the GTN group at 
baseline and therefore the treatment effect could have been overestimated. However, the 
analysis of covariance (ANCOVA) will have tended to correct for this because it has the 
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advantage of being unaffected by baseline imbalances. Third, the number of milder, 
subcortical strokes included in the study was larger than expected, hence the findings may 
not be generalisable. Future studies should aim to recruit more severe subjects with 
cortical strokes. Finally, the study was small and the CI were wide. Therefore the 
possibility of a type 2 error for the neutral measurements cannot be excluded, e.g. plasma 
NOx, CO, TPR and MCA velocity. Reassuringly, the estimate of difference between control 
and GTN for all these measurements was close to zero.  
 
In summary, this chapter has demonstrated that it is feasible to lower BP <48 hours from 
stroke onset with transdermal GTN. BP was probably influenced, in part, by an 
improvement in aortic compliance but not by changes in TPR or CO. Also, GTN did not 
appear to compromise indirect measures of cerebral perfusion, although further studies 
are required. Early administration of GTN is desirable in order to make the most of its 
potentially neuroprotective and vasculoprotective properties. The optimum time window 
remains unclear, however this question will be addressed following completion of the 
ongoing ‘Efficacy of Nitric Oxide in Stroke’ (ENOS) trial.363  
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Table 6.1 Demographic characteristics and haemodynamic measurements at 
baseline. Mean (SD), median * (IQR), or frequency (%). 
 
 Control GTN 
Subjects 21 21 
Age (years) † 74 (9) 68 (11) 
Gender, male (%) † 13 (62) 11 (52) 
Previous hypertension (%) 10 (48) 7 (33) 
Previous antihypertensive therapy (%) 6 (29) 5 (24) 
Previous stroke (%) 4 (19) 2 (10) 
Smoker (current, %) 5 (24) 7 (33) 
Stroke to randomisation (hours) *† 29 (16) 31 (18) 
Scandinavian Stroke Scale (/58) *† 39 (29) 43 (20) 
Stroke type, ischaemic (%) 17 (81) 19 (91) 
Cortical (TACS, PACS) (%) 8 (38) 6 (29) 
   
Systolic BP (mmHg) † 176 (28) 163 (20) 
Diastolic BP (mmHg) 90 (16) 95 (13) 
Heart rate (bpm) 75 (13) 69 (12) 
Central systolic BP (mmHg) 165 (29) 147 (20) 
Central diastolic BP (mmHg) 93 (16) 91 (14) 
† Minimisation variable 
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Table 6.2 Effect of transdermal GTN on measurements at 1 hour. Mean (SD), 95% CI, comparison by ANCOVA with adjustment 
for baseline. 
Measurement  Control, 
subjects 
GTN, 
subjects 
Control GTN Difference, 
95% CI 
2p 
Peripheral  Systolic BP (mmHg) 21 21 174.9 (27.9) 151.3 (18.1) -15.1 (-26.6, -3.5) 0.01* 
 Diastolic BP (mmHg) 21 21 89.0 (14.8) 84.7 (13.7) -6.5 (-14.4, 1.3) 0.10 
 Mean arterial BP (mmHg) 21 21 117.6 (18.6) 106.9 (14.3) -10.0 (-18.9, -1.1) 0.03* 
 PP (mmHg) 21 21 85.9 (16.9) 66.6 (11.3) -9.9 (-18.4, -1.4) 0.02* 
 Heart rate (beats/min) 21 21 75.3 (12.1) 72.6 (16.4) +3.2 (-2.4, +8.7) 0.25 
        
Systemic Central systolic BP (mmHg) 21 20 160.0 (24.5) 133.7 (17.5) -15.6 (-24.2, -7.0) <0.01* 
 Central diastolic BP (mmHg) 21 20 92.3 (13.2) 86.5 (13.3) -5.4 (-11.2, +0.4) 0.07 
 Central mean arterial BP (mmHg) 21 20 114.8 (16.2) 102.2 (13.8) -8.7 (-14.8, -2.6) <0.01* 
 Central PP (mmHg) 21 20 67.7 (15.7) 47.2 (11.8) -11.5 (-18.2, +4.8) <0.01* 
 AI (%) 21 20 144.2 (22.4) 122.0 (22.0) -20.4 (-31.3, -9.6) <0.01* 
 BI (%) 20 20 150.5 (45.2) 179.3 (53.6) +4.1 (-15.3, +23.6) 0.67 
 CO (L/min) 13 14 7.2 (3.4) 6.3 (1.9) +1.1 (-0.2, +2.4) 0.81 
 TPR (LogN, m-units) 13 14 0.9 (0.5) 0.9 (0.3) -0.1 (-0.5, +0.2) 0.44 
        
Cerebral Ipsilateral MCA velocity (cm/s) 15 17 27.2 (14.3) 26.0 (10.8) -2.2 (-8.7, 4.3) 0.50 
 Ipsilateral MCA PI (LogN) 15 17 1.9 (0.8) 1.4 (0.8) -0.2 (-6.8, +0.2) 0.33 
 Contralateral MCA velocity (cm/s)  18 17 28.9 (16.5) 31.9 (12.5) -0.7 (-7.7, +6.3) 0.84 
 Contralateral MCA PI (LogN) 18 17 1.8 (0.9) 1.4 (0.5) -0.0 (-0.4, 0.3) 0.86 
        
Laboratory Plasma NO (mmol.l-1) 16 18 25.8 (11.2) 38.2 (19.3) +2.1 (-3.0, 7.2) 0.42 
 Soluble p-selectin (ng.ml-1) 19 17 93.1 (48.1) 112.1 (51.3) -3.7 (-34.4, +27.0) 0.81 
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Figure 6.1 Trial flow profile 
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Figure 6.2a Systolic BP change from baseline by treatment group  
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Figure 6.2b Diastolic BP change from baseline by treatment group 
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Chapter 7. 
Transdermal GTN maintains CBF and perfusion pressure 
whilst lowering blood pressure in patients with acute stroke 
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7.1 Abstract 
Background: High BP is common in acute stroke and independently associated with a 
poor outcome. Lowering BP might improve outcome if it did not adversely affect CBF or 
cerebral perfusion pressure. Hence, the effect of GTN on quantitative CBF, BP and 
cerebral perfusion pressure in patients with recent stroke was investigated. Methods: 18 
patients with recent (<5 days) ischaemic (n=16) or haemorrhagic (n=2) stroke were 
randomised (2:1) to transdermal GTN (5 mg) or control. CBF (global, hemispheric, arterial 
territory, lesion, using XeCT) and BP (peripheral and central) were measured before and 1 
hour after treatment with GTN. The effect of GTN on CBF and BP were adjusted for 
baseline measurements (ANCOVA). Result: GTN lowered peripheral systolic BP by 
(mean) 23 mmHg (95% CI 2, 45, p=0.03), and central systolic BP by 22 mmHg (95% CI 0, 
44, p=0.048). In contrast, GTN did not alter CBF (mls/min/100 g): global -1.2 (95% CI –6.5, 
+4.2, p=0.66), ipsilateral hemisphere –1.4 (-7.6, +4.9, p=0.65); or area of stroke oligaemia, 
penumbra or core (as defined by critical CBF limits). Contralateral CBF did not change: 
hemisphere 0 (95% CI –7, +6, p=0.96). GTN did not alter cerebral perfusion pressure or 
zero filling pressure. Conclusions: Significant reductions in BP following transdermal GTN 
are not associated with changes in CBF or cerebral perfusion pressure, or cerebral steal in 
patients with recent stroke. Trials need to assess the effect of lowering BP on functional 
outcome. 
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7.2 Background 
High BP is present in more than three-quarters of patients at presentation with acute IS 
and is independently associated with a poor outcome and early recurrence.138,457 Similar 
findings have been reported for patients with PICH.132 These observational data raise the 
possibility that lowering BP might improve functional outcome providing both CBF and 
cerebral perfusion pressure (CPP) do not fall. 
 
Drugs which lower BP in patients with recent IS vary in their effect on CBF. Calcium 
channel blockers (CCB) reduced cerebral perfusion in parallel with their effect on BP.458,459 
In contrast, angiotensin modifying drugs such as captopril and perindopril (angiotensin 
converting enzyme inhibitors, ACE-I), and losartan (angiotensin receptor antagonist, ARA) 
did not appear to alter CBF or MCA blood velocity.175,177,460 Hence, the effect of altering BP 
on CBF may be drug or class specific. 
 
CPP is the difference between upstream (mean arterial pressure) and downstream 
pressure, the latter being determined by intracranial pressure (ICP) and central venous 
pressure (CVP). Cerebral vasodilators may increase or decrease CPP depending on their 
relative effects on these three measures, e.g. venodilators may both increase cerebral 
blood volume and reduce CVP thereby maintaining ICP. Previous work has shown that 
vasodilators, including nitrous oxide,461 can increase CPP by reducing zero flow pressure, 
a measure of cerebral downstream (venous) pressure. 
 
In a previous trial transdermal GTN lowered both peripheral and central BP in a dose-
dependent manner, improved aortic compliance, and did not alter platelet function or 
activation.166,362 Indirect evidence also suggested that nitrates lowered BP without 
attenuating CBF, confirming preclinical data.163,192,343 SNP did not alter CBF, assessed 
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qualitatively using SPECT.162 Similarly, GTN did not change MCA blood velocity and PI, 
these being indirect measures of CBF.362 The aim of the present study was to assess 
simultaneously the effects of GTN on BP, CBF and CPP. 
 
7.3 Methods 
Design 
A prospective, single-centre, patient and measurement-blinded randomised controlled trial 
was performed. Approval was obtained from the local Research Ethics Committee 
(EC01/69) and Medicines Control Agency (DDX MF8000/13187). Patients gave written 
informed consent to participate; assent was obtained from the next-of-kin if the patient was 
unable to give consent. Enrolment into the study was made prior to neuroimaging or 
estimation of CBF. The study conformed to the Declaration of Helsinki and International 
Conference on Harmonisation guidelines. Enrolment took place between September 2002 
and September 2004. 
 
Subjects 
18 previously independent (modified Rankin Scale, mRS 0-2) adult patients with a clinical 
stroke syndrome and limb weakness (Scandinavian Stroke Scale, SSS Arm and/or leg 
<6), were recruited within 5 days of ictus (figure 7.1). All subjects had an elevated systolic 
BP (140–220 mmHg) at enrolment. Subjects were excluded if they had a requirement for, 
or a contraindication to, nitrate therapy; had a definite need for prior antihypertensive 
therapy or vasoactive drugs; or could not cooperate with scanning. 
 
Treatment 
Subjects were randomised using computerised minimisation (on age, gender, baseline 
systolic BP, baseline SSS, hours from onset and the presence of a visible stroke lesion on 
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CT) to receive either a 5 mg GTN patch (‘Transiderm-Nitro 5’, Novartis Pharmaceuticals) 
or control in a ratio of 2:1. Treatment was given once daily for 7 days. Patients and the 
assessor who performed haemodynamic and XeCT measurements were blinded to 
treatment by placement of a large gauze dressing over the patch or empty skin to conceal 
treatment status. GTN patches were changed at 08:00 hours each day and kept on for a 
full 24 hours. Any prior antihypertensive medication was discontinued at the time of 
admission, as is routine at Nottingham City Hospital. 
 
CBF 
Quantitative regional CBF was measured using the stable XeCT method (Diversified 
Diagnostic Products XeCT system 2, Houston, USA).271 A baseline CT head scan was 
performed to confirm the diagnosis of stroke (ischaemia, haemorrhage) and to obtain a 
‘scout’ image; subsequent scans comprised four adjacent 10 mm thick slices chosen to 
encompass the maximum axial dimensions of the stroke lesion. If no lesion was visible, 
slices included the basal ganglia and internal capsule. The patient was connected to the 
XeCT system via a facemask and breathed room air for 30 seconds while two baseline 
sets of images were recorded. Subsequently, the patient breathed a mix of Xe (28%) and 
oxygen (25%) with monitoring of end tidal Xe concentration. Further sets of images were 
then collected over five minutes. A second XeCT scan series was performed one hour 
after administration of GTN or control; careful positioning of the patient ensured that near-
identical brain slices as determined by neuroradiological landmarks were imaged in pre 
and post-GTN scans. 
 
CBF was calculated on a PC using XeCT software in an identical manner for pre and post-
GTN scans. Images with excessive movement artefact or where an old stroke lesion was 
present were discarded. Analyses were blinded to treatment and concentrated on the slice 
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with the largest visible area of stroke lesion. If no lesion was visible, an appropriate level 
was selected according to the clinical presentation. Global and hemispheric regions of 
interest (ROIs) were sited using a rectangular shaped template, the former touching the 
inside of the skull anteroposteriorly and laterally, and the latter dividing the skull at the 
midline. Anterior, middle and posterior cerebral artery territory ROIs were placed over the 
cortex using a template generated by the XeCT software (figure 7.2a).  
 
An additional pixel based analysis was used to assess the effect of GTN on CBF in the 
stroke lesion, if visible. A rectangular ROI was placed to cover the whole of the stroke 
lesion and surrounding brain tissue (figure 7.2b). A CBF filter was then used to determine 
the number of pixels within the ROI matching pre-specified CBF values for ‘core’ <10 
ml/min/100g, ‘penumbra’ 10-19 ml/min/100g, and ‘oligaemia’ 20-36 ml/min/100g.287-290 
Matching ROIs were sited on pre and post treatment scans to ensure consistency and the 
areas (in pixels) of reduced CBF compared. 
 
TCD 
MCA blood velocity was determined bilaterally by TCD (Nicolet EME Companion, 
Kleimoftheim, Germany) with the trans-temporal window accessed at depths from 30 to 60 
mm.462 Duplicate mean, systolic and diastolic velocities and PI were measured separately 
for affected and unaffected hemispheres.166,362 
  
BP 
BP was measured immediately before the baseline XeCT scan and immediately after the 
post-treatment scan. Duplicate measurements of peripheral systolic and diastolic BP was 
measured in the non-hemiparetic arm with a validated digital readout oscillometric device 
(Omron HEM-705CP, Omron Corp, Tokyo, Japan).235 Central BP was assessed by 
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applanation tonometry of the left radial artery and using the Pulse Wave Analysis (PWA) 
system (Sphygmocor, Sydney, Australia).362 Duplicate recordings were taken, comprising 
a screen of data satisfying the quality control criteria of the PWA system (pulse height and 
diastolic variability ≤ 10%). The recorded radial artery pressure wave was transformed to 
the corresponding central wave using a validated transfer function and central BP derived 
automatically. 
  
CPP 
CPP and zero ZFP were estimated from measures of MCA blood flow velocity (FV), 
assessed using TCD, and peripheral BP using the method of Mahajan and 
colleagues:461,463  
 
CPP = (mean FV / (mean FV – diastolic FV)) x (mean BP –diastolic BP) 
ZFP = mean BP - CPP 
 
Statistical methods 
The study assumed that a between group difference in CBF of 10 ml/min/100g (standard 
deviation 6) would be of clinical relevance. Assuming significance 0.05, power 0.80, 2:1 
randomisation, the sample size was estimated at 18. Data were entered and analysed by 
intention to treat using SPSS (Apple Mac version 11.0.2, SPSS Inc, Chicago, IL). Mean 
(standard deviation [SD]), median (interquartile range [IQR]) or frequencies (%) are given. 
All comparisons of haemodynamic and BP data between the treatment groups were 
analysed with adjustment for baseline values using analysis of covariance (ANCOVA). 
Linear regression was used to assess the relationship between on treatment CBF and BP 
with adjustment for baseline values. Significance was set at p<0.05. 
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7.4 Results 
Subject characteristics were balanced between the two groups except that more patients 
randomised to GTN were female or had a cortical-based stroke on CT scan (table 7.1). 
Peripheral BP was elevated at baseline and higher than central BP. Although the mean 
areas of oligaemia, penumbra and core were similar in size between the two groups, 
baseline measures of global, hemispheric and regional CBF, both ipsilateral and 
contralateral to the lesion, and zero filling pressure were non-significantly higher in patients 
randomised to GTN (table 7.2). Patients randomised to control tended to have higher 
cerebral perfusion pressure. 
 
GTN lowered peripheral and central systolic BP by 23 mmHg (14%) and 22 mmHg (13%) 
respectively (p=0.034, p=0.048). Non-significant reductions in peripheral and central 
diastolic BP were present, 4 mmHg (3%) for each (p=0.47, 0.55). GTN did not alter heart 
rate. In contrast to BP, GTN did not alter any measure of global, hemispheric or regional 
CBF whether on the side ipsilateral or contralateral to the lesion (table 7.3, figures 7.2a, 
7.3, 7.4). Nevertheless, the CI were wide and GTN might have reduced ipsilateral 
hemispheric CBF by 7.6 ml/min/100g or increased it by 4.9 ml/min/100g. When defined by 
blood flow levels, GTN had no effect on the size of presumptive core, penumbra or 
oligaemic areas (figure 7.2b). Similarly, GTN did not significantly alter estimates of 
cerebral perfusion pressure and zero flow pressure (table 7.3). 
 
There was no association between on-treatment measures of ipsilateral CBF and systolic 
BP (p=0.83, with adjustment for baseline CBF and systolic BP) in patients randomised to 
GTN. 
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All patients completed 7 days of treatment. One serious adverse event occurred during the 
treatment phase; a patient receiving GTN had a non-hypotension related fall leading to 
trauma of the affected arm. Headache occurred in one GTN patient. There were no deaths 
and the modified Rankin Scale (telephone assessment blinded to treatment) did not differ 
between the groups at 90 days, median (interquartile range) GTN 2 (1), control 2 (1) 
(Mann-Whitney U test,464 2p=0.89). 
 
7.5 Discussion 
This chapter has shown that transdermal GTN lowers BP modestly (by 14/3%) without 
having any detrimental effect on CBF or CPP in patients with recent stroke. The neutral 
effect on CBF was present whether global CBF, ipsilateral and contralateral hemispheric 
CBF, or ipsilateral and contralateral arterial regions of interest were studied. Similarly, 
GTN did not alter the size of lesion core, penumbral or oligaemic areas, as defined by pre-
specified CBF levels, and did not appear to cause a ‘cerebral steal’ effect. 
 
Examination of the results for individual patients (figure 7.3a) suggest that GTN may, in 
some cases, increase CBF both within and around the hypodense tissue, and both 
superficially and deep within the brain. Similarly, an increase in peri-lesional CBF was 
seen in a patient with a PICH (figure 7.3b). 
 
Acute stroke, whether of ischaemic or haemorrhagic type, is associated with dysfunctional 
cerebral autoregulation so that, in the extreme, cerebral perfusion becomes dependent on 
systemic BP. The mechanism by which GTN can lower BP whilst maintaining CBF was not 
addressed in this study. However, GTN forms NO which is a potent modulator of 
cerebrovascular reactivity, especially in collateral vessels such as pial arteries.347,350 
Vascular NO levels are low in stroke94 so collateral vessels may not be maximally dilated. 
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Hence, CBF might be held constant with GTN if moderate reductions in systemic BP were 
counter-balanced by increases in collateral blood supply, which would be potentially 
beneficial in acute stroke. 
 
It is commonly held that cerebral vasodilators will reduce cerebral perfusion pressure 
through increasing cerebral blood volume and ICP. However, this hypothesis neglects the 
effect that such drugs will have on zero flow pressure, a measure of downstream pressure. 
Both CPP and ZFP were estimate in this study and GTN did not alter either significantly. 
The observation that GTN did not alter CPP is new and contrary to the expectation that 
cerebral vasodilators will increase ICP and therefore reduce CPP; presumably venodilation 
increases blood flow out of the cranium thereby maintaining CPP (and ICP). 
 
Several caveats should be placed on the study. First, it was small and the CI for the 
haemodynamic effects of GTN were wide such that GTN could have moderately reduced 
or increased CBF and CPP. Nevertheless, the point estimates for differences in a variety 
of CBF measurements (and lesion areas) for GTN and control treated patients all lay on or 
close to zero. Second, the effect of GTN on CBF and CPP in the acute and subacute 
phases of stroke was assessed (median time to randomisation 78 hours) and hence the 
effect that GTN has on CBF during the hyperacute period cannot be commented on. Third, 
patients were included irrespective of stroke type since the CT diagnosis of stroke type 
was only made at the time of study to reduce radiation doses; since only two patients with 
PICH were included (one in each group), the effect of GTN on CBF in PICH cannot be 
specifically addressed, although blood flow was seen to increase adjacent to the 
haemorrhage in one patient. Fourth, few patients with cortical syndromes were included 
reflecting the problems of intensive studying of such patients. Finally, there was no direct 
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measure of ICP but rather an indirect estimate of cerebral perfusion pressure461,463 to 
avoid the need for measuring inserting invasive pressure transducers. 
 
In summary it is possible to lower BP with transdermal GTN without reducing CBF or CPP, 
or inducing cerebral steal, in patients with acute stroke. These data support testing the 
effect of lowering BP in patients with acute stroke and high BP with the aim of improving 
functional outcome and reducing stroke recurrence.  
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Table 7.1 Demographic characteristics of patients. Mean (SD), median * (IQR), or 
frequency (%). 
 
 Control GTN 
Subjects 6 12 
Age (years) † 70.3 (10.8) 69.0 (5.6) 
Gender, male (%) † 3 (50) 2 (17) 
Previous hypertension (%) 4 (67) 3 (25) 
Previous antihypertensive therapy (%) 3 (50) 3 (25) 
Previous stroke (%) 1 (17) 2 (17) 
Smoker (current, %) 3 (50) 8 (67) 
Stroke to randomisation (hours) *† 77 (54) 79 (38) 
Scandinavian Stroke Scale (/58) *† 47 (18) 42 (11) 
Stroke type, ischaemic (%) 5 (83) 11 (92) 
Cortical syndrome (%) 1 (17) 5 (42) 
† Minimisation variable 
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Table 7.2 Haemodynamic measurements at baseline. Mean (SD), median * (IQR), or 
frequency (%). 
 
 Control 
N=6 
GTN 
N=12 
BP (mmHg)   
   Peripheral   
      Systolic † 166 (18) 162 (16) 
      Diastolic 87 (10) 92 (17) 
   Central   
      Systolic 151 (17) 152 (13) 
      Diastolic 91 (15) 95 (16) 
Heart rate (bpm) 66 (15) 69 (14) 
CBF (ml/min/100g)   
   Global 31.1 (6.0) 38.4 (10.6) 
   Ipsilateral   
      Hemisphere 30.4 (4.9) 37.8 (12.8) 
      ACA territory 32.3 (14.7) 38.4 (12.4) 
      MCA territory 32.1 (5.7) 42.1 (15.0) 
      PCA territory 30.0 (9.2) 40.6 (17.5) 
   Contralateral   
      Hemisphere 31.9 (7.8) 39.4 (8.9) 
      ACA territory 34.0 (9.9) 40.4 (11.5) 
      MCA territory 38.2 (10.0) 45.8 (10.3) 
      PCA territory 29.8 (12.4) 38.9 (12.1) 
Lesion area (pixels)   
   Oligaemia 364 (221) 351 (140) 
   Penumbra 258 (196) 262 (197) 
   Core 207 (273) 235 (288) 
Cerebral perfusion pressure (mmHg) 59.7 (12.0) 43.4 (18.0) 
Zero filling pressure (mmHg) 59.5 (14.8) 72.5 (26.6) 
† Minimisation variable 
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Table 7.3 Effect of transdermal GTN on CBF and estimates of cerebral perfusion pressure. Mean (SD), 95% confidence interval, 
comparison by ANCOVA with adjustment for baseline values. 
 
 Control, 
subjects 
GTN, 
subjects 
Control GTN Difference, 
95% CI 
2p 
CBF (ml/min/100g) 6 12 32.8 (7.3) 37.8 (9.7) -1.2 (-6.5, +4.2) 0.66 
   Global 6 12 32.8 (7.3) 37.8 (9.7) -1.2 (-6.5, +4.2) 0.66 
   Ipsilateral       
      Hemisphere 6 12 33.4 (8.3) 37.2 (9.8) -1.4 (-7.6, +4.9) 0.65 
      ACA territory 6 12 30.3 (8.0) 39.5 (14.6) +6.3 (-6.5, +19.0) 0.31 
      MCA territory 6 12 37.0 (10.8) 43.5 (10.8) +0.6 (-8.4, +9.6) 0.89 
      PCA territory 6 12 35.3 (10.2) 39.1 (11.8) -0.7 (-11.4, +10.1) 0.90 
   Contralateral       
      Hemisphere 6 12 32.2 (6.3) 38.4 (10.0) 0 (-7, +6) 0.96 
      ACA territory 6 12 33.3 (8.1) 41.1 (16.8) +5.7 (-10.6, +21.9) 0.47 
      MCA territory 6 12 35.3 (9.6) 44.2 (10.8) +4.6 (-5.5, +14.7) 0.35 
      PCA territory 6 12 32.7 (7.3) 42.0 (15.1) +2.6 (-8.6, +13.9) 0.63 
Lesion area (pixels)       
   Oligaemia 4 9 329 (146) 355 (167) +35 (-120, +191) 0.63 
   Penumbra 4 9 222 (166) 247 (141) +23 (-76, +123) 0.62 
   Core 4 9 243 (318) 266 (290) -2 (-210, +206) 0.98 
Cerebral perfusion pressure (mmHg) 3 10 59.1 (32.4) 50.9 (15.8) -4.4 (-37.4, +28.6) 0.77 
Zero flow pressure (mmHg) 3 10 73.4 (47.2) 60.8 (10.5) -13.6 (-48.8, +21.5) 0.41 
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Figure 7.1 Trial flow profile 
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Figure 7.2 A) Example of template for anterior cerebral artery (areas 1, 6), MCA (2, 5) 
and posterior cerebral artery (3, 4) cortical regions of interest in a patient with a 
large right hemisphere infarct. 
 
 
Right 
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B) Measurement of CBF in a region of interest encompassing an area of ‘oligaemia’ 
(20-36 ml/min/100g) in a patient with a left hemisphere infarct. Similar CBF filters 
were used to identify lesion ‘core’ (CBF <10 ml/min/100g) and ‘penumbra’ (CBF 10-
20 ml/min/100g). 
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Figure 7.3 A) Patient with a left hemisphere borderzone infarct (bottom left); CBF 
before (top left) and 1 hour after GTN (top right); CBF has increased with GTN in and 
around the hypodense lesion and no ‘cerebral steal’ is present, as shown by the 
difference between pre and post scans (bottom right) 
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B) Patient with a left intracranial haemorrhage (bottom left); CBF before (top left) 
and 1 hour after GTN (top right); CBF has increased with GTN around the bleed and 
no ‘cerebral steal’ is present, as shown by the difference between pre and post 
scans (bottom right) 
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Figure 7.4 CBF difference scans (post GTN – baseline) for all patients. Patients receiving active treatment: rows a) and b); 
control: row c). Axial slices are shown at the level of the largest lesion diameter, or an appropriate level for the clinical 
presentation if no lesion was visible on the CT scan. The side of lesion (R: right; L: left) and Oxfordshire Community 
Stroke Project classification (LACS: lacunar syndrome; PACS: partial anterior circulation syndrome; TACS: total anterior 
circulation syndrome) is given for each scan. 
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Chapter 8. 
General discussion and conclusions 
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8.1 Discussion 
Physiological disturbances like hypertension, hyperglycaemia and 
hyperthermia are common following stroke and appear to be related to 
outcome. Consequently, there has been interest in whether optimising 
physiological parameters could lead to improved outcome. This thesis has 
investigated the potential for NO therapeutics for lowering BP in acute stroke. 
More specifically, it has addressed a number of questions and issues about 
this treatment strategy, namely;  
 
• There are inconsistencies in the relationship between high BP and 
outcome in published observational studies.  
• NO related therapeutics have demonstrated contradictory findings in 
animal stroke models. 
• There is paucity of clinical data on the effects of BP lowering with NO 
less than 48 hours from stroke onset. 
• Acute BP lowering with NO may not improve outcome because it risks 
compromising cerebral perfusion. 
 
Chapter 3 dealt with the first of these issues by attempting to clarify the 
relationship between high initial BP and outcome. This was necessary 
because previous observational studies have given conflicting data. In 
addition, some have demonstrated a more positive outcome in patients with 
high BP suggesting that BP lowering would be harmful. Hence, a systematic 
review was performed of all published observational studies reporting BP and 
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outcome in patients with acute stroke. Data from 10,892 patients were pooled 
using the Cochrane Review Manager software.  
 
The main findings included the confirmation of associations between death 
and elevated mean arterial BP and diastolic BP. Furthermore in PICH, 
combined death or dependency was associated with high systolic BP and 
diastolic BP, and in IS high systolic BP, mean arterial BP and diastolic BP 
were associated with death or dependency. The relationship between 
outcome and BP tended to be stronger in patients with PICH as compared 
with those with IS. Unfortunately, without access to individual patient data it 
was not possible to judge if the findings were independent of confounding 
factors such as stroke severity or timing of measurements. Nevertheless the 
data corroborated with a post hoc analysis of the International Stroke Trial 
where a high systolic BP (>140 mmHg) was independently related to an 
increased risk of early death, and combined death or dependency.138 Hence, 
the findings from chapter 3 support the contention that high BP is a 
therapeutic target in acute stroke because it is linked to worse outcome. 
 
Chapter 3 also provided evidence for mechanisms that link high BP to worse 
outcome; In IS high BP was linked to early stroke recurrence and in PICH 
high BP was linked to early re-bleeding. Since antihypertensive agents 
prevent recurrent vascular events in the chronic phase after stoke 52 and limit 
haematoma expansion, 465 it is conceivable that they might interfere with the 
same processes in acute stroke and improve outcome. Unfortunately, due to 
paucity of data the relationship between low BP and outcome was not 
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examined. Previous studies have raised concerns that outcome worsens 
when the initial systolic BP is below 150mmHg.138 Consequently, until the 
results from further studies are available it would be prudent to avoid BP 
lowering in stroke patients with low or normal BP at onset.  
 
Having established that high initial BP is a therapeutic target, chapters 4 and 
5 went on to examine inconsistencies in the evidence base for NO related 
therapeutics in animal stroke models. NO might be a useful treatment for 
lowering BP in acute stroke because it is a key participant in the regulation of 
vascular tone and contributes to BP control through relaxation of vascular 
smooth muscle cells.74 Furthermore, gene knockout studies confirm that 
eNOS derived NO has additional neuroprotective, anti-thrombotic and anti-
inflammatory properties.99 By contrast, NO produced by iNOS and nNOS was 
found to be detrimental in gene knockout studies.365-370 Therefore, many pre-
clinical studies have assessed the effect of administering NO or inhibiting 
NOS on stroke in animal models. Unfortunately, the data from individual 
studies has been contradictory, and this has raised questions about whether 
NO related therapeutics would work in humans. Thus it was decided to 
determine systematically what effect NO donors and NOS inhibitors have on 
experimental infarct volume and CBF. The impact of differences in drug 
pharmacology, dosage, route of administration, timing of treatment, animal 
model and type of ischaemia were examined. Unfortunately it was not 
possible to look at the impact on BP since physiological parameters are kept 
tightly controlled in the majority of animal stroke studies. 
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First, in chapter 4 studies of NO sources (L-Arg and NO donors) in 
experimental IS were identified. Data were analysed using the Cochrane 
Collaboration Review Manager software and SMD calculated. Altogether 25 
eligible studies were identified. When analysed together, NO sources reduced 
total cerebral infarct volume in both permanent and transient models. Sub-
group analysis revealed that NO was less effective when the source was L-
Arg or when it was given >1hour after onset and to transient models. Drug 
administration increased cortical CBF in permanent but not transient models, 
suggesting that exogenous NO might be beneficial partly though increases in 
cerebral perfusion.  
 
In general, chapter 4 supports the continued development of NO sources, 
such as GTN, for treatment of human stroke. However, there are a couple of 
caveats. First, there are no studies specifically addressing the effect of BP 
lowering with NO on experimental infarct volume. Second, lack of benefit on 
infarct volume after 1 hour from stroke onset suggests that NO may have 
limited therapeutic window for neuroprotection. However, beneficial effects on 
CBF were observed at 1 hour in permanent stroke models (and beyond 1 
hour in individual studies337,346), suggesting that vasculoprotective properties 
may be present for longer and in a more suitable time frame for use in human 
stroke.  
 
In chapter 5 studies of NOS inhibitors in experimental stroke were identified in 
a second systematic review. Of 456 references found, 73 studies involving 
2321 animals were included. NOS inhibitors reduced total infarct volume in 
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both permanent and transient ischaemia. Selective inhibitors (iNOS and 
nNOS) were better than the non-selective inhibitors, which were ineffective in 
permanent ischaemia. Cortical CBF was reduced in permanent models, 
mainly after administration of non-selective inhibitors. 
 
The data in chapter 5 support the development of selective NOS inhibitors as 
treatments for clinical IS, assuming that side effects are tolerable. Importantly, 
the NOS inhibitors were observed to be neuroprotective several hours after IS 
suggesting that they are practical to give in clinical IS. The future may see the 
development of combined therapeutic strategies in order to get even greater 
beneficial effects, e.g. combining a NO donor with an iNOS inhibitor. Such an 
approach has already been adopted in the case of the ‘dual action’ 
compounds like the ‘nitroaspirins’197 and the antioxidant / nNOS inhibitor 
BN80933.466 
 
Having established that high BP is a therapeutic target and that animal data 
support the use of NO sources in acute stroke the next step was to undertake 
an assessment of BP lowering with a candidate NO donor. A 5mg GTN patch 
was selected as it is easy to administer, can be given to dysphagic patients, 
compliance can be monitored and the effects can be reversed by removing 
the patch. Moreover, previous studies have demonstrated an approximately 7-
8% reduction in 24hour ambulatory BP when 5mg GTN patches are given 3-4 
days after onset. As demonstrated in chapter 4, early administration of NO is 
desirable in order to maximise its potentially neuroprotective and 
vasculoprotective properties. Hence, a clinical trial was designed to test the 
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haemodynamic effects and assess feasibility of administration of GTN when 
given <48 hours after onset.  
 
A single centre sub-study forming part of an ongoing, prospective, 
international, multicentre, randomised, controlled, trial was performed. 51 
patients with ischaemic or haemorrhagic stroke were randomised within 48 
hours to transdermal GTN (5 mg) or control. When administered at a median 
31 hours after onset, GTN significantly lowered peripheral and central systolic 
BP by ~15mmHg compared with the control group. At 1 hour peripheral 
systolic BP was approximately 7% lower than at baseline, which is beneath 
the maximum limit of <20% suggested by published guidelines.153,437 The fall 
in BP was mediated by an effect on the central arterial tree (increased aortic 
compliance), rather than through effects on the heart (CO) or peripheral 
arterioles (TPR). Furthermore, GTN reduced BP without compromising 
indirect measures of cerebral perfusion, suggesting that it may be safe to give 
when autoregulation is impaired. Overall, Chapter 6 successfully 
demonstrates the feasibility of lowering BP with GTN patches and extends the 
information available at an earlier time interval than any previous studies. 
 
Unfortunately, MCA velocity may not be a good measure of regional cerebral 
perfusion since it is affected by vessel diameter as well as blood flow.261,453 
Since GTN is a vasodilator the possibility that blood velocity was maintained 
in chapter 6 despite a reduction in CBF cannot be excluded. Hence it was felt 
necessary to undertake a fuller assessment of the effects of GTN on 
quantitative measures of CBF to dispel concerns that it can compromise 
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cerebral perfusion. In chapter 7, 18 patients with recent ischaemic or 
haemorrhagic stroke (<5 days) were randomised (2:1) to transdermal GTN (5 
mg) or control. Global, hemispheric, arterial territory and lesion CBF were 
measured using XeCT before and 1 hour after treatment with GTN. In addition 
the effects on CPP and ZFP were estimated from measures of MCA velocity, 
assessed using TCD, and peripheral BP 
 
When GTN was administered at a median 79 hours after onset it lowered BP 
modestly by 23 mmHg (14%) without having any detrimental effect on CBF. 
The neutral effect on CBF was present whether global CBF, ipsilateral and 
contralateral hemispheric CBF, or ipsilateral and contralateral arterial regions 
of interest were studied. Similarly, GTN did not alter the size of lesion core, 
penumbral or oligaemic areas, as defined by pre-specified CBF levels, and 
did not appear to cause a ‘cerebral steal’ effect. Finally GTN did not alter CPP 
or ZFP countering concerns that vasodilators will increase intracranial 
pressure and therefore reduce CPP.  
 
An unanswered question is how GTN can lower BP without compromising 
cerebral perfusion? The thesis does not address this question directly, 
although it is possible to speculate based on the findings from individual 
chapters. First, in chapter 6 transdermal GTN was found to reduce BP by a 
modest 7%. This is much less than the >20% BP drop seen with high dose i.v. 
nimodipine that was associated with neurological worsening in one trial.156 
Hence the dose may have been insufficient to alter CBF. Second, the effect of 
moderate reductions in BP may be counter-balanced by NO induced 
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increases in collateral blood supply. This theory is indirectly supported by 
evidence from chapter 4 where increased CBF was observed following 
administration of NO in experimental stroke. Furthermore, in chapter 7 GTN 
appeared to increase CBF in some individuals (figure 7.3a, figure 7.3b).  
 
8.2 Conclusion 
Overall this thesis has addressed several questions concerning the 
investigation of GTN as a BP lowering agent in acute stroke. It has 
demonstrated that high BP is linked to poor outcome and is a therapeutic 
target. It has shown that experimental data support the use of NO sources in 
acute stroke. It has shown that 5mg GTN patches lower BP modestly within a 
narrow time frame, and it has found that there is no detrimental effect on CBF. 
However, at the present time the data in this thesis cannot be used to justify 
the routine treatment of high BP following stroke. Until data on the effect of 
GTN on functional outcome arrives the long standing controversy of how to 
best manage BP immediately after stroke will remain unresolved.  
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9.2 Appendix II - Abbreviations 
 
(?) Value not reported  
(7-NI) 7-nitroindinazole  
(AAMI) Association for the Advancement of Medical Instrumentation  
(ABPM) Ambulatory blood pressure monitor 
(ACA) Anterior cerebral artery 
(ACE) Angiotensin converting enzyme  
(ADL) Activities of daily living 
(ADP) Adenosine diphosphate 
(AF) Atrial fibrillation 
(AI) Augmentation index 
(ANCOVA) Analysis of covariance 
(ARA) Angiotensin receptor antagonist 
(ARB) Angiotensin receptor blockers 
(ATP) Adenosine triphosphate 
(BH4) Tetrahydrobiopterin  
(BHS) British Hypertension Society 
(BI) Buckberg index 
(BP) Blood pressure 
(bpm) Beats per minute 
(C) Cats  
(CBF) Cerebral blood flow  
(cGMP) Cyclic guanidine monophosphate 
(CI) Confidence interval 
(CO) Cardiac output 
(CPP) Cerebral perfusion pressure 
(CSF) Cerebrospinal fluid 
(CVP) Central venous pressure 
(EAFT) European atrial fibrillation trial 
(EDRF) Endothelium derived relaxing factor 
(EDV) End diastolic velocity  
(ENOS) Efficacy of nitric oxide in stroke trial 
(eNOS) Endothelial nitric oxide synthase  
(FAD) Flavin adenine dinucleotide  
(FMN) Flavin mononucleide  
(FR) Fischer Rats  
(FV) Flow velocity 
(GTN) Glyceryl trinitrate 
(HR) Heart rate 
(i.a.) Intra-arterial  
(i.p.) Intra-peritoneal  
(i.v.) Intra-venous  
(IC 50) 50% Inhibition 
(ICA) Internal carotid artery 
(ICP) Intracranial pressure 
(infarct vol.) Infarct volume  
(iNOS) Inducible nitric oxide synthase  
(IQR) Interquartile range 
(IS) Ischaemic stroke 
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(ISDN) Isosorbide di-nitrate 
(L) Lambs  
(LACS) Lacunar stroke 
(L-Arg) L-arginine 
(LER) Long-Evans rat  
(L-NAME) NG-nitro-L-arginine methyl ester  
(L-NIL) NG-iminoethyl-L-lysine  
(L-NIO) NG-iminoethyl-L-ornithine  
(L-NMMA) NG-monomethyl-L-arginine  
(L-NNA) NG-nitro-L-arginine  
(LR) Lewis Rats  
(M) Mice  
(MCA) Middle cerebral artery 
(MFV) Mean flow velocity  
(MG) Mongolian Gerbil  
(mmHg) Millimetres mercury 
(mRs) Modified Rankin scale 
(n) Number of subjects 
(NADP) Nicotinamide adenine dinucleotide phosphate  
(NANC) Non-adrenergic, non-cholinergic  
(NF-κB) Nuclear transcription factor - κB  
(nNOS) Neuronal nitric oxide synthase  
(NO) Nitric oxide  
(NO2-) Nitrite  
(NO3-) Nitrate 
(NOS) Nitric oxide synthase  
(NOx) Nitrate and nitrite 
(O2.-) Superoxide anion radical  
(OR) Odds ratio 
(OT) Occupational therapy 
(P) Piglets  
(PACS) Partial anterior circulation stroke 
(PCA) Posterior cerebral artery 
(PET) Positron emission tonometry 
(PI) Pulsatility index  
(PICH) Primary intracerebral haemorrhage 
(PMT) Photomultiplier tube 
(POCS) Posterior circulation stroke 
(PP) Pulse pressure 
(PSV) Peak systolic velocity 
(PWA) Pulse wave analysis 
(PWV) Pulse wave velocity 
(R) Rabbits  
(RCT) Randomised controlled trial 
(RD) Risk difference 
(RI) Resistance index  
(ROIs) Regions of interest 
(RR) Risk ratio 
(rTPA) Recombinant tissue plasminogen activator 
(S) Number of studies  
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(SAH) Subarachnoid haemorrhage 
(SD) Standard deviation  
(SDR) Sprague-Dawley rat  
(SEVR) Subendocardial viability ratio  
(SGC) Soluble guanylate cyclase 
(SHR) Spontaneously hypertensive rats  
(SMD) Standardised mean difference  
(SNP) Sodium nitroprusside 
(SNSS) Scandinavian neurological stroke scale 
(SPECT) Single photon emission tonometry 
(STAIR) Stroke Therapy Academic Industry Roundtable  
(SV) Stroke volume 
(TACS) Total anterior circulation stroke 
(TCD) Transcranial Doppler 
(TNFα) Tumour necrosis factor  
(TPR) Total peripheral resistance 
(TRIM) Tri(fluoromethylphenyl)imidazole  
(WHO) World Health Organisation 
(WMD) Weighted mean difference 
(WR) Wistar rats  
(Xe) Xenon 
(XeCT) Xenon CT 
(ZFP) Zero flow pressure 
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9.3 Appendix III – Publications arising from this thesis 
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